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ABSTRACT
EARLY DIAGNOSIS OF PULMONARY EMBOLISM:
REVIEW AND COST-EFFECTIVENESS ANALYSIS
Efstathios Polychronopoulos
Old Dominion University
Director: Dr. Anna H. Jeng

Pulmonary embolism (PE) is a serious, life-threatening thrombotic disease, which
results in considerable health and economic consequences each year for the United
States. These consequences include a toll of 83,000 deaths and an economic impact
between $1.5 and $5 billion. Approaches to strategy selection by physicians and other
health-care specialists are based mainly upon cost, technology availability, and cultural
tolerance regarding radiation exposure. The purpose of this study was to determine the
most cost-effective diagnostic strategy with patients suspected of PE among several
strategies currently used by examining their detection failure rates. This objective was
met by (a) assessing parameter estimates and their uncertainty using triangular and y
distributions, (b) conducting a cost-effectiveness analysis, and (c) testing the model for
errors using sensitivity analysis.
Cost-effectiveness analysis based upon a decision tree model revealed that among
the investigated strategies for patients with suspected PE the most cost-effective strategy
appears to be strategy 3, composed of a clinical decision rule (CDR), a D-dimer test
(DD), a compression ultrasonography test (CUS), and a computed tomography
pulmonary angiography (CT). Strategy 5, composed by a CDR, DD, a CT, a CUS, and an
invasive pulmonary angiography (PA) appeared to be a cost-effective method, but it was
more expensive than strategy 3 and included an invasive pulmonary angiography (PA).

The results of a Monte Carlo simulation sensitivity analysis were robust over a
number of distributions regarding the PE diagnostic test costs, sensitivities, specificities,
and strategy effectiveness. Additionally, the results of this investigation were valid over
an extensive range of one-way, two-way, and three-way sensitivity analyses regarding PE
diagnostic test costs. Overall, the proposed analyses identified uncertainty and eliminated
error; thus, it provides a practical approach to help medical professionals estimate
uncertainty in the diagnosis of PE. Although this research has broadened the ability to
identify uncertainty and eliminate error, further research is needed to validate these
findings in a prospective clinical trial before the delivery of a clinical recommendation.
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CHAPTER 1
INTRODUCTION
Pulmonary embolism (PE) is a serious, life-threatening thrombotic disease, which
results in considerable health and economic consequences each year for the United
States. These consequences include a toll of 83,000 deaths and an economic impact
between $1.5 and $5 billion (Anderson et al., 1991; Dobesh, 2009; Eichinger et al., 2004;
Goldhaber, 2004; Heit, 2006, 2008; Heit, Mohr, et al., 2000; Kniffin, Baron, Barrett,
Birkmeyer, & Anderson, 1994; MacDougall, Feliu, Boccuzzi, & Lin, 2006; Silverstein et
al., 1998; Spyropoulos & Lin, 2007; Stein, Kayali, & Olson, 2004a; U.S. Department of
Health and Human Services, 2008). PE incidence approximates 207,000 cases per year in
the United States, the vast majority of which require hospitalization and expensive
treatment (De Lissovoy & Subedi, 2002; Dobesh, 2009; MacDougall et al., 2006;
McGarry, Thompson, Weinstein, & Goldhaber, 2004; Ollendorf, Llonch, & Oster, 2002;
Silverstein et al., 1998; Spyropoulos & Lin, 2007; U.S. Department of Health and Human
Services, 2008). The cost of diagnostic management and treatment of an initial PE
episode ranges between $9,500 and $16,700, whereas the diagnostic management and
treatment of PE combined with deep vein thrombosis (DVT) costs approximately
$25,000 (De Lissovoy & Subedi, 2002; Dobesh, 2009; MacDougall et al., 2006; McGarry
et al., 2004; Ollendorf et al., 2002; Silverstein et al., 1998; Spyropoulos & Lin, 2007;
U.S. Department of Health and Human Services, 2008). Survivors are affected for the
rest of their lives, and those who experience an initial PE episode are at high risk for
recurrent PE within 10 years with the highest risk occurring during the first year
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(Douketis, Kearon, Bates, Duku, & Ginsberg, 1998; Eichinger et al., 2004; Heit, 2006;
Heit, Mohr, et al., 2000; Spencer et al., 2008; Stein, Hull, & Raskob, 2000; White, 2003).
PE diagnostic strategies have been developed based upon combinations of clinical
decision rules and available laboratory and imaging PE diagnostic tests such as the (a) Ddimer test, (b) computed tomography pulmonary angiography scan, (c) ventilationperfusion lung scan, (d) compression ultrasonography test, and (e) invasive pulmonary
angiography test (Elias et al., 2004; Gibson et al, 2008; Hudson et al., 1996; Sostman et
al., 2008; Stein et al., 2006; Toulon, Lecourvoiser, & Meyniard, 2009; Wells et al., 2000).
The costs associated with these tests and rules, implemented as diagnostic strategies, or
screenings, are continually being evaluated. Current cost-effectiveness analyses of PE
screenings result in variable findings because of several combinations of these tests and
rules employed in medical conditions to which they are applied. The factors of cost and
effectiveness of each screening present constant challenges to physicians as they decide
which diagnostic strategy to select for use with certain conditions (Doyle et al., 2004;
Hull, Graham, Stein, Mah, & Butcher, 2001; Paterson & Schwartzman, 2001; Perrier,
Mathieu, Francois, Nigel, & Bounameaux, 2003; Quiroz & Schoepf, 2005).
Statement of the Problem
PE is difficult to diagnose. Misdiagnosis or delay in PE detection can be fatal. It is
estimated that 10% of all patients with symptomatic PE die within 60 minutes of onset,
and 15% of diagnosed patients die within three months after diagnosis (Goldhaber,
Visani, & De Rosa, 1999; Kearon, 2003).
Although clinicians are responsible for accurate diagnoses and must use care in
the application of the available technologies for PE diagnosis, their selection of
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diagnostic strategies varies greatly (Le Gal, Righini, Sanchez, et al., 2006; Nijkeuter et
al., 2007; Perrier et al., 2005; Stone et al., 2003; Wells et al., 2001). Approaches to
strategy selection by physicians and other health-care specialists are based mainly upon
cost, technology availability, and cultural tolerance regarding radiation exposure
(Brenner & Hall, 2007; Kline, Courtney, Beam, King, & Steuerward, 2009; Perrier, 2007;
Piazza & Goldhaber, 2009; Sodhi & Kaur, 2005). Determining the most cost-effective PE
diagnostic screening strategy might ease the challenge to health-care professionals of
selecting the most appropriate strategy with which to diagnose a patient with suspected
PE and might provide insight regarding the variability among currently available
strategies.
Purpose of the Study
The purpose of this study was to determine the most cost-effective diagnostic
strategy among several strategies currently used with patients with suspected PE based
upon the failure rates of the respective strategies. The ability to identify the most costeffective strategy may result in wider implementation of a particular strategy for PE
detection that is less costly and more effective when compared to alternate strategies.
Factors Influencing the Cost-Effectiveness Analysis (CEA) of Pulmonary Embolism
Early Diagnosis
CEA basics.
A cost-effectiveness analysis (CEA) of PE diagnostic strategies is used to
compare the cost and effectiveness of a reference strategy with available alternate
strategies by assessing the value of each using specific units of cost and effectiveness
(e.g., dollars spent per additional life gained, dollars spent per additional PE episode
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avoided) (see Doyle et al., 2004; Fenwick, 2009a; Gold, 1996; Hull et al., 2001; Hunink
& Krestin, 2002; Jan, 2009; Kaplan, 2006; Kastanioti, 2009; Kuntz, Fleischmann,
Hunink, & Douglas, 1999; Muennig, 2008; Paterson & Schwartzman, 2001; Perrier et al.,
2003; Quiroz & Schoepf, 2005; Yeh, 2009). There are three very important elements of a
CEA for PE diagnostic strategies: composition, costs, and effectiveness. The composition
of each PE diagnostic strategy includes specific clinical decision rules (CDRs), D-dimer
tests, and imaging tests for detecting PE (Doyle et al., 2004; Hull et al., 2001; Paterson &
Schwartzman, 2001; Perrier et al., 2003; Quiroz & Schoepf, 2005).
CEA of PE diagnostic strategies can be conducted from a third-party payer cost
perspective or a societal cost perspective, depending upon the particular set of decisionmaking interests. The third-party payer cost perspective considers the economic impact
on the payer, and the societal cost perspective examines the economic impact of costs
without regard to who initiates the costs or who finances the costs. Typically, CEAs of
PE diagnostic strategies have been conducted with consideration to the third-party payer
perspective, which includes only direct costs of PE diagnostic strategies such as
laboratory tests or diagnostic tests, treatment, and hospitalization. A CEA from a societal
perspective includes indirect costs (e.g., costs due to productivity loss, waiting or travel
time, or other economic impact on patients and their families) and opportunity costs (e.g.,
costs of market competition, income, and taxes). This type of examination is rarely
employed (see Doyle et al., 2004; Fenwick, 2009a; Gold, 1996; Hull et al., 2001; Hunink
& Krestin, 2002; Jan, 2009; Kaplan, 2006; Kastanioti, 2009; Kuntz et al., 1999; Muennig,
2008; Paterson & Schwartzman, 2001; Perrier et al, 2003; Quiroz & Schoepf, 2005; Yeh,
2009).
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Finally, the effectiveness of each PE diagnostic strategy reflects the performance
of the entire strategy, including failure to detect a PE, which could result in another PE
episode that might be fatal. The effectiveness of a PE diagnostic strategy is commonly
measured by mortality or survival rates (Doyle et al., 2004; Fenwick, 2009a; Gold, 1996;
Hull et al., 2001; Hunink & Krestin, 2002; Jan, 2009; Kaplan, 2006; Kastanioti, 2009;
Kuntz et al., 1999; Muennig, 2008; Paterson & Schwartzman, 2001; Perrier et al., 2003;
Quiroz & Schoepf, 2005; Yeh, 2009).
Pulmonary embolism diagnostic costs.
A PE diagnostic strategy is a procedure that combines CDR with laboratory tests
and imaging tests that surpasses the accuracy of a clinical assessment conducted using
only D-dimer or imaging tests (Le Gal, Righini, Sanchez, et al., 2006; Nijkeuter et al.,
2007; Perrier et al., 2005; Stone et al., 2003; Wells et al., 2001). PE diagnosis usually
begins with a clinical assessment that includes CDR, history, physical examination, and
instrumental examination followed by a D-dimer test and other imaging tests, if
necessary (Daniel, Courtney, & Kline, 2001; Gibson et al., 2008; Goekoop et al., 2007;
Le Gal, Righini, Roy, et al., 2006; Miniati et al., 2003; Nijkeuter et al., 2007; PIOPED
Investigators, 1990; Sanson et al., 2000; Sonne, Kamphuisen, Van Mierlo, & Buller,
2005; Stein et al., 2007; Stein & Henry, 1997; Stein et al., 2008; Wells et al., 2000; Wicki
et al., 2001).
The high PE incidence, combined with the high average cost for PE diagnostic
management and treatment, generates substantial economic cost consequences of as
much as $5 billion annually for the U.S. health-care system (De Lissovoy & Subedi,
2002; Dobesh, 2009; Knight et al., 2005; MacDougall et al, 2006; McGarry et al., 2004;
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Ollendorf et al., 2002; Spyropoulos & Lin, 2007). In general, the average cost for a PE
episode appears to be greater than a DVT episode, mainly due to longer hospitalization
and greater treatment and medical costs (Dobesh, 2009). It is estimated that in the United
States the cost of a first PE episode ranges between $9,500 and $16,600. The cost of an
initial DVT episode ranges between $7,700 and $10,800. Overall, the annual economic
impact of VTE for the entire U.S. health care system reaches at least $1.5 billion
(Dobesh, 2009).
De Lissovoy and Subedi (2002) estimated median costs of initial PE, DVT, and
PE with DVT at $6,424, $3,131, and $6,678, respectively. The median costs of each
recurrent VTE event, each bleed event, and each recurrent VTE with bleed event were
estimated at $5,736, $4,999, and $10,185, respectively. Applying these estimates to
annual PE and DVT incidences in the United States (207,000 and 143,000, respectively)
reveals an annual economic cost of $1.33 billion for PE and $0.45 billion for DVT. Thus,
the total annual VTE economic cost for the entire nation is approximately $1.8 billion.
According to a 2007 study (Spyropoulos & Lin, 2007), the average annual direct
medical costs of a PE episode were $16,644 and about $10,804 for a DVT episode. The
cost for a recurrent PE was $14,722 and $11,862 for a recurrent DVT. Applying these
estimates to annual PE and DVT incidences in the United States (207,000 and 143,000,
respectively) reveals direct medical costs of $3.4 billion for PE and $1.5 billion for DVT.
The total annual VTE direct medical costs for the entire nation are approximately $5
billion.
MacDougall et al. (2006) studied a cohort of 26,958 patients to determine that the
annual median total reimbursed cost was $18,901 for a PE episode, $17,512 for a DVT
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episode, and $25,554 when both PE and DVT were present. Applying these cost amounts
to annual PE and DVT incidences in the United States (207,000 and 143,000,
respectively) reveals annual direct medical costs of $3.9 billion for PE and $2.5 billion
for DVT. The total annual VTE reimbursed cost for the entire nation is approximately
$5.4 billion.
The Decision Tree Framework for Assessing Cost-Effectiveness
A common decision-making theoretical framework used in previous studies to
assess the cost-effectiveness of PE diagnostic strategies is the decision tree framework
(Doyle et al., 2004; Muennig, 2008; Paterson & Schwartzman, 2001; Perrier et al., 2003;
Quiroz & Schoepf, 2005). This theoretical framework offers a meaningful presentation of
very complex decision-making problems by (a) overcoming the restriction of presenting
data in a tabular format and (b) offering the advantages of outlining all potential actions,
delineating all probable events, and demonstrating all possible outcomes (Lapin &
Whisler, 2002). The decision tree framework is based upon three major concepts—act,
event, and outcome—as described by Lapin & Whisler (2002) (see Figure 1).
Act is defined as the decision maker's choices. In each decision, an initial action
occurs. For example, when one must choose among four diagnostic strategies to detect a
disease, each strategy represents a potential initial action. The decision tree framework
demonstrates all actions on the left side of the tree's structure.
An event is defined as the component of the decision that contains an element of
uncertainty following an initial action. Probability values are assigned to each event in
the decision tree structure, the sum of which equals 1.00. For example, with uncertainty
regarding diagnostic test results from diagnostic strategy 1 (Action 1), two events can
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occur: either the patient receives treatment or another test is administered. If the
probability of receiving treatment is p, then the probability of the administration of
another test is 1-p.
A new action can follow an event. For example, after selecting the initial action of
applying a diagnostic strategy (Action 1) and selecting another test (Event 2), the new
action is the administration of another test, which creates a new event that presents a
different element of uncertainty. In the decision tree framework, there is a chronological
progression of events. Those indicated on the left side are assumed to occur before events
indicated on the right side of the decision tree.
Outcome is defined as any component that can be used to measure the
investigating condition. A clear measure of an outcome is its payoff value in dollars per
life saved. Using an example of disease detection, if the decision maker chooses to apply
diagnostic strategy A, then the outcome will be $1.00 per life saved. If he or she selects
diagnostic strategy B, then the payoff will be $1.50 per life saved. If diagnostic strategy
A results in greater effectiveness but is more expensive than strategy B, then the outcome
should be expressed in an incremental cost-effectiveness ratio of dollars per additional
life saved. However, calculations that are more complicated follow when expressing an
outcome in an incremental cost-effectiveness ratio of dollars spent per additional life
saved. The decision tree framework demonstrates the outcomes or the consequences of
the events on the right side of the decision tree.

Outcome
Outcome 11

c < Outcome

12

c< Outcome
Outcome,

nl

n2

Figure 1. Decision tree framework. A square represents a decision node. A circle
represents a chance node. Several events can occur with corresponding outcomes under
each action . For example, under Action 1, Events 1-lor 1-2 can occur with
corresponding Outcomes 1-1 or 1-2, while under Action j , Events n-1 or n-2 can occur
with corresponding Outcomes n-1 or n-2.

Significance of the Study
At the time of this dissertation limited research was available to identify the most
cost-effective diagnostic strategy currently in use that detects PE. This study assessed the
cost and effectiveness of several diagnostic strategies currently in use for patients with
suspected PE. Specifically, this research attempted to determine the most cost-effective
diagnostic strategy, particularly with attention to its screening value (i.e., screening
failure rate).

1

The decision tree framework for assessing cost-effectiveness is based upon the decision tree framework as
described by Lapin and Whisler (2002).
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The individual cost and effectiveness components of PE detection, though
significant, do not describe the combined effect of the performance and the economic
impact of a PE diagnostic strategy compared to alternate strategies. When a PE diagnostic
strategy results in better effectiveness, but costs more than an alternate strategy, the
incremental cost-to-incremental effectiveness ratio (ICER) should be calculated.
Therefore, this study examined the combined effect of performance and economic impact
of costs and effectiveness with particular attention to the failure rates of each diagnostic
strategy for detecting PE.
This study is one of only a few studies, which have investigated factors
influencing PE diagnostic strategies from a cost-effectiveness perspective. This study is
the only study that has addressed these strategies using a CEA in combination with
triangular distributions, y distributions, and Monte Carlo Simulation to evaluate which PE
diagnostic strategy is more cost-effective based upon the failure rates for PE detection.
Assumptions
A few assumptions were made about diagnostic tests, treatment, and utilization of
secondary data. First, if PE is ruled out, then patients will not receive treatment or further
tests. Additionally, if PE is confirmed, then patients will receive treatment, and no further
tests will be performed. Also, if PE is not ruled out or confirmed, then further imaging
test(s) will follow. Finally, it was assumed that the secondary data identified in literature
are true and unbiased.
Limitations
Several limitations can be applied to this study. First, this research is based upon
data collected solely from the literature cited, which limits the applicability of the data to
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the design and methodology presented in the original research. In addition, it is assumed
that all tests included in the investigated strategies are available and that any strategy
could be selected based upon the cost-effectiveness analysis (CEA). This analysis
approached the implementation of treatment and the nondiagnostic imaging test results in
the same manner that they were approached in the cited literature. Further, this study did
not distinguish between different types of the same imaging test because it is focused
upon early PE diagnosis in patients, in general, and not upon an evaluation of each of the
available types of imaging tests.
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CHAPTER 2
LITERATURE REVIEW
This chapter reviews the literature that addressed this study's components: a
theoretical decision-making framework, individual screening tools for diagnosing
pulmonary embolism (PE), their combinations into distinct diagnostic strategies, and
cost-effectiveness analysis (CEA) studies of these strategies. The decision tree
framework (Lapin & Whisler, 2002) is described, and its application to a CEA for
assessing PE diagnostic strategies is presented.
PE is a serious disease. It is difficult to diagnose and it has considerable health
and economic impacts on a community (Dobesh, 2009; U.S. Department of Health and
Human Services, 2008). Diagnostic challenges are mainly associated with the
implementation of clinical decision rules, the availability of diagnostic laboratory and
imaging tests, and the medical costs associated with them (Brenner & Hall, 2007; Kline,
Courtney, Beam, King, & Steuerward, 2009; Perrier, 2007; Piazza & Goldhaber, 2009;
Sodhi & Kaur, 2005). The application of cost-effective diagnostic strategies could reduce
costs and decrease mortality and recurrence rates of the disease in patients with suspected
PE (Horlander, Mannino, & Leeper, 2003; Perrier, 2007; Stein, Kayali, & Olson, 2004a).
Theoretical Framework: The Decision Tree Framework
The theoretical framework for this study is based upon the comprehensive
decision tree framework, as described by Lapin & Whisler (2002). It was selected for its
flexibility in combining three constructs—Actions, Events, and Outcomes—of a decision
and for its use in previous studies that evaluated the cost- effectiveness of PE diagnostic
strategies (Doyle et al., 2004; Paterson & Schwartzman, 2001; Perrier, Mathieu, Francois,
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Nigel, & Bounameaux, 2003; Quiroz & Schoepf, 2005). The PE diagnostic strategies
were assigned to the Actions construct. The components of these strategies (i.e., the
diagnostic tools that include clinical decision rules, laboratory tests, and imaging tests)
were assigned to the Events construct. A probability value that the event will occur was
assigned to each Events construct. The supposition of a payoff was assigned to the
Outcomes construct.
The Actions construct includes the PE diagnostic strategies investigated in this
study. Diagnostic strategy is defined as a series of diagnostic procedures based upon a
combination of clinical decision rules (CDR), laboratory tests, and imaging tests that can
maximize the accuracy of a stand-alone clinical decision rule, D-dimer test, or imaging
test performed to detect a disease. First, patients are evaluated for PE by a clinical
decision rule. If PE is not excluded, then a D-dimer test is administered. If PE still is not
excluded, then an imaging test or tests are performed to rule out or confirm PE (see
Doyle et al., 2004; Hull, Graham, Stein, Mah, & Butcher, 2001; Paterson &
Schwartzman, 2001; Perrier et al., 2003; Quiroz & Schoepf, 2005).
The Events construct includes clinical decision rules (CDR) used to detect a
disease. A CDR is defined as "an instrument containing variables obtained from history,
physical examination, and simple diagnostic tests, quantifying the likelihood of a
diagnosis, prognosis, or likely response to treatment in an individual patient" (Klok et al.,
2008, p. 2131). The Events construct also includes the diagnostic tests performed to
detect a disease. A diagnostic test is defined as the laboratory or imaging test applied to
detect a disease (Elias, Colombier, et al., 2004; Hudson et al., 1996; Sostman, Stein, et
al., 2008; Stein, Fowler, et al., 2006; Toulon et al., 2009). The D-dimer test (DD) is a
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laboratory blood test used to exclude PE and to eliminate the need for imaging testing
(Hogg et al., 2005; Kline, Runyon, Webb, Jones, & Mitchell, 2006; Stein, 2007a; Stein,
Hull, et al., 2004). Imaging tests are diagnostic tests based upon a range of imaging
modalities to diagnose a disease (Elias, Colombier, et al., 2004; Hudson et al., 1996;
Perrier, 2007; Perrier et al., 2005; Sostman, Stein, et al., 2008; Stein, Fowler, et al., 2006;
Toulon et al., 2009). Several different imaging tests can be performed to detect PE. These
include a computed tomography pulmonary angiography (CT), a ventilation-perfusion
lung scan (VQ), a compression ultrasonography (CUS), and an invasive pulmonary
angiography (PA). Also included in this construct is the probability that a test will
exclude (rule out) or confirm PE and the probability that a new (i.e., additional) test will
follow (Doyle et al., 2004; Hull et al., 2001; Paterson & Schwartzman, 2001; Perrier et
al., 2003; Quiroz & Schoepf, 2005).
The Outcomes construct includes any payoff for each event. The payoff in this
study was defined as the combined cost and effectiveness of each event (Doyle et al.,
2004; Hull et al., 2001; Paterson & Schwartzman, 2001; Perrier et al., 2003; Quiroz &
Schoepf, 2005). Accordingly, direct costs are defined as "Costs associated with goods
and services consumed", and effectiveness is defined as "The performance of health
intervention in the real world" (Muennig, 2008, p. 250).
The basic tenet of the decision tree framework, also well-known as decision tree
model, is that events are presented in a chronological sequence. Events indicated on the
left side of the framework occur before events on the right side of the framework,
beginning with the event node at the furthest left (Doyle et al., 2004; Ishwaran & Rao,
2009; Lapin & Whisler, 2002; Paterson & Schwartzman, 2001; Perrier et al., 2003;
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Sonnenberg & Hagerty, 2009). The initial component of the decision tree framework is
the decision node, usually depicted by a small square with at least two lines originating
from it that represent possible options. In this study, the lines beginning at the decision
node symbolized the available PE diagnostic strategies as options.
The next component of a decision tree framework is the chance node, usually
depicted by a small circle. Several lines originate from each chance node, which
represents the possible events that cannot be controlled by the decision maker, for
example, laboratory test results. Assume that the implementation of strategy 1 included a
D-dimer test. If the test results are negative, then no treatment will be administered; if the
test results are positive, then a CT will be performed. Regardless, the decision maker has
no control or foreknowledge of the event's results.
The probabilities for a single event in this study are (a) the probability of a test to
rule out or confirm PE and (b) the probability of a new (i.e., additional) test to follow.
For example, if the probability that a D-dimer test is negative is 0.30, then the probability
that an additional test will follow is 0.70 because the summing of the event's probabilities
must equal 1.00. The last component of a decision tree framework is the payoff, the
triangle at the far right side of the decision tree, which began at a decision node that was
followed by a chance node in the Actions and Events constructs. Payoffs are the
consequences of the events. In this study, a payoff was described as the 3-month followup mortality rates and the VTE (i. e., PE and/or DVT) recurrence rates occurring among
patients with suspected PE after the implementation of a certain diagnostic test or a series
of tests with their corresponding costs. Figure 2 depicts a decision tree framework for
selecting diagnostic strategies to detect PE among patients with suspected PE.
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Figure 2. Decision tree framework for PE diagnostic strategies. A square represents a
decision node. A circle represents a chance node. A triangle represents a terminal node.
Several events can occur with corresponding probabilities and outcomes under each
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2

The decision tree framework for PE diagnostic strategies is based upon the decision tree
framework as described by Lapin and Whisler (2002).

17
Pulmonary Embolism Diagnostic Tools
A review of the literature was conducted to identify diagnostic tools for PE
screening currently in use. Identified diagnostic tools included clinical decision rules, Ddimer tests, and imaging tests such as computed tomography pulmonary angiography
(CT), ultrasonography (CUS), ventilation-perfusion lung scan (VQ) and invasive
pulmonary angiography (PA). This review highlights CDR scoring systems as well as Ddimer and imaging test sensitivity and specificity values to detect PE in patients with
suspected PE.
In this study, sensitivity was defined as the percentage of patients with PE who
obtained a positive test result. Conversely, specificity was defined as the percentage of
patients without PE who obtained a negative test result. Additionally, five sensitivity and
specificity levels were established: very low with a value of less than 60%, low with a
value between 60 and 79.99%, moderate with a value between 80 and 89.99%, high with
a value between 90 and 95.99%, and very high with a value between 96 and 100%. A test
with very high sensitivity/low specificity or low sensitivity/very high specificity values
was considered a poorly performing test. Only a test demonstrating both very high
sensitivity and very high specificity values was considered an excellent test.
Clinical decision rules.
Historically, PE detection has been empirically based upon the patient's medical
history and a physical examination. However, during the past decade several clinical
decision rules (CDRs) have been introduced that use a scoring system, which measures
the pretest probability of PE with certain clinical variables (Klok et al., 2008). In
particular, during the past decade, seven CDRs for PE detection currently in use have
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been identified and discussed in the literature: (a) the extended Wells CDR (Wells et al.,
2000); (b) the simplified Wells CDR (Gibson et al., 2008); (c) the original Geneva CDR
(Wicki et al., 2001); (d) the revised Geneva CDR (Le Gal et al., 2006); (e) the Pisa CDR
(Miniati et al., 2003); (f) the Pennsylvania CDR (Aujesky et al 2005); and (g) the
Charlotte CDR (Kline et al., 2002). A brief presentation of each CDR follows.
Extended and simplified Wells CDRs. The extended Wells CDR and the
simplified Wells CDR are Canadian clinical models (Gibson, Sonne, et al., 2008; Wells
et al., 2000) based upon standardized scores, the maximum of which are 12.5 and 7,
respectively. Wells CDRs include the following seven clinical variables: clinical signs
and symptoms of DVT, heart rate higher than 100 beats per minute, immobilization or
surgery in the past four weeks, previous PE or DVT episode, hemoptysis, cancer, and an
alternative diagnosis is less likely than a PE diagnosis. There are two main differences
between the extended and simplified Wells CDRs. First, in the extended CDR, a score of
3 is assigned for two variables; a score of 1.5 is assigned for three variables; and a score
of 1 is assigned for two variables resulting in a maximum score of 12.5. In the simplified
CDR, the same score of 1 is assigned to all seven variables resulting in a maximum score
of 7. Second, PE is considered unlikely if the total score is 4 or less in the extended CDR
and 1 or less in the simplified CDR. In the extended Wells CDR, a total score of less than
2 represents a low clinical probability of PE, while a score between 2 and 6 signifies a
moderate clinical probability of PE, and a score greater than 6 indicates a high clinical
probability of PE.
Original and revised Geneva CDRs. The original Geneva CDR is a clinical
model based upon a scoring system of clinical variables combined with an arterial blood
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gas analysis, while the revised Geneva CDR is a scoring system with clinical variables
without a blood gas analysis (Le Gal, Righini, Roy, et al., 2006; Wicki et al., 2001). The
level of probability for PE in the original Geneva CDR is based upon a total score
achieved by combining scores assigned to clinical variables and blood gas analysis. A
score of 0 to 4 indicates a low clinical probability of PE; a score of 5 to 8 signified a
moderate clinical probability of PE; and a score of 9 or higher represents a high clinical
probability of PE (Wicki, Perneger, Junod, Bounameaux, & Perrier, 2001). Similarly, in
the revised Geneva CDR, a score of 0 to 3 indicates a low clinical probability of PE; a
score of 4 to 10 represents a moderate clinical probability of PE; and a score of 11 or
higher denotes a high clinical probability of PE (Le Gal, Righini, Roy, et al., 2006).
Clinical probability levels for PE for the extended Wells, simplified Wells, original
Geneva, and revised Geneva CDRs are presented in Table 1.

Table 1
Clinical Probability Levels for PE of the Wells and Geneva CDR Scoring Systems
Clinical Probability Levels for PE

Study

Low, moderate, high

Unlikely, Likely

First Author & Year

Extended Wells CDR

Extended Wells CDR

Wells, 2000

Simplified Wells CDR

Simplified Wells CDR

Gibson, 2008

Original Geneva CDR

Wicki, 2001

Revised Geneva CDR

Le Gal, 2006

Note. PE = pulmonary embolism; CDR = clinical decision rule.

Pisa, Pennsylvania, and Charlotte CDRs. In 2003, Miniati, Monti, and Bottai
proposed a clinical model to predict PE (Pisa CDR) that included 10 variables associated
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with a high risk of PE and five variables associated with a low risk of PE (Miniati, Monti,
& Bottai, 2003). High-risk indicators include, but are not limited to, male gender, older
age, sudden-onset dyspnea, chest pain, and hemoptysis. According to the Pisa CDR, the
clinical probability of PE is classified into four distinct categories: low (score of less than
or equal to 10%), intermediate (score of greater than 10% to less than or equal to 50%),
moderate (score of greater than 50% to less than or equal to 90%), and high (score of
greater than 90%). The implementation of this model demonstrated excellent accuracy in
predicting PE, specifically, the classification into the high-risk group of 28% of the
patients, 98% of whom were accurately diagnosed with PE. Although the Pisa CDR
revealed excellent results, it has the major disadvantage of difficult implementation
(Miniati et al., 2003; Stein, 2007b).
In 2005, Aujesky and colleagues conducted an analysis of 15,531 hospital
discharges of PE patients from 186 Pennsylvania hospitals that used a PE diagnosis CDR
of 11 variables, which categorized patients into five risk classes (Aujesky et al., 2005).
According to this CDR, a score of less than or equal to 65 indicates very low risk (Class
I); a score of 66 to 85 inclusive suggests low risk (Class II); a score of 86 to 105 inclusive
denotes intermediate risk (Class III); a score of 106 to 125 inclusive signifies high risk
(Class IV); and a score above 125 represents very high risk (Class V). In a follow-up
study, the researchers concluded that this CDR is useful in identifying low-risk patients
with PE (Aujesky et al., 2006).
The Charlotte CDR proposed by Kline and colleagues (2002) is a flow protocol to
rule out PE based upon specific criteria in combination with the use of a D-dimer test
(Kline, Nelson, Jackson, & Courtney, 2002). The criteria include (a) suspicion for PE; (b)
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the shock index (heart rate divided by systolic blood pressure) greater than 1 or the
patient age is greater than 50; (c) non-smoker, no asthma, no COPD, or unexplained
hypoxemia (Sa0 2 less than 95%); (d) unilateral leg swelling; (e) recent surgery; and (f)
hemoptysis (Kline et al., 2002; Kline & Wells, 2003). Although accurate, the Charlotte
CDR is disadvantaged by the complexity of its variables, scoring, classifications, and its
D-dimer test requirement (Kline et al., 2002; Kline, Webb, Jones, & Hernandez-Nino,
2004; Kline & Wells, 2003; Runyon, Webb, Jones, & Kline, 2005).
D-dimer tests.
There are several types of D-dimer tests (DD) available, including (a) enzyme
linked immuno-sorbent assay (ELISA), (b) ELISA rapid quantitative, (c) ELISA rapid
semi-quantitative, (d) latex quantitative agglutination assay, (e) latex semi-quantitative
agglutination assay, (f) whole-blood agglutination assay, and (g) simplify D-dimer assay.
The time-to-results for these tests are approximately 8 hours, 35 minutes, less than 10
minutes, 7 to 15 minutes, 3 to 4 minutes, 2 minutes, and about 10 minutes, respectively
(Bruinstroop, van de Ree, & Huisman, 2009; De Moerloose et al., 2008; Di Nisio et al.,
2007; Ghanima & Sandset, 2007; Hogg et al., 2005; Kline et al., 2006; Parent et al.,
2007; Stein, 2007a; Than et al., 2009; Toulon et al., 2009; van Belle et al., 2006).
Although D-dimer tests have been used since the 1980s, their contribution to PE
diagnosis is controversial, particularly regarding their sensitivity and specificity values. A
negative D-dimer test for patients with either low or moderate clinical probability of PE
safely rules out PE, while a positive D-dimer test is nonspecific (Stein, 2007a).
The sensitivity and specificity levels of several D-dimer assays derived from
studies published between 2004 and 2009 are presented in Table 2.
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Table 2
Sensitivity and Specificity Levels of D-dimer Assays
D-dimer Assay

Sensitivity Level

Specificity Level

Study
First Author & Year

ELISA

H

VL

Stein, 2004

standard

H

VL

Di Nisio, 2007

VH

VL

Than, 2009

ELISA rapid

H

VL

Stein, 2004

quantitative

VH

VL

Parent, 2007

ELISA rapid

H

VL

Stein, 2004

Latex

M

VL

Stein, 2004

Quantitative

VH

VL

Di Nisio, 2007

VH

VL

Than, 2009

Latex

H

VL

Stein, 2004

semi-quantitative

M

L

Di Nisio, 2007

Simplify

M

L

Hogg, 2005

M

L

Kline, 2006

VH

VL

Toulon, 2009

VH

VL

Ghanima, 2007

VH

VL

De Moerloose, 2008

VH

VL

Toulon, 2009

VH

VL

Ghanima, 2007

VH

VL

Toulon, 2009

semi-quantitative

VIDAS

STA-Liatest

Note. ELISA = enzyme linked immuno-sorbent assay; Simplify = whole-blood agglutination D-dimer
assay; VIDAS = rapid quantitative ELISA D-dimer assay; STA-Liatest = Diagnostica Stago Liatest latex
rapid quantitative agglutination D-dimer assay. M = moderate sensitivity level with a value between 80 and
89.99%; H = high sensitivity level with a value between 90 and 95.99%; VH = very high sensitivity level
with a value between 96 and 100%; VL= very low specificity level with a value less than 60%; L = low
specificity level with a value between 60 and 79.99%.
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Computed tomography pulmonary angiography.
Computed tomography pulmonary angiography (CT) is a combination of X-ray
and computer images providing cross-sectional views of organs and tissues of a patient
(Brenner et al., 2007; Odle, 2006). "In helical CT, which is commonly used for body
scans, the table moves continuously as the x-ray source and detectors rotate, producing a
spiral or helical scan" (Brenner et al., 2007, p. 2279). CT scanning systems currently in
use are single or multiple-row (also called multiple-slice) systems.
Early in the 1990s, the noninvasive and quick CT emerged with great potential for
PE detection. Since then, as the number and speed of CT detectors have increased and the
sensitivity and specificity values have improved, CT has become the imaging technique
of choice for PE diagnosis (Perrier et al., 2005). Several systematic reviews have
collectively chronicled the technological improvements in CT (Eng et al., 2004; Rathbun,
Whitsett, Vesely, & Raskob, 2004; Roy et al., 2005; van Beek, Brouwers, Bing,
Bongaerts, & Oudkerk, 2001; Van Rossum et al., 1996). In 2002, a sensitivity of 91%
and a specificity of 94% were reported for CT (Nilsson et al., 2002).
According to reviews and meta-analyses published between 2000 and 2006, CT
demonstrated summary sensitivities ranging from 79 to 89% and summary specificities
ranging from 89 to 95% (Cueto, Cavanaugh, Benenson, & Redclift, 2001; Harvey,
Gefter, Hrung, & Langlotz, 2000; Hayashino, Goto, Noguchi, & Fukui, 2005; Hogg,
Brown, et al., 2006; van Beek et al., 2001). The investigators in the large PIOPED II
study, which used 4-, 8-, and 16-multidetector-row CT scanners, reported a sensitivity of
83%> and a specificity of 96% for PE (Stein, Fowler, et al., 2006). In 2009, Wang and
colleagues established a sensitivity of 91.7% and a specificity of 100% with 16- or 64-
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multidetector-row CT for PE (Wang et al., 2009). CT is an adequate test and is
considered by several researchers as the new, diagnostic gold standard for PE detection,
despite the challenges of detecting pulmonary embolisms at the small vessel level, a
common hurdle for all PE diagnostic tests (Goodman & van Beek, 2009; Mos et al.,
2009; Quiroz et al., 2005).
Compression ultrasonography.
Compression ultrasonography (CUS) is an imaging test appropriate for PE
detection. Its diagnostic validity is based upon the lack of compressibility of a venous
segment. There are three CUS techniques: (a) segmental compression CUS of the
common femoral and popliteal veins; (b) extended compression CUS of the complete
deep thigh and popliteal veins; and (c) complete compression CUS of all segments of the
deep thigh and calf veins (Beyer et al., 2007).
CUS of the veins in the lower limbs is usually performed following a D-dimer test
or a VQ lung scan to detect indirectly PE in patients with suspected PE. The CUS is
performed because PE and DVT in a lower limb (i.e., leg) are considered conditions
related to the same disease, and DVT is present in about 30% of all patients with PE
(Elias et al., 2005; Elias, Colombier, et al., 2004; Galle et al., 2001; Kalva, Jagannathan,
Hahn, & Wicky, 2008; Kearon & Ginsberg, 1998; Le Gal, Righini, Sanchez, et al., 2006;
Michiels et al, 2005; Paterson & Schwartzman, 2001; Perrier, 2007; Perrier et al., 2003;
Perrier et al., 2004; Quiroz et al., 2005; Righini et al., 2008; Righini et al., 2009; Turkstra
etal., 1997).
CUS sensitivity levels have been reported as low as 50% with a range of 30 to
60% and a specificity of 95 to 100% (Perrier, 2007; Perrier et al., 2003) to as high as
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82.4% with a range of 50 to 90% and a specificity of 86 to 100% (Paterson &
Schwartzman, 2001). A sensitivity of 93% and a specificity of 84% were reported for a
CUS of proximal and distal veins to detect PE (Elias, Colombier, et al., 2004). In 2006,
Le Gal and colleagues determined a sensitivity of 39% and a specificity of 99% for CUS
investigating the presence of PE (Le Gal, Righini, Sanchez, et al., 2006). More recently,
Righini and colleagues revealed a poor sensitivity of 22% and a high specificity of 94%
for CUS in PE detection (Righini et al., 2009).
Although studies of CUS sensitivity and specificity have indicated variability
within those two determinants, CUS presents some advantages for PE detection (Elias et
al., 2005; Galle et al., 2001; Michiels et al., 2005; Perrier et al., 2004; PIOPED
Investigators, 1990; Quiroz et al., 2005). First, CUS is useful as a diagnostic tool
subsequent to a nondiagnostic VQ lung scan or nondiagnostic CT (PIOPED Investigators,
1990). For instance, a positive CUS subsequent to a nondiagnostic VQ lung scan can
confirm PE (PIOPED Investigators, 1990). Also, the combination of a negative CUS and
a negative CT can rule out PE (Elias et al., 2005; Perrier et al., 2004; Quiroz et al., 2005).
Second, CUS can help reduce the total number of patients requiring additional imaging
tests (Elias et al., 2005; Michiels et al., 2005; Perrier et al., 2004; Quiroz et al., 2005).
Third, an advantage of its ease of use, practicality, and accessibility is its application as a
bedside test with intensive care patients (Galle et al., 2001).
Ventilation-perfusion lung scan.
A ventilation-perfusion lung scan (VQ) comprises two imaging procedures:
perfusion and ventilation. Perfusion evaluates the blood flow in the lungs, and ventilation
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assesses the air space distribution in the lungs (Dutton et al., 2009). There are two main
VQ techniques in use, the traditional PLANAR VQ and the SPECT VQ.
During the 1980s and 1990s, VQ lung scan was the dominant diagnostic tool for
suspected PE (see Bajc & Jonson, 2009; Bajc et al., 2009a; Bajc, Olsson, Olsson, Palmer,
& Jonson, 2004; Cook & Kyriou, 2005; De Geeter, Reinartz, & Buell, 2005; Douma,
Kamphuisen, Rijnders, Ten Wolde, & Biiller, 2009; Einstein, Henzlova, & Rajagopalan,
2007; Freeman & Haramati, 2009; Freeman, Stein, Sprayregen, Chamarthy, & Haramati,
2008; Gutte et al., 2010; Gutte et al., 2009; Hull, Raskob, Coates, & Panju, 1990; Itti et
al., 2002; Meignan, 2002; Parker et al., 2005; Perrier, 2007; Reinartz et al., 2004; Roach,
Thomas, Bajc, & Jonson, 2008; Scarsbrook, Bradley, & Gleeson, 2007; Sostman,
Miniati, et al., 2008; Sostman, Stein, et al., 2008; Stein et al., 2009; Stein, Kayali, &
Olson, 2004b; Stein, Woodard, et al., 2006; Uren, 2009; Zophel, Bacher-Stier, Pinkert, &
Kropp, 2009). However, after the publication of the PIOPED I (Prospective Investigation
of Pulmonary Embolism Diagnosis I) in 1990, a controversy ignited about the accuracy
of the VQ lung scan due to low sensitivity and substantial numbers of nondiagnostic
results.
This controversy continued after the publication of the PIOPED II (Prospective
Investigation of Pulmonary Embolism Diagnosis II) in 1996, and although significant
improvements were made in the interpretation of VQ lung scans, this controversy
continues (Bajc et al., 2004; De Geeter et al., 2005; Douma, Kamphuisen, et al., 2009;
Freeman et al., 2008; Gutte et al., 2010; Meignan, 2002; Perrier, 2007; Reinartz et al.,
2004; Roach et al., 2008; Sostman, Stein, et al., 2008; Stein et al., 2009; Uren, 2009).
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A high-probability VQ lung scan indicates the presence of PE; normal- or lowprobability results indicate the absence of PE. Using the results of the PIOPED I study,
Perrier (2007) reported a sensitivity of 99% for normal-probability VQ lung scans and a
specificity of 91% for high-probability VQ lung scans for PE. From the PIOPED II study
results, Sostman, Stein, and colleagues (2008) reported a sensitivity of 77.4% for highprobability VQ lung scans and a specificity of 97.7% for normal- or low-probability VQ
lung scans. None of the VQ lung scans was nondiagnostic.
Comparisons of the tomographic ventilation-perfusion lung imaging (SPECT VQ)
to traditional planar ventilation-perfusion lung imaging (Planar VQ) indicated that the
SPECT VQ is a more accurate tool for diagnosing PE (Bajc et al., 2004; De Geeter et al.,
2005; Douma, Kamphuisen, et al., 2009; Freeman et al., 2008; Gutte et al., 2010;
Meignan, 2002; Perrier, 2007; Reinartz et al., 2004; Roach et al., 2008; Sostman, Stein, et
al., 2008; Stein et al., 2009; Uren, 2009). In 2004, greater sensitivity and specificity for
the SPECT VQ than for the Planar VQ in PE detection were reported (Bajc et al., 2004;
Reinartz et al., 2004). More recently, it was corroborated that the SPECT VQ had a
greater sensitivity (100%) and specificity (87%) than did the Planar VQ (64% and 72%,
respectively) (Gutte et al., 2010).
Invasive pulmonary angiography.
Invasive pulmonary angiography (PA) is the most accurate procedure for
diagnosing PE and served as the diagnostic gold standard for many decades. It has a very
high sensitivity of 96% and a very high specificity of 97%, but it is no longer widely used
by physicians because of its expense and, more importantly, its invasiveness, which has
associated risks with complications at a rate of 1 to 5% and mortality at a rate of up to
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0.5%, inclusive (Hudson et al., 1996; Paterson & Schwartzman, 2001; Perrier, 2007;
PIOPED Investigators, 1990; Stein et al., 1992; van Loveren, van Beek, & Oudkerk,
2009).
PA complications during the 1960s, 1970s, and 1980s occurred at an average rate
of 2.1%) (see Mills, Jackson, Older, Heaston, & Moore, 1980; Nilsson, Carlsson, & Mare,
1998; Oudkerk et al., 2002; van Beek, Brouwers, Song, Stein, & Oudkerk, 2001; van
Loveren et al., 2009). Complication rates dropped in the 1990s to an average of 0.62%,
due to technological advances such as the development of a safer catheter and rapid
imaging equipment improvements (see Hudson et al., 1996; Nilsson et al., 1998; Stein et
al., 1992; Stein, Sostman, et al., 2008; van Beek, Reekers, Batchelor, Brandjes, & Biiller,
1996; van Loveren et al., 2009). Currently, non-fatal complication rates have dropped as
low as 0.3 to 0.5%) and as low as 0.03% for fatal complications (see Nilsson et al., 1998;
Stein, Sostman, et al., 2008; van Loveren et al., 2009).
Today, PA remains important as the final diagnostic tool for specific categories of
patients with suspected PE for whom noninvasive methods produce nondiagnostic results
or for whom interventions are under consideration (see Hudson et al., 1996; Paterson &
Schwartzman, 2001; Perrier, 2007; PIOPED Investigators, 1990; Qanadli et al., 2000;
Stein et al., 1992; van Loveren et al., 2009; Winer-Muram et al., 2004).
Pulmonary Embolism Diagnostic Strategies
Various PE diagnostic strategies that combine the diagnostic components of CDR,
DD, CT, VQ, CUS, and/or PA were identified in the literature. Each of the PE diagnostic
strategies identified in this review includes a CDR as well as a DD. Each strategy was
identified either as independent or as a branch of a strategy that could be subsumed into
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one of five categories. The composition of the 14 identified diagnostic strategies is
presented in Table 3.

Table 3
Composition ofPE Diagnostic Strategies
Category

Strategy

Clinical
Assessment

Imaging Tests
First

Second

Third

I

1

CDR, DD

II

2

CDR, DD

CT

3

CDR, DD

PA

4

CDR, DD

CT

CUS

5

CDR, DD

CT

CUS

VQ

6

CDR, DD

CT

CUS

PA

7

CDR, DD

CUS

CT

8

CDR, DD

CUS

PA

9

CDR, DD

CUS

CT

PA

10

CDR, DD

CUS

VQ

PA

11

CDR, DD

VQ

CUS

12

CDR, DD

VQ

CUS

CT

13

CDR, DD

VQ

CUS

PA

14

CDR, DD

VQ

CT

PA

III

IV

V

Note. PE = pulmonary embolism; CDR = clinical decision rule; DD = D-dimer test; CT = computed
tomography pulmonary angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion
lung scan; PA = invasive pulmonary angiography.
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Clinical decision rule and D-dimer test.
Strategy 1 comprises a combination of the clinical decision rule (CDR) and the Ddimer test (DD) as components for assessing pulmonary embolism in patients. Patients
are evaluated first with a CDR followed by a DD. Studies suggest that PE can be safely
ruled out in patients with a low clinical probability of PE and a negative DD, which is the
outcome in 24 to 47% of the patients with suspected PE. Patients with a moderate or high
clinical probability of PE and a positive DD usually undergo further diagnostic tests (see
Carrier et al., 2009; Corwin, Donohoo, Partridge, Egglin, & Mayo-Smith, 2009; Djurabi
et al., 2009; Gibson, Sohne, Gerdes, et al., 2008; Gupta, Kakarla, Kirshenbaum, &
Tapson, 2009; Hammond & Hassan, 2005; Kabrhel et al., 2009; Kearon et al., 2006;
Kruip, Slob, Schijen, van der Heul, & Biiller, 2002; Pasha et al., 2009; Perrier et al.,
2005; Righini et al., 2006; Rodger et al., 2006; Segal, Eng, Tamariz, & Bass, 2007;
Soderberg, Brohult, Jorfeldt, & Larfars, 2009; Stein, Hull, et al., 2004; Teismann,
Cheung, & Frazee, 2009; van Belle et al., 2006; Wells et al., 2000; Wells et al., 2001).
There are concerns regarding the accuracy of this diagnostic strategy for the
elderly, mostly because DD levels increase with age (Righini, Goehring, Bounameaux, &
Perrier, 2000). There are also concerns regarding its accuracy with pregnant women
because DD levels are higher in pregnancy and overlap the normal values of the test for
PE diagnosis (Damodaram, Kaladindi, Luckit, & Yoong, 2009). However, pregnant
women with suspected PE undergo additional testing such as a ventilation-perfusion
(VQ) lung scan or CT with the former being conducted more frequently than the latter
(Cahill, Stout, Macones, & Bhalla, 2009).
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A summary of the percentages of patients for whom PE was excluded by a low or
intermediate clinical probability or PE unlikely CDR and a negative DD by study are
presented in Table 4.

Table 4
Percentages of Patients Excluded by CDR and DD Combined by Study
Study
First Author

CDR Probability Level

D-dimer

% Patients with PE

forPE

Results

Excluded by

&Year

CDR & DD

Wells, 2001

Low

N

47.0

Kruip, 2002

Low

N

25.6

Perrier, 2005

Low/Intermediate

N

30.7

Hammond, 2005

Low

N

24.2

Righini, 2006

Low

N

31.8

Kearon, 2006

Low

N

32.6

van Belle, 2006

Unlikely

N

31.0

Gibson, 2008

Unlikely

N

27.7

Soderberg, 2009

Low

N

42.0

Kabrhel, 2009

Low

N

25.3

Corwin, 2009

Low

N

42.8

Djurabi, 2009

Unlikely

N

46.6

Low/Intermediate

N

27.4

Not Reported

N

41.4

Carrier, 2009

Low/Intermediate/Unlikely

N

40.0

Pasha, 2009

Unlikely

N

33.8

Gupta, 2009
Teismann, 2009

Note. PE = pulmonary embolism; CDR = clinical decision rule; DD = D-dimer test; N = negative.
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Clinical decision rule, D-dimer test, and computed tomography pulmonary
angiography or invasive pulmonary angiography.
The CT and the PA are used in PE diagnostic strategies as the only imaging tests
following a CDR and a DD in Strategy 2 and Strategy 3. The components of Strategy 2
include the CDR, the DD, and a CT as the only imaging test (Anderson et al., 2007; Eng,
Wansaicheong, Goh, Earnest, & Sum, 2009; Ghanima et al., 2005; Ghaye &
Dondelinger, 2008; Huisman & Klok, 2009; Kamphuisen & Agnelli, 2005; Nijkeuter et
al., 2007; Perrier et al., 2005; Righini et al., 2008; Sohns, Amarteifio, Sossalla, Heuser, &
Obenauer, 2008; Stein, Woodard, et al., 2006; van Belle et al., 2006).
The use of single or multidetector-row CT following the evaluation of a CDR and
a DD was strongly indicated by several researchers who suggested that there is not
enough evidence to withhold anticoagulation treatment from a patient after only a
negative CT without involving a CDR and/or a DD (Anderson et al., 2007; British
Thoracic Society, 2003; Eng et al., 2009; Ghanima et al., 2005; Ghaye & Dondelinger,
2008; Hogg, Brown, et al., 2006; Huisman & Klok, 2009; Kamphuisen & Agnelli, 2005;
Kruip, Leclercq, Heul, Prins, & Biiller, 2003; Musset et al., 2002; Nijkeuter et al., 2007;
Nijkeuter, Ginsberg, & Huisman, 2006; Perrier et al., 2005; Rathbun et al., 2004; Righini
et al., 2008; Schoepf, Goldhaber, & Costello, 2004; Sohns et al., 2008; Stein, Woodard,
et al., 2006; Trowbridge, Araoz, Gotway, Bailey, & Auerbach, 2004; van Belle et al.,
2006; Wells, 2007).
In the Christopher study (see van Belle et al., 2006), 3,306 patients with suspected
PE were examined. Upon examination, 2,206 patients were classified with a PE unlikely
CDR. Of those, 1,057 obtained negative DD results and 1,149 obtained positive DD
results. DDs were not performed for the other 1,100 patients who were classified with a
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PE likely CDR. In the same study, CTs were ordered for 2,249 of the 3,306 patients:
1,149 PE unlikely patients with positive DD results and the 1,100 PE likely patients. CTs
were not performed for the 1,057 patients with PE unlikely CDRs and negative results for
a DD assay. Of the 2,249 patients scheduled for either a single- or multidetector-row CT,
PE was confirmed in 674, ruled out in 1,505, and was inconclusive for 20. Fifty of the
scheduled CTs were not performed. The 3-month follow-up VTE rate was 1.3%> (van
Belle et al., 2006).
A 4-multidetector-row CT was used to diagnose 432 patients with suspected PE
who also were evaluated in conjunction with a DD and a CDR (Ghanima et al., 2005). PE
was ruled out in 103 patients with a negative DD and a low or intermediate clinical
probability of PE. Among the 329 patients with a positive DD, the CT confirmed PE in
93, ruled out PE in 221, and was inconclusive for 15.
The combination of a CDR, a DD, and a CT was investigated in a study of 408
patients with suspected PE (Hogg, Dawson, et al., 2006). Among the 403 patients who
completed follow-up, PE was detected in 22 patients and excluded in 381 patients, with a
3-month follow-up VTE rate of 0.8%. Nijkeuter and colleagues (2007) evaluated the
combination CDR, DD, and CT in a study of inpatients and outpatients with suspected
PE. Among the 190 patients who were indicated as having a previous PE episode, likely
clinical probability of PE, and/or a positive DD, results from CTs excluded recurrent PE
in 127 and confirmed recurrent PE in 63 of these patients, with a 3-month follow-up VTE
rate of 0.8%>, indicating that this combination safely ruled out PE in patients with a
history of PE.
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From a population of 1,693 patients with suspected PE, Righini and colleagues
(2008) evaluated the combination of a CDR, a DD, and a CT using a randomly selected
sample of 815 patients. The CT confirmed PE in 160 and excluded PE in 361 of the
sample patients with a PE low or intermediate CDR and a positive DD. The CT was
inconclusive for 14 patients. PE was excluded in 280 sample patients who obtained a
negative DD and a PE low or intermediate CDR.
Results from 200 patients with suspected PE who were tested using the
combination of a CDR, a DD, and a 64-multidetector-row CT were analyzed. Each of the
200 patients was assessed with a high clinical probability of PE. Each achieved positive
results from a DD. Then, each patient underwent a 64-multidetector-row CT. PE was
confirmed in 60 patients; PE was ruled out for 140 patients. It was determined that the
64-multidetector-row CT has an increased ability to detect conditions that mimic PE,
including pneumonia, pneumothorax, and cardiovascular diseases. A total of 120
incidental findings of these conditions were reported (Sohns et al., 2008).
A follow-up of 219 cases of patients with suspected PE revealed that the
multidetector-row CT confirmed PE in 42 patients with high clinical probability of PE
and a positive DD. Results from this CT ruled out PE in 177 patients, including 49 who
had a negative DD (Eng et al., 2009).
An examination of the findings for 5,344 cases of emergency department patients
was conducted in 2009 by Corwin and associates. They evaluated the results from the
combination of a CDR, a DD, and a CT that used a 4- or 16-detector-row CT. PE was
ruled out in 4,580 patients, and of those, 3,091 obtained a PE low CDR in combination
with DD and CT tests, while 1,489 obtained a PE high CDR and a negative CT without a
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DD test. Of the remaining 764 cases, PE was confirmed in 159 patients. Of those, 20
obtained a PE low CDR in combination with DD and CT tests and 139 obtained a PE
high CDR with a positive CT without a DD test. CTs were not performed in 605 patients
who obtained a PE low CDR with positive DD and discharged for diagnoses other than
PE (Corwin et al., 2009).
Strategy 3 combines the testing components of a CDR, a DD, and a PA as the sole
imaging test (Soderberg et al., 2009; van Beek et al., 2001; Winer-Muram et al., 2004).
Using the combination of a CDR, a DD, and PA to determine PE in patients with
suspected PE was evaluated in a study of 120 outpatients. PA confirmed PE in 34
(28.3%) of the outpatients (Soderberg et al., 2009). Winer-Muram and colleagues (2004)
ascertained that the combination of CDR and PA ruled out PE in 75 (80.6%) and
confirmed PE in 18 (19.4%) of the 93 patients. Conversely, with the same patients, the
combination of CDR and a 4-multidetector-row CT ruled out PE in 67 (72%>) and
confirmed PE in 26 (28%) of them; the use of DD was unspecified in this study (WinerMuram et al., 2004). A review of eight studies conducted between 1978 and 1999
investigating the validity of PA in patients with suspected PE revealed that the test ruled
out PE in 1,050 patients and that the recurrence rate was 1.7% (see van Beek et al., 2001).
The use of CDR and DD was unspecified in this review.
Clinical decision rule, D-dimer test, computed tomography pulmonary
angiography, and other imaging tests.
The CT has been used in several PE diagnostic strategies as the first imaging test
that follows a CDR and a DD. This sequence of diagnostic components is used in
Strategies 4, 5, and 6.
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Strategy 4 comprises the following sequence of diagnostic components: CDR, a
DD, a CT as the first imaging test, and a CUS. In a cohort study of 858 patients with
suspected PE, Anderson and colleagues used a CDR, a DD, a CT, and a CUS sequence to
diagnose PE. The main results of this study follows (Anderson et al., 2005). PE was ruled
out in 469 and confirmed in 10 patients who obtained a PE low CDR in combination with
DD, CT, and CUS tests. PE was ruled out in 280 and confirmed in 44 patients who
obtained a PE moderate CDR in combination with DD, CT, and CUS tests. PE was ruled
out in 29 and confirmed in 26 patients who obtained a PE high CDR in combination with
DD, CT and CUS tests.
The sequence of diagnostic components that comprise Strategy 5 is the CDR, the
DD, a CT, a CUS, and a VQ lung scan. The CT remains the first imaging test performed
with patients with suspected PE. Perrier and colleagues (2005) evaluated Strategy 5 in a
study of 674 patients in which 193 PE cases were detected by a CT, CUS, or VQ lung
scan: 187 by a multidetector-row CT, 4 by a CUS, and 2 by a VQ lung scan (Perrier et
al., 2005).
The CT is also the first imaging test used in Strategy 6. The diagnostic
components sequence of this strategy begins with a CDR followed by the DD, a CT, a
CUS, and a PA. Perrier and colleagues (2005) used Strategy 6 to confirm PE in patients
with a high clinical probability of PE. They were evaluated with a CDR and experienced
a testing battery (DD, a multidetector-row CT, and CUS) followed by a PA. PE was
confirmed in 82 patients by the CT and ruled out by PA for 3 patients. No VTE episodes
occurred during the 3-month follow-up among patients for whom PE was excluded.

37

Clinical decision rule, D-dimer test, compression ultrasonography, and other
imaging tests.
The CUS is used in four PE diagnostic strategies as the first imaging test
following a CDR and a DD: Strategies 7, 8, 9, and 10. In Strategy 7 (CDR, DD, CUS,
and CT), the CUS precedes the CT. It is important to note that CUS is used to detect
DVT, and it can indirectly detect PE in patients with suspected PE because DVT is
present in about 30% of the patients with PE (Righini et al., 2008).
Michiels and colleagues (2005) noted that the combination of a moderate or high
clinical probability of PE, a positive DD, and a positive CUS detect DVT in 20 to 25% of
patients. Michiels et al. (2005) also asserted that the use of CDR, a DD, and a CUS could
reduce the need for CTs by 40 to 50%. The combination of CDR, a DD, and CUS was
investigated by Elias and colleagues (2005) in a study of 274 patients with suspected PE
(Elias et al., 2005). PE was ruled out in 165 patients and confirmed in 109 patients. CUSs
were performed on all 274 patients: 102 were positive (i.e., PE diagnosis confirmation)
and 64 were negative (i.e., PE excluded). The other 108 were followed by a CT,
indicating a potential reduction of 166 (60.6%) additional imaging tests.
In a study of 828 patients with suspected PE, Righini and colleagues (2008)
investigated the combination of CDR, a DD, and a CUS. PE was ruled out for 660
patients, confirmed for 150 patients, and inconclusive for 18 patients with an overall 3month follow-up risk of developing VTE of 0.3% (Righini et al., 2008). Of the 547 CUS
tests performed, 38 were positive (i.e., PE diagnosis confirmation), 397 were negative
(i.e., PE excluded), and 112 were false negative, indicating a potential reduction of 435
(52.5%) additional imaging tests. Perrier and colleagues (1999) investigated the
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combination of CDR, a DD, CUS, and VQ lung scans with 918 patients and found that
CUS reduced the need for VQ lung scans in 393 (42.8%) of the patients.
In Strategy 8 (CDR, DD, CUS, and PA), the first imaging test in the diagnostic
tool sequence is the CUS. If necessary, then it is followed by a PA. The use of CUS was
evaluated in an investigation of the combination of a CDR, a DD, CUS, and PA in 234
patients with suspected PE. PE was ruled out in 182 patients and confirmed in 52 patients
with a 3-month follow-up VTE risk for the entire strategy of 1%. Of the 174 CUSs
performed, 27 were positive (i.e., PE confirmation) and 122 were negative (i.e., PE
excluded), with 25 being false negatives, indicating a potential reduction of 149 (63.7%)
additional imaging tests (Kruip et al., 2002). Reducing the need for additional imaging
tests with the use of CUS as indicated by Strategies 7 and 8 is presented in Table 5.

Table 5
Percent Reduction in Use of Additional Imaging Tests Following a CUS
Study

Patient Category

First Author & Year

% Reduction in Use of Additional
Imaging Tests Following CUS

Perrier, 1999

Outpatient

42^8

Kruip, 2002

Outpatient and Inpatient

63.7

Elias, 2005

Outpatient

60.6

Righini, 2008

Outpatient

52.5

Note. CUS = compression ultrasonography.

In Strategy 9, the CDR, DD, and CUS are followed by a CT and a PA. This
strategy was evaluated by Perrier and colleagues (2004) in a study that included 965
patients with suspected PE. Of those 965, 685 patients obtained positive DDs (Perrier et

39
al., 2004). Among those patients, DVT was excluded by CUS in 593 and confirmed in
92. A subsequent CT (of the 593 patients in which DVT was excluded by CUS) excluded
PE in 450 patients with low or intermediate clinical probability of PE, confirmed PE in
124 patients, and was nondiagnostic in 11 patients. Among the eight patients who were
assessed as having a high clinical probability of PE, PA excluded PE in six and
confirmed it in two individuals.
In Strategy 10 (CDR, DD, CUS, VQ lung scan, and PA), the first imaging test in
the diagnostic tool sequence is a CUS, followed by a VQ lung scan and a PA, if
necessary. Perrier and colleagues (1999) evaluated this strategy with 918 patients. A DD
ruled out PE/DVT in 286 of the patients (Perrier et al., 1999). Of the 632 CUS performed,
393 ruled out PE/DVT, 2 confirmed DVT, and 237 were followed by a VQ lung scan. Of
the 237 VQ lung scans performed, 37 obtained normal-probability results (i.e., PE
excluded), 43 obtained high-probability results (i.e., PE diagnosis confirmation), and 157
were nondiagnostic. Of the 157 nondiagnostic VQ lung scans performed, 107 ruled out
PE in combination with a low probability for PE, a positive DD, and a negative CUS, and
the 50 VQ lung scans followed by a PA obtain negative results for 37 tests and positive
results for 13 of the PAs.
Clinical decision rule, D-dimer test, ventilation-perfusion lung scan, and
other imaging tests.
The ventilation-perfusion (VQ) lung scan has been used in the following PE
diagnostic strategies as the first imaging test after a CDR and a DD: Strategies 11, 12, 13,
and 14. In Strategy 11 (CDR, DD, VQ lung scan, and CUS), the imaging test sequence is
a VQ lung scan followed by a CUS. Patients may repeat CUS in one week if necessary
(Kearon et al., 2006; Perrier et al., 2000; Ten Wolde et al., 2004; Wells et al., 2001).

The performance of this strategy was evaluated in a randomized control trial
involving 712 patients. The use of VQ lung scans confirmed VTE in 75 patients, ruled
out VTE in 247 patients, and produced nondiagnostic readings in 386 patients. VQ lung
scans were not performed with four patients. The use of CUS following the nondiagnostic
VQ lung scans among the 386 patients resulted in 15 positive CUS (i.e., VTE diagnosis
confirmation), 360 negative CUS (i.e., VTE excluded), and 11 false negative CUS tests.
Also, CUS was repeated in one week for 78 patients obtaining negative results from the
first CUS test (Anderson et al., 2007).
This strategy was also evaluated by Kearon and colleagues (2006) using two
groups of randomly selected patients with suspected PE. Group 1 comprised 670 patients
with a low probability of PE, a negative or positive DD, and a VQ lung scan. Group 2
comprised 456 patients with a moderate or high clinical probability of PE and a VQ lung
scan. The VQ lung scan in 186 Group 1 patients (low clinical probability of PE and
negative DD) excluded PE in 97 patients and produced nondiagnostic VQ lung scans in
86 patients. Three VQ lung scans were not performed. Among the 456 Group 2 patients
(moderate or high clinical probability of PE, without performing a DD), 241 attained a
nondiagnostic VQ lung scan. A CUS confirmed PE in 15 of these patients and ruled out
PE for the remaining 226. A serial CUS was performed in 41 of the 226 patients with a
negative DD for whom PE was excluded. Results excluded PE in 40 patients.
Ten Wolde et al. (2004) examined this strategy through a study of 631 patients
with suspected PE. The use of serial CUS in 224 patients with moderate or high clinical
probability of PE, a positive DD, and a nondiagnostic VQ lung scan excluded PE in 210
patients and confirmed PE in 14 patients. Wells et al. (2001) used a cohort study
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composed of 930 patients with suspected PE to investigate Strategy 11. PE was excluded
in 437 patients with a PE low probability CDR and a negative DD; 471 patients
underwent a VQ lung scan. Among the remaining 22 patients, a DD was not performed
with 1 patient and 21 did not receive VQ lung scans. The use of VQ lung scans among
471 patients confirmed PE in 64 patients, ruled out PE in 183 patients, and produced
nondiagnostic readings in 224. This study also determined that of the ordered 173 CUSs,
which followed a nondiagnostic VQ lung scan combined or not combined with a DD, PE
was excluded for 148 patients and confirmed for one patient. Twenty-four (24) scheduled
CUSs were not performed. Perrier and colleagues (2000) assessed this strategy using the
results from 837 patients with suspected PE. Of the 180 patients with a low clinical
probability of PE and an inconclusive VQ lung scan, a follow-up CUS excluded PE in
175 (20.9%) and confirmed DVT in 5 (0.6%) of these patients. A 3-month follow-up
revealed a VTE rate of 1.7%. The probability levels for diagnosing PE with VQ lung
scans after a CDR and DD is presented in Table 6.

Table 6
Probability Levels of Diagnosing PE with VQ Lung Scan in Patients with Suspected PE
Study's

CDR Probability

D-dimer

VQLung Scan

First Author

Level

Test

% Probability of PE

and Year

Normal

High

Nondiagnostic

Ten Wolde, 2004

Moderate or High

Positive

30.2

18.6

51.2

Kearon, 2006

Moderate or High

Positive

21.5

25.1

53.4

Anderson, 2007

Moderate or High

Positive

34.9

10.6

54.5

Note. PE = pulmonary embolism; VQ = ventilation-perfusion lung scan; CDR = clinical decision rule.
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In Strategy 12 (CDR, DD, VQ lung scan, CUS, and CT), the VQ lung scan is the
first imaging test performed in this diagnostic tool sequence. If necessary, it is followed
by a CUS, then a CT. In a randomized control trial, Anderson et al. (2007) evaluated the
performance of Strategy 12 with 712 patients. The use of CT following a nondiagnostic
VQ lung scan and a positive CUS, confirmed PE in 6 additional patients and ruled out PE
in 17 patients.
In Strategy 13 (CDR, DD, VQ lung scan, CUS, and PA), the VQ lung scan is the
first imaging test performed in this diagnostic tool sequence. It is followed by a CUS,
then a PA, if necessary (Perrier et al., 1996; Quinn et al., 1994). In the Anderson and
colleagues (2007) study cited with strategy 12, a PA following the VQ lung scan-CUS
sequence and performed independently of the CT tests confirmed PE in 3 patients and
ruled out PE in 3 additional patients. Perrier and colleagues (1996) investigated this
strategy in 308 patients with suspected PE. VQ lung scan ruled out PE in 43 patients,
confirmed PE in 63 patients, and was nondiagnostic in 202 patients. The use of CUS
indicated no DVT in 77 patients and confirmed DVT in 22 patients with a nondiagnostic
VQ lung scan, a PE moderate CDR, and a positive DD. Among these 77 patients, testing
with a follow-up PA ruled out PE in 55 patients and confirmed PE in 22. The 6-month
follow-up VTE risk rate for the entire strategy was 1%.
An investigation of 36 patients with suspected PE indicated intermediateprobability VQ lung scan results for PE in all 36 patients. PE was confirmed by a followup CUS in 7 patients and by a follow-up PA in 15 patients (Quinn et al., 1994).
As in the previous three strategies, Strategy 14 (CDR, DD, VQ lung scan, and CT
or PA) incorporates a VQ lung scan as the first imaging test conducted on patients with
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suspected PE. It is followed by a CT or a PA. This strategy was suggested by Bajc and
colleagues (2009b) in the guidelines of the European Association of Nuclear Medicine.
Review of PE Diagnostic Strategy CEA Studies
CEA studies published in the 1990s and 2000s.
In an early application of a cost-effectiveness analysis (CEA) for PE diagnostic
strategies Oudkerk, van Beek, van Putten, and Biiller (1993) classified nine diagnostic
strategies that did not employ clinical decision rules (CDR) or D-dimer tests (DD) into
three categories (CEA 1). Oudkerk and colleagues concluded that the most cost-effective
strategy should include PA and that the use of VQ lung scan and CUS can reduce the
need for PA from 40 to 50%.
Hull, Feldstein, Stein, and Pineo (1996) also evaluated three diagnostic strategies
that did not include a CDR or DD (CEA 2). The first strategy included VQ lung scan and
PA; the second strategy included VQ lung scan, CUS, and PA; the third strategy
employed a VQ lung scan, serial CUS, and PA. The average cost per patient by strategy
was assessed at $14,421, $14,407, and $13,842, respectively. Hull et al. concluded that
the combination of a VQ lung scan, serial CUS, and PA was the most cost-effective
method of diagnosing a pulmonary embolism.
In their examination of diagnostic strategies using a VQ lung scan, a CDR, a DD,
a PA, and a CUS, Michel, Seerden, Rutten, van Beek, and Biiller (1996) analyzed
assigned CDR cut-off points and DD cut-off values (CEA 3). They identified a PE
diagnosis cost-per-patient for 12 strategies between $4,118 and $4,339 with 6-month
survival rates between 91.05% and 97.42%. The strategy that emerged as the most cost-

effective commenced with a VQ lung scan followed by a CDR with an assigned cut-off
value of 0.075, a DD with an assigned cut-off value of 300, a PA, and a CUS.
Twelve PE diagnostic strategies evaluated by van Erkel, van Rossum, Bloem,
Kievit, and Pattynama (1996) comprised a single or a combination of as many as five PE
diagnostic tools. Four (4) of the 12 diagnostic strategies employed the PA as the final
test, and 8 incorporated CT as the final test (CEA 4). The researchers determined that the
strategy that combined a CUS with a subsequent CT was the most cost effective with a
cost of $20,562 per life saved. This evaluation demonstrated that the use of CT in PE
diagnostic strategies could reduce mortality rates and achieve more cost-effective results.
Perrier and associates investigated six PE diagnostic strategies that included
combinations of VQ lung scan, DD, CUS, and/or PA (CEA 5) (Perrier et al., 1997). Each
of the six strategies included a VQ scan, and five strategies employed PA as the final test.
The research concluded that strategies with a DD and a CUS preceding or following a
VQ lung scan are cost effective given that they resulted in a 37 to 47% decrease in the
need for PA tests.
A CEA conducted by Larcos, Chi, Shiell, and Berry (2000) investigated three PE
diagnostic strategies. The first employed a CT only. The second included a CT with CUS
and PA. The third was composed of a VQ lung scan, CUS, and PA (CEA 6). The third
diagnostic strategy was assessed as the most cost-effective with a cost of $940 per life
saved.
Hull et al. (2001) also examined three PE diagnostic strategies with data
extrapolated from the Prospective Investigation of Pulmonary Embolism (PIOPED I)
study of 662 patients with suspected PE (CEA 7). All three strategies included the VQ
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lung scan as the first test. The first strategy combined the VQ lung scan and a subsequent
PA. The second strategy combined the VQ lung scan with a subsequent CUS and PA.
The third strategy combined the VQ lung scan with subsequent serial CUS and PA. The
cost per patient for the first, second, and third strategies was $10,761, $10,364, and
$8,915 (Canadian dollars), respectively. This study revealed that the third strategy is the
most cost-effective method of PE diagnosis among patients with suspected PE.
Combinations of VQ lung scan, CUS, CT, and PA were included in a CEA of PE
diagnostic strategies conducted by Paterson and Schwartzman (2001). They investigated
seven different strategies (CEA 8), three of which involved the PA as the final test. Three
other strategies employed the CT as the final procedure, and one strategy used the CUS
as the last test performed. This analysis revealed two of the seven strategies examined as
cost-effective. The more cost-effective strategy of the two identified as such combined a
VQ lung scan, a CUS, and the CT that produced a survival rate of 953.4 per 1,000
patients at a cost-per-patient of $1,391 (Canadian dollars).
Perrier and Bounameaux (2001) reviewed the performance of several diagnostic
strategies in patients with suspected PE (CEA 9). The first strategy combined the CDR
and DD with a subsequent CUS, VQ lung scan, and PA. The five strategies resulted in a
savings per additional QALY (quality-adjusted life year) of $2,467, $2,447, $2,700,
$3,202, and $3,439, respectively. Overall, this study revealed that the first strategy was
the most cost-effective with 38 lives saved per 1,000 patients and a savings per additional
QALY of $2,467.
Low, intermediate, or high clinical probability of PE patient classifications as well
as CT in eight PE diagnostic strategies was the basis for a CEA conducted by Perrier et
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al. (2003) (CEA 10). For patients with a low clinical probability of PE, the most costeffective strategy employed the DD, CUS, and VQ lung scan at a cost of $845 per
patient. For patients with an intermediate clinical probability of PE, this analysis
demonstrated that the most cost-effective strategy included a DD, CUS, VQ lung scan,
and CT at a cost of $2,674 per patient. For those in the high clinical probability of PE
group, the strategy that included a DD, CUS, and PA was the most cost-effective at a cost
of $4,598 per patient because it required a subsequent PA in 25% of the cases.
An evaluation of the cost effectiveness of three PE diagnostic strategies in
pregnant women with suspected PE was conducted by Doyle and colleagues (2004)
(CEA 11). The first strategy commenced with a CUS followed by a VQ lung scan, a CT,
or a PA. The second strategy used a VQ lung scan as the primary test in a combination of
diagnostic tools, and the third strategy employed the CT as the first procedure in a
combination with other diagnostic tools. Doyle et al. revealed that the CT scan as the
primary test (i.e., third strategy) resulted in the most cost-effective diagnostic strategy
with a cost of $ 17,208 per life saved compared to a cost of $24,004 per life saved for the
first strategy and a cost of $35,906 per life saved for the second strategy.
The cost-effectiveness of CUS as a diagnostic tool for determining PE was
investigated (Elias, Molinier, et al., 2004) in a CEA, which includes nine separate
diagnostic strategies (CEA 12) that comprised various combinations of CDR, DD, CUS,
CT, VQ lung scan, and PA. Three strategies emerged as cost effective. One such strategy
included a DD, extensive CUS, and CT with a cost of $3,679 per patient and a survival
rate of 95.11%. A second cost-effective strategy included a DD, CUS, and CT with a cost
of $3,719 and a survival rate of 95.53%). The third diagnostic strategy that emerged as
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cost effective included a CUS and CT with a cost of $3,804 per patient and a survival rate
of 95.89%o. Of these three, the most cost-effective strategy was that which included the
CUS and CT with an ICER of $23,649 per additional life saved.
Ten imaging strategies for diagnosing PE were investigated by Duriseti, Shachter,
and Brandeau (2006) by examining the assigned values of five different cut-off points for
DD and the level of clinical probability of PE (CEA 13). The researchers concluded that
the DD with CUS as the pulmonary imaging test has utility, but when a CT is available,
the DD does not result in a cost-effective strategy.
The influence of age was evaluated by Righini, Nendaz, Le Gal, Bounameaux,
and Perrier (2007) in a study of four strategies used to diagnose patients with suspected
PE (CEA 14). One diagnostic strategy commenced with a CDR and DD followed by
CUS and CT. Another commenced with a CDR and DD in combination with only a
subsequent CT. The strategy employing a CUS was more expensive than strategies not
using a CUS. The strategy that included a CDR, a DD, and CT was the most economical
with a 3-month VTE risk of less than 1%.
Costs.
The expense of diagnosing PE involves several costs, including laboratory and
imaging tests as well as those associated with treating patients, which, in addition to
prescribed treatment, may include treatment for any complications and hospital stays.
Each is a very significant element in a CEA and represents the direct costs related to PE
screening under a third-party payer perspective.
However, none of the CEAs published in the 1990s as well as in the past decade
calculated indirect costs such as productivity loses in PE patients due to hospitalization or

the costs of long-term effects of PE in patients (see Cox, Carson, & Biddle, 2003; Doyle
et al., 2004; Elias, Molinier, et al., 2004; Hull et al., 1996; Hull et al., 2001; Larcos et al.,
2000; Michel et al., 1996; Paterson & Schwartzman, 2001; Perrier et al., 1997; Perrier et
al., 2003; Righini et al., 2007; van Erkel et al., 1996).
In the 1990s, direct costs associated with diagnostic tests, patient treatment, and
patient hospitalization were assessed by Hull and colleagues (1996), Michel and
colleagues (1996), Perrier and colleagues (1997), and van Erkel and colleagues (1996).
Hull and colleagues used the average costs of $510 for a VQ lung scan, $300 for CUS,
$1,500 for serial CUS, and $2,553 for PA in their CEA. The average cost-per-patient of
treatment of $6,522 was classified as costs related to anticoagulant treatment, including
the medications, laboratory tests performed to monitor anticoagulant treatment, and
physicians' fees, as well as costs of complications and side effects. The average
hospitalization cost was $575 per day and included the hospital stay, laundry charges, and
meals (Hull et al., 1996). In their systematic examination of extrapolated data retrieved
from published studies, van Erkel and colleagues determined that the most expensive
imaging test was the PA with an associated cost of $660 (van Erkel et al., 1996). Direct
costs also were studied by Michel and colleagues (1996). These costs included medical
expenses such as hospital stays, diagnostic tests, and treatment. Indirect costs such as
productivity losses were not calculated. It was determined that the most expensive test
was the PA with an associated cost of $765 (Michel et al., 1996). Only direct costs were
estimated in the Perrier et al. (1997) CEA, which included costs for diagnostic tests,
treatments, and major complications. The average costs of a VQ lung scan and PA were
calculated at $301 and $1,038, respectively.
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As in the previous decade, CEA studies published in first decade of the 21st
century used only direct costs in their analyses (see Cox et al., 2003; Doyle et al., 2004;
Elias, Molinier, et al., 2004; Hull et al., 2001; Larcos et al., 2000; Paterson &
Schwartzman, 2001; Perrier et al., 2003; Righini et al., 2007). A study conducted in
Australia calculated average costs for hospital stays and treatment derived from the
country's Medicare benefits schedule for diagnostic tests and from groups monitoring
hospital admissions. The average hospitalization cost for a PE patient per day was $325,
and the average cost for PE treatment per day was $1,977 (Larcos et al., 2000).
The CEA by Hull and colleagues (2001) considered the costs of the diagnostic
tests performed as well as the costs of the treatment, including therapy, hospitalization,
and medical side effects. Specifically, therapy costs included the price of drugs,
laboratory tests used to monitor treatment, and corresponding physicians' fees.
Hospitalization costs were composed of room and laundry charges with an average costper-patient of $604 (Canadian dollars) per day. The costs of side effects, which averaged
$4,644 (Canadian dollars) per patient per day, were those associated with medical side
effects and complications from the anticoagulant therapy (Hull et al., 2001). In their
CEA, Paterson and Schwartzman (2001) determined average direct costs derived from
Canadian financial services monitoring hospital costs and physicians' fees. Expenditures
for PE diagnostic tests included technical, professional, and capital costs. An average cost
for a PE hospital stay was calculated using several categories of costs, including
diagnostic tests, physician and nursing fees, prescription drugs, and hospital bed/room
with an average hospitalization cost of $7,798 (U.S. dollars).
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Direct costs were retrieved from a hospital database by Perrier et al. (2003) for
their CEA; they did not calculate indirect costs. An overall average cost for PE treatment
of $5,982 per patient was reported. This amount included costs for diagnostic tests,
hospital stays, treatment and monitoring, and those related to major bleeding episodes.
The D-dimer test was the most economical ($33), and the PA was the most expensive
($1,038).
Direct costs retrieved from the literature were used in a CEA that indicated an
average cost of $7,839 per PE episode, ranging from $5,252 to $10,426 inclusive, as well
as an average cost of $807 per day for hospitalization, ranging from $505 to $1,009 (Cox
et al., 2003). Direct costs retrieved from previous CEA studies were used by Doyle and
colleagues (2004) to determine average costs for diagnostic tests and treatment. An
average cost of $200 was assigned to CUS and an average cost of $5,982 per patient was
assigned for treatment (Doyle et al., 2004). Direct costs also were examined in the
Righini and colleagues (2007) CEA; indirect costs were not. An average cost of $184 was
assigned to CUS, and an average cost of $5,982 was assigned for treatment (Righini et
al., 2007).
In any presentation of costs associated with PE diagnostic tools, costs of tests and
treatment may differ widely among countries and even among hospitals within a
particular country. These differences may seriously affect the accuracy of a CEA to
determine the most cost-effective PE diagnostic strategy. Most CEAs investigating the
diagnosis and treatment of PE were conducted in North America (i.e., USA and Canada)
and in northern European countries (e.g., the Netherlands and Switzerland) (see Cox et
al., 2003; Doyle et al., 2004; Elias, Molinier, et al., 2004; Hull et al., 1996; Hull et al.,
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2001; Larcos et al., 2000; Michel et al., 1996; Paterson & Schwartzman, 2001; Perrier et
al., 1997; Perrier et al., 2003; Righini et al., 2007; van Erkel et al., 1996). A study of
costs among six countries, Austria, France, Great Britain, Switzerland, The Netherlands,
and the United States (van Erkel, van Den Hout, & Pattynama, 1999), revealed that the
most economical diagnostic test for PE detection is the D-dimer test. The average cost of
its administration was cited as $19 U.S. dollars. The study also revealed that the most
expensive diagnostic test is the PA; its average cost was cited as $432, ranging from $190
in France to $797 in the Netherlands. The average cost of treating PE ranges widely
among the six countries with a low of $1,385 in Great Britain and a high of $21,182 in
the United States (van Erkel et al., 1999).
Effectiveness.
Defining and measuring effectiveness are essential components of a CEA. How
effectiveness is defined varies among CEAs published in the 1990s and 2000s (see Cox et
al., 2003; Doyle et al., 2004; Elias, Molinier, et al., 2004; Hull et al., 1996; Hull et al.,
2001; Larcos et al., 2000; Michel et al., 1996; Paterson & Schwartzman, 2001; Perrier et
al., 1997; Perrier et al., 2003; Righini et al., 2007; van Erkel et al., 1996). CEA studies
published in the 1990s measured effectiveness by (a) establishing criteria for the correct
(accurate) detection of PE and the correct (appropriate) withholding of treatment or (b)
the 3-month mortality and morbidity rates as well as the 6-month survival rate (Hull et
al., 1996; Michel et al., 1996; Perrier et al., 1997; van Erkel et al., 1996). To measure
effectiveness, Hull and colleagues established two criteria: (a) the accuracy of PE
detection in conjunction with the costs associated with a correctly treated patient and (b)
the number of patients with suspected PE for whom treatment was accurately withheld in
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conjunction with the costs associated with establishing that these patients did not require
any treatment (i.e., diagnostic strategy implemented) (Hull et al., 1996). Three-month
mortality and morbidity rates were used to measure effectiveness in the van Erkel CEA.
The marginal effectiveness of a diagnostic strategy was calculated based upon the costs
associated with each additional life saved. The diagnostic strategy with the lowest
marginal effectiveness was the most cost-effective (van Erkel et al., 1996). Effectiveness
was estimated using 6-month survival rates, mortality rates retrieved from CEA data, and
mortality rates subsequent to a PA retrieved from the literature by Michel et al. (1996). In
the Perrier and colleagues (1997) CEA, effectiveness was measured using parameters that
included mortality rates of treated PE, untreated PE, and treatment subsequent to PA
results (Perrier et al., 1997).
CEA studies published during the first decade of the 21st century measure
effectiveness using several methodologies. The ratio of average costs per life-year was
used by the Larcos and colleagues (2000) CEA in which the total cost of each diagnostic
strategy was calculated and then divided by the life-years experienced in each group of
patients (Larcos et al., 2000). The Hull and colleagues (2001) CEA applied the two
criteria used in Hull et al. (1996): the accurate detection of VTE followed by the accurate
identification of patients in which treatment was withheld. This study identified 194, 195,
and 169 patients who correctly received treatment, and 468, 467, and 493 patients who
were correctly left untreated based upon the first, second, and the third evaluated
strategies, respectively (Hull et al., 1996). Paterson and Schwartzman (2001) measured
effectiveness with a 3-month survival rate following an initial PE episode, 3-month
mortality rates for untreated PE (31%), and for treated PE (6.5%>) from both older and
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more recent studies of PE diagnostic strategies they examined. Effectiveness was
measured in a CEA using the 3-month quality-adjusted expected survival rate (Perrier et
al., 2003). In this study, calculations of the 3-month survival rate involved parameters,
such as treated PE or untreated PE, mortality rate of treated PE (based upon older
studies), and anticoagulant therapy. In the Doyle and colleagues (2004) CEA,
effectiveness was measured by mortality rates for untreated and treated PE retrieved from
previous CEA studies. Effectiveness in the Elias, Molinier, et al. (2004) CEA was
measured by the 3-month survival rates from the literature that were based upon mortality
rates associated with a CT, PA, and PE treatment (see Barritt & Jordan, 1960; Carson et
al., 1992; Dalen & Alpert, 1975; Douketis, Kearon, Bates, Duku, & Ginsberg, 1998;
Elias, Molinier, et al., 2004; Giuntini, Di Ricco, Marini, Melillo, & Palla, 1995; Levine,
Raskob, Beyth, Kearon, & Schulman, 2004; Perrier et al., 2003; Stein et al., 1992).
Righini and colleagues (2007) used the 3-month quality adjusted expected survival rate as
it was described in the Perrier CEA (Perrier et al., 2003) to measure effectiveness.
Righini et al. used mortality rates for CT, PA, and treatment protocols retrieved from the
literature. Concerns were expressed by Rosen (1999) that the mortality rate for untreated
PE of 25%) used in the van Erkel CEA was very high (see Barritt & Jordan, 1960; Dalen
& Alpert, 1975; Rosen, 1999; van Erkel et al., 1996). This mortality rate continued to be
used in later CEA studies (see Elias, Molinier, et al., 2004; Perrier et al., 2003). Concerns
also were expressed by Lipchik et al. (2004) regarding the lack of CT venography
inclusion in the 2003 Perrier CEA. Additional concerns were expressed by Sodhi and
Kaur (2005) about the findings in the 2004 Doyle CEA regarding the use of CT during
pregnancy.
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Summary
Pulmonary embolism diagnosis continues to challenge physicians who must select
a diagnostic strategy from a variety of adequate diagnostic tools that includes CDRs, Ddimer tests, and imaging tests. Clinical decision rules (CDRs) can exclude PE in 10% of
the patients and can assign a high clinical probability of PE in 14 to 23%> of patients with
suspected PE. Both the exclusion of PE in some patients and the assignment of a high
clinical probability of PE in others contributes to the reduction of diagnostic costs by
eliminating the need for further diagnostic procedures (Chagnon et al., 2002;Gibson,
Sonne, Kruip, et al., 2008; Klok et al., 2008; Laupacis, Sekar, & Stiell, 1997; Le Gal,
Righini, Roy, et al., 2006; Miniati et al., 2003; Shapiro, 2006; Stein, 2007b; Wells et al.,
2000; Wicki et al., 2001). D-dimer tests (DD) are blood tests with a sensitivity ranging
from 82 to 100%>, but a specificity ranging from 36 to 58%, which allows physicians to
rule out PE in a significant proportion of the patients with negative DD, thereby reducing
the need for additional costly diagnostic imaging tests (see Bruinstroop et al., 2009; De
Moerloose et al., 2008; Di Nisio et al., 2007; Ghanima & Sandset, 2007; Hogg et al.,
2005; Kline et al., 2006; Parent et al., 2007; Stein, 2007a; Than et al., 2009; Toulon et al.,
2009; van Belle et al., 2006). Normal- and high-probability VQ lung scans have excellent
sensitivity and specificity for PE diagnosis. The use of VQ lung scans can reduce the cost
of PE diagnosis by eliminating the need for further imaging tests; unfortunately, most (50
to 70%>) of these scans are nondiagnostic and necessitate further diagnostic procedures
(see Bajc & Jonson, 2009; Bajc et al., 2009a; Bajc et al., 2004; Cook & Kyriou, 2005; De
Geeter et al., 2005; Douma, Kamphuisen, et al., 2009; Einstein et al., 2007; Freeman &
Haramati, 2009; Freeman et al., 2008; Gutte et al., 2010; Gutte et al., 2009; Hull et al.,
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1990; Itti et al., 2002; Meignan, 2002; Parker et al., 2005; Perrier, 2007; Reinartz et al.,
2004; Roach et al., 2008; Scarsbrook et al., 2007; Sostman, Miniati, et al., 2008;
Sostman, Stein, et al., 2008; Stein et al., 2009; Stein, Kayali, et al., 2004b; Stein,
Woodard, et al., 2006; Uren, 2009; Zophel, et al., 2009). Compression ultrasonography
(CUS) of the lower limb veins is a noninvasive test that can be performed in a hospital's
intensive care unit and detects PE indirectly by diagnosing DVT. However, only about
30% of the patients with confirmed PE have DVT detected by compression
ultrasonography (see Elias et al., 2005; Elias, Colombier, et al., 2004; Galle et al., 2001;
Kalva et al., 2008; Kearon & Ginsberg, 1998; Le Gal, Righini, Sanchez, et al., 2006;
Michiels et al., 2005; Paterson & Schwartzman, 2001; Perrier, 2007; Perrier et al., 2003;
Perrier et al., 2004; Quiroz et al., 2005; Righini et al., 2009; Righini et al., 2008; Turkstra
et al., 1997). Computed tomography pulmonary angiography (CT) is a noninvasive, quick
test that has been the first-line imaging test for PE detection during the past 10 years. A
negative CT can exclude PE in about 98%> of patients with suspected PE, while
approximately 3% of CT scans are nondiagnostic (see Brenner & Hall, 2007; De Monaco
et al., 2008; Ghaye & Dondelinger, 2008; Goodman & Lipchik, 1996; Goodman & van
Beek, 2009; Kalva et al., 2008; Mos et al., 2009; Perrier et al., 2005; PIOPED
Investigators, 1990; Quiroz et al., 2005; Remy-Jardin et al., 1996; Remy-Jardin et al.,
1992; Revel et al., 2005; Schoepf & Costello, 2005; Stein, Fowler, et al., 2006; Stein,
Kayali, et al., 2004b; Stone et al., 2003; Turkstra et al., 1997; van Belle et al., 2006; Van
Rossum et al., 1996; Vigo et al., 2006; Wang et al., 2009). Invasive pulmonary
angiography (PA) was the gold standard procedure of PE diagnosis for many decades, but
despite its excellent accuracy with a very high sensitivity of 96% and a very high
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specificity of 97%, physicians resort to it as the last procedure because it is invasive, not
available in all hospitals, and expensive (see Brenner & Hall, 2007; De Monaco et al.,
2008; Ghaye & Dondelinger, 2008; Goodman & Lipchik, 1996; Goodman & van Beek,
2009; Kalva et al., 2008; Mos et al., 2009; Perrier et al., 2005; PIOPED Investigators,
1990; Quiroz et al., 2005; Remy-Jardin et al., 1996; Remy-Jardin et al., 1992; Revel et
al., 2005; Schoepf & Costello, 2005; Stein, Fowler, et al., 2006; Stein, Kayali, et al.,
2004b; Stone et al., 2003; Turkstra et al., 1997; van Belle et al., 2006; Van Rossum et al.,
1996; Vigo et al., 2006; Wang et al., 2009).
Diagnostic tools such as the D-dimer tests and the multidetector-row CT, continue
to improve as research innovations are tested. However, Balas and Boren (2000) noted
that clinical research findings enter daily practice after about 17 years, which represents a
considerable lag between research and practice, which affects all aspects of diagnosis,
including costs and effectiveness.
Combinations of certain diagnostic criteria that match the level of clinical
probability of PE and the findings of DD and imaging tests can safely rule out or confirm
PE in patients with suspected PE. Studies have demonstrated that the combination of low
clinical probability of PE and a negative D-dimer test can safely rule out PE without
further imaging tests in 24 to 47% of the patients with suspected PE. Also, certain studies
have revealed that PE can be detected in a significant segment of patients with suspected
PE by using a simple diagnostic tool combination of a CDR, a DD, and CT or PA (see
Anderson et al., 2007; Eng et al., 2009; Ghanima et al., 2005; Ghaye & Dondelinger,
2008; Huisman & Klok, 2009; Kamphuisen & Agnelli, 2005; Nijkeuter et al., 2007;
Perrier et al., 2005; Righini et al., 2008; Sohns et al., 2008; Stein, Woodard, et al., 2006;
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van Belle et al., 2006). Findings from other studies have indicated that PE can be detected
in a large portion of patients with suspected PE by using more complex diagnostic
strategies of CDR and DD with various combinations of CT, CUS, VQ lung scan, and PA
(see Anderson et al., 2007; Anderson et al., 2005; Elias et al., 2005; Hammond & Hassan,
2005; Kearon et al., 2006; Kruip et al., 2002; Perrier et al., 2004; Perrier et al., 2005;
Righini et al., 2008; Wells et al., 2001). As Table 7 demonstrates, triangular distributions,
y distributions, and Monte Carlo Simulation analysis were not applied in previous CEA
studies. A list of studies summarizing the CEA methodology of PE diagnostic strategies
is presented in Table 7.

Table 7
Summary of CEA Methodology of PE Diagnostic Strategies
Study

Decision Tree

Triangular and y

Deterministic

Monte Carlo

First Author & Year

Model

Distributions Applied

Sensitivity

Simulation

Applied to CEA

to Parameter Estimates

Analysis

Sensitivity
Analysis

Larcos, 2000

X

X

Paterson, 2001

X

X

Perrier, 2003

X

X

Doyle, 2004

X

X

Elias, 2004

X

X

Righini, 2007

X

X

Polychronopoulos, 2011

X

X

Note. PE = pulmonary embolism; CEA = cost-effectiveness analysis.

X
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Gap in the Literature
The literature review demonstrated that a substantial amount of research
examined PE clinical decision rules (CDR); evaluated PE diagnostic tests such as the Ddimer test (DD), the computed tomography pulmonary angiography (CT), the
compression ultrasonography (CUS), the ventilation-perfusion (VQ) lung scan, and the
invasive pulmonary angiography (PA); and appraised the performance of PE diagnostic
strategies to detect PE in patients with suspected PE. The literature also suggested that a
cost-effectiveness analysis (CEA) might be a valuable technique for assessing the
performance of these strategies; however, as Table 7 indicates, there is a dearth of
research regarding CEA of PE diagnostic strategies. No research was discovered
regarding a CEA in conjunction with triangular distributions, y distributions, and Monte
Carlo Simulation as a methodology for evaluating the performance of PE diagnostic
strategies. Hence, there exists a need for a CEA that applies the triangular and y
distributions as well as the Monte Carlo Simulation as a method by which the costeffectiveness of PE diagnostic strategies can be assessed when examining PE detection
failure rates. Such an approach may prove to be a valuable addition to the literature
regarding decisions about diagnostic strategy selection for pulmonary embolism
diagnosis.
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CHAPTHER 3
METHOD
Overview
The purpose of this study was to assess the most cost-effective diagnostic strategy
among several strategies currently in use for patients with suspected PE based upon their
screening failure rates. Diagnostic strategy selection directly influences the cost and
effectiveness of a PE diagnosis. The identification of cost-effective strategies and/or the
most cost-effective strategy is significant to the medical decision making process (PE
early diagnosis) and for the delivery of health services (PE treatment). Such discovery
can result in a broader use of a particular strategy or strategies that are less expensive and
more effective than alternate strategies (Cox et al., 2003; Doyle et al., 2004; Elias,
Molinier, et al., 2004; Hull et al., 1996; Hull et al., 2001; Larcos et al, 2000; Michel et al.,
1996; Paterson & Schwartzman, 2001; Perrier et al., 1997; Perrier et al., 2003; Righini et
al., 2007; van Erkel et al., 1996).
Human Subjects Review
Secondary aggregated data were used for this study and retrieved from published
studies in the literature. Thus, there was no need to obtain consent from the subjects who
participated in the original studies analysed for this research. Therefore, an approval for
exemption was obtained from Old Dominion University's College of Health Sciences
Human Subjects Review Committee.
Target Population
The population of this study was patients with suspected PE who were either
outpatients in hospital emergency departments or inpatients following a hospital
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admission. The study population consisted of patients with suspected PE who participated
in studies published from January 2000 to December 2010, as either an outpatient or
inpatient, of all adult age groups, without restrictions to race or gender or socioeconomic
status.
Definitions of Input Variables
PE diagnostic strategy tests and treatment, the three constructs of the decision tree
model, the statistical methods that comprise this research, the measurement tools applied,
and the variables tested were identified, operationally defined, and described from the
literature (see Beyer & Scellong, 2007; Brenner & Hall, 2007; De Milto & Odle, 2006;
Dutton et al., 2009; Fenwick, 2009b; Ford-Martin, 2006; Jekel et al., 2001; Klok et al.,
2008; Lapin & Whisler, 2002; Mazur, 2009; Miller, 2009; Muennig, 2008; Odle, 2006;
Petitti, 2000; Sonnenberg, 2009; van Loveren et al., 2009; Wells, 2007a, 2007b). PE
diagnosis consisted of the following terms: strategy, treatment, CDR, D-dimer test, CT,
VQ lung scan, CUS, and PA. The decision tree model constructs were act, event, and
outcome. The analytical methods that comprise the design of the study include parameter
estimation, a decision tree model applied to a cost-effectiveness analysis (CEA), Monte
Carlo Simulation as well as one-way, two way, and three-way sensitivity analyses.
Measurement terms included prior probability, posterior probability, dominant strategy,
and dominated strategy. The variables that were examined were the direct costs and
effectiveness of PE diagnosis and treatment as well as the incremental cost-effectiveness
ratio. Each of these terms is defined in Table 8.
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Table 8
Definitions and Descriptions of the Study Terms
Theoretical Definition/

Operational Definition/

Decision, Diagnostic, and

General Description

Operational Description

Measuring Tools

Act

Act

Act

Action chosen by the decision maker

PE diagnostic strategies

All actions on the left side of

(Lapin & Whisler, 2002)

representing initial actions

the decision tree structure
(Lapin & Whisler, 2002)

Clinical decision rule (CDR)

CDR

CDR

Decision tool based upon clinical

Scoring system measuring the

Pretest probability of PE is

variables assessing the probability of

pretest probability of PE based

expressed in numbers in two

a disease diagnosis in a patient (Klok

upon clinical variables

categories (PE unlikely or PE
likely) or in three categories

et al., 2008)

(low, intermediate or high)
Compression ultrasonography

CUS

CUS

Three CUS techniques: "(a)

Imaging test to detect DVT

Results are read as negative,

segmental CUS, examining the

and an essential test to

positive, or nondiagnostic for

common femoral vein and the

indirectly detect PE using the

PE

popliteal vein; (b) extended CUS,

two-point compression

examining the complete deep thigh

ultrasound (2-CUS), the

veins and popliteal vein; (c) complete

extended compression

CUS, of all segments of the deep

ultrasound (E-CUS), or the

thigh and calf veins (Beyer &

complete compression

Scellong, 2007)

ultrasound (C-CUS)

(CUS)
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Table 8 (continued)
Theoretical Definition/

Operational Definition/

Decision, Diagnostic, and

General Description

Operational Description

Measuring Tools

Computed tomography pulmonary

CT

CT

Combination of X-ray and computer

Fast, noninvasive PE

Results are read as negative,

images providing cross-sectional

diagnostic test able to directly

positive, or nondiagnostic for

views of patient organs and tissues

image a clot as the X-ray

PE

(Brenner & Hall, 2007; Odle, 2006)

source and detectors rotate,

angiography (CT)

producing a spiral or helical
scan
Cost-effectiveness analysis (CEA)

CEA

CEA

Method of comparing two or more

Comparison of cost and

Assessing the value of each

strategies in terms of their costs and

effectiveness of a PE strategy

PE diagnostic strategy under

effectiveness (Muennig, 2008)

with other available

specific units of cost and

alternative PE strategies

effectiveness

D-dimer test (DD)

DD

DD

By-product of the breakdown of

Blood tests that allow

Results are read as negative,

fibrin found in blood clots (Wells,

physicians to rule out PE in

positive, or nondiagnostic for

2007a)

patients with suspected PE

PE

Decision tree model (DTM)

DTM

DTM

A decision-making model combining

The action construct includes

Triangular and y distributions

three constructs,

PE diagnostic strategies. The

of costs and effectiveness as

action, event, and outcome

event construct includes

well as event probabilities

(Lapin & Whisler, 2002)

CDRs, diagnostic tests, and
probabilities. The outcome
construct includes any payoff.
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Table 8 (continued)
Theoretical Definition/

Operational Definition/

Decision, Diagnostic, and

General Description

Operational Description

Measuring Tools

Direct costs

Direct costs

Direct costs

The use of services and goods

PE diagnostic tests costs, PE

Laboratory and imaging tests

(Petitti, 2000)

treatment costs, and PE

costs, treatment costs, and

hospitalization costs

hospitalization costs

Diagnostic strategy

Diagnostic strategy

Diagnostic strategy

Diagnostic procedure based upon

Combinations of PE clinical

PE diagnostic strategy

combinations of clinical decision

decision rules, D-dimer tests,

composition

rules, diagnostic laboratory tests, and

and PE imaging tests to detect

imaging tests

PE

Dominant strategy

Dominant strategy

Dominant strategy

Strategy that demonstrates greater

Strategy considered the

Effectiveness and cost units

effectiveness and lower cost than one

dominant strategy if it is more

competing strategy (Miller, 2009)

effective and less expensive
compared to an alternative
strategy

Dominated strategy

Dominated strategy

Dominated strategy

Strategy that demonstrates less

Strategy dominated if it is less

Effectiveness and cost units

effectiveness and higher cost than

effective and more expensive

one competing strategy (Miller,

than an alternative strategy

2009)
Effectiveness

Effectiveness

Effectiveness

Measure of an intervention's

Performance of an entire PE

Includes the failure rate to

performance (Muenning, 2008)

diagnostic strategy

Detect PE after implementing
a strategy
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Table 8 (continued)
Theoretical Definition/

Operational Definition/

Decision, Diagnostic, and

General Description

Operational Description

Measuring Tools

Event

Event

Event

Component of the decision under

PE diagnostic tests or

A chronological progression

uncertainty that follows an initial

treatment, representing

with events on the left side

action (Lapin & Whisler, 2002)

potential events

assumed to occur before
events on the right (Lapin &
Whisler, 2002)

Incremental cost-effectiveness ratio

ICER

ICER

Incremental cost divided by

Incremental cost divided by

Cost of strategy A minus cost

incremental effectiveness

incremental effectiveness of

of strategy B divided by

(Fenwick, 2009b)

two PE diagnostic strategies

effectiveness of strategy A

(ICER)

minus effectiveness of
strategy B
PA

PA

Imaging procedure that displays the

Invasive test that examines

The most accurate PE

blood vessels and organs and uses an

blood circulation to the lungs

diagnostic test with very high

injection of a radio contrast agent, X-

using radio contrast material,

sensitivity and specificity

ray techniques and a catheter inserted

X-ray imaging, and catheter

into the vein, the heart, and

inserted into the vein, the

pulmonary artery (Ford-Martin,

heart, and the pulmonary

2006; van Loveren et al., 2009)

artery

Invasive pulmonary angiography
(PA)
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Table 8 (continued)
Theoretical Definition/

Operational Definition/

Decision, Diagnostic, and

General Description

Operational Description

Measuring Tools

Monte Carlo Simulation (MCS)

MCS

MCS

Sensitivity analysis involving

Sensitivity analysis involving

Input: Probability distributions

probability distributions for each

repeated random sampling

Output: Distribution of

variable in the decision model

from input distributions

samples; mean incremental

(Mazur, 2009)

assigned for each variable in

cost-effectiveness ratio

the PE decision model

(ICER)

One-way, two-way and three-way

One-way, two-way and three-

One-way, two-way and three-

sensitivity analyses

way sensitivity analyses

way sensitivity analyses

Test of the impact on a decision

Test of the effect on the PE

Input: Range of plausible

model's outputs by varying the

decision tree model results by

values and a baseline value

values of a variable, or two variables

varying values of an uncertain

Output: Error in the model

or three variables of interest in a

variable or two variables or

results and findings based

range of plausible values, while

three variables with a range of

upon the baseline value

holding all other variables constant

plausible values and holding

(Sonnenberg, 2009)

all other variables in the
model constant

Outcome

Outcome

Outcome

Measurement of the evaluating

Cost and effectiveness of PE

Outcomes or the

condition (Lapin & Whisler, 2002)

diagnostic strategies, e.g.,

consequences of the events

dollars per life saved

Table 8 (continued)
Theoretical Definition/

Operational Definition/

Decision, Diagnostic, and

General Description

Operational Description

Measuring Tools

Parameter estimates

Parameter estimates

Parameter estimates

Determination of parameter estimates

Determination of estimates by

Estimation of diagnostic tests'

for variables with uncertainty to use

applying triangular and y

costs, sensitivities,

them as inputs in the decision tree

distributions to address

probabilities, and PE

model to conduct a CEA

variability to resolve

diagnostic strategy failure

uncertainty and eliminate

rates.

error
Posterior probability

Posterior probability

Posterior probability

Likelihood of disease estimated after

Estimation of the presence of

Measured using Bayes's

a test is conducted (Jekel et al., 2001)

PE after performing PE

theorem

laboratory or imaging tests
Prior probability

Prior probability

Prior probability

Likelihood of disease estimated

Estimation of the presence of

Measured by the prevalence of

before a test is conducted (Jekel et

PE before the performance of

PE among patients with

al.,2001)

PE diagnostic laboratory or

suspected PE

imaging tests
Pulmonary embolism (PE)

PE

PE

PE is the condition in which clots

Diagnostic strategies for early

CDR, DD, CT,

block the pulmonary artery

diagnosis of PE in patients

CUS, VQ, PA

(U. S. DHHS, 2008; Virchow,

with suspected PE

1860/2009)
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Table 8 (continued)
Theoretical Definition/

Operational Definition/

Decision, Diagnostic, and

General Description

Operational Description

Measuring Tools

Strategy failure rate (SFR)

SFR

SFR

The performance of the entire

The performance of the five

Three-month follow-up

strategy

investigated PE diagnostic

mortality rates and three-

strategies

month follow-up VTE (i. e.
PE and/or DVT) recurrence
rates.

Treatment (Tr)

Tr

Tr

Thrombolytic therapy to dissolve

Anticoagulant treatment

Treatment cost

blood clots (De Milto & Odle, 2006)

received by patients with PE
to dissolve and/or prevent clot
formation

Ventilation-perfusion (VQ)

VQ

VQ

Two imaging procedures: perfusion

Noninvasive imaging

Results are read as negative,

lung scan evaluates blood flow in the

diagnostic test for detecting

positive, or nondiagnostic for

lungs; ventilation study assesses the

PE using two imaging

PE

air space distribution in the lungs

procedures: ventilation and

(Dutton et al., 2009)

perfusion scanning of PE

Venous thromboembolism (VTE)

VTE

VTE

VTE can be described as the

VTE includes the medical

CDR, DD, CT,

condition in which blood clots exist

conditions of pulmonary

CUS, VQ, PA

in a remote vein

embolism (PE) and deep vein

(U. S. DHHS, 2008)

thrombosis (DVT)
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Data Collection
Data parameter.
The purpose of triangular and y distribution in this dissertation was to determine
appropriate summary estimates for variables with uncertainty and to use them as inputs in
the decision free model for conducting a cost-effectiveness analysis. Specific inclusion
criteria were established for selecting and retaining a study for determining parameter
estimates by employing triangular and y distributions. They included (a) a publication
date from January 2000 to December 2010 inclusive, (b) at least one criterion from the
performance criteria 1 through 5, and (c) criterion 6:
1. PE CDR, D-dimer test, and CT.
2. PE CDR, D-dimer test, CT, and CUS.
3. PE CDR, D-dimer test, CUS, and CT.
4. PE CDR, D-dimer test, VQ lung scan, and CUS.
5. PE CDR, D-dimer test, CT, CUS, and PA.
6. Sufficient information about PE diagnostic strategy failure rates to detect PE
is provided.
With regard to sensitivity, specificity, cost, and effectiveness values, a study must
have satisfied either criterion 7 or 8 or both criteria to be selected for and retained in
determining parameter estimates by employing triangular and y distributions.
7. Sufficient information about PE diagnostic test sensitivity and/or specificity
values was provided.
8. Sufficient information about costs of a PE diagnostic test or treatment or about
effectiveness (i. e. strategy failure rates) was provided.
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There were no restrictions on the type of CDR or PE diagnostic test, hospital
location, outpatient or inpatient status, gender, age, or total number of patients.
CEA data.
Data for direct costs (diagnostic test and treatment) was entered in the decision
tree model to conduct a CEA. Indirect costs were not included in this study, such as costs
due to productivity lost, waiting or travelling, or other economic impact on the patients
and their families as well as the opportunity costs of market competition, income, and
taxes. Inclusion of indirect costs was unnecessary since this study did not examine the
well-being of PE patients (i.e., a societal perspective) to assess social welfare
maximization. Rather, this study focused upon direct costs by examining certain variables
that affect medical decision-making, not societal decision-making.
Direct costs data was identified from the literature for the following components
of PE screening: (a) diagnostic test costs, including laboratory tests costs, imaging tests
costs, and physician fees for D-dimer test, CT, CUS, VQ lung scan, PA and (b) treatment
costs, including drugs, laboratory tests performed for monitoring the anticoagulant
treatment, and physician fees.
Effectiveness data was entered into the proposed CEA decision tree model to
detect PE after implementing a strategy. These data included PE detection failure rates,
which could result in a new PE episode or a fatality. Effectiveness data was identified
from the literature or was calculated using (a) the three-month follow-up mortality rates
and (b) the three-month follow-up VTE (i. e. PE and/or DVT) recurrence rates.
Probabilities data was entered into the proposed CEA decision tree model. These
probabilities were calculated from several events related to PE diagnostic procedures: (a)
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ruling out PE after performing a PE diagnostic test, (b) administering treatment after
performing a PE diagnostic test, and (c) performing an additional PE diagnostic test
following negative or nondiagnostic results from the previous diagnostic test.
Research Question and Hypothesis
Research question.
To assess the most cost-effective PE diagnostic strategy among five strategies
currently in use, the following research question was established based upon the CEA
decision tree model and review of the literature: Which sfrategy offers the best possible
effectiveness at the lowest or most acceptable cost?
Hypothesis.
The null and alternate hypotheses for this CEA were derived from the five PE
diagnostic strategies investigated. The composition of each strategy involved a CDR and
a D-dimer test as initial diagnostic procedures followed by one or more imaging tests in
the described sequence.
Strategy 1: CDR, D-dimer test, with or without CT;
Strategy 2: CDR, D-dimer test, CT, with or without CUS;
Sfrategy 3: CDR, D-dimer test, CUS, with or without CT;
Sfrategy 4: CDR, D-dimer test, VQ lung scan, with or without CUS; and
Strategy 5: CDR, D-dimer test, CUS, with or without PA; and
The following null and alternative hypotheses were investigated.
Ho:

There is no difference in cost-effectiveness among the five PE diagnostic strategies
investigated.
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Ha:

At least one sfrategy is more cost-effective among the five PE diagnostic strategies
investigated.

The following alternative decisions (Dan) based upon the study's hypothesis were
evaluated:
Dai:

At least strategy 1 is more cost-effective than strategy 2, strategy 3,

sfrategy 4 and strategy 5.
Da2:

At least sfrategy 2 is more cost-effective than sfrategy 1, strategy 3,

sfrategy 4 and strategy 5.
Da3:

At least strategy 3 is more cost-effective than strategy 1, strategy 2,

strategy 4 and strategy 5.
Da4:

At least strategy 4 is more cost-effective than strategy 1, strategy 2,

strategy 3 and sfrategy 5.
Das:

At least strategy 5 is more cost-effective than strategy 1, strategy 2,

sfrategy 3 and strategy 4.
Data Analysis
Parameter estimates.
Triangular and y distributions were powerful statistical methods that were
appropriate for determining parameter estimates for this study. They increased the power
and precision of the earlier, individual studies that investigated the performance of PE
diagnostic tests or PE diagnostic strategies. This research suggested that applying
triangular and y distributions in a CEA to assess parameter estimates of pulmonary
embolism diagnostic tests' cost, sensitivity and specificity, and effectiveness addressed
variability in data retrieved from the literature. Additionally, it resolved the uncertainty

72

surrounding the values of cost, effectiveness, and sensitivity and specificity, and it
eliminated error in the assigned baseline values in the CEA model. For a more detailed
discussion of triangular and y distributions see Mendenhall and Sincich as well as
TreeAge Software (Mendenhall & Sincich, 2007; TreeAge Software, 2009).
CEA methodology.
CEA techniques mainly were developed during the past four decades, with
significant research pertaining to cost, effectiveness, incremental cost-effectiveness ratio,
probabilities, sensitivity analysis, and Monte Carlo Simulation. During the same period,
CEA techniques concentrating on health issues have been discussed by several authors
(see Alemi & Gustafson, 2007; Briggs, Goeree, Blackhouse, & O'Brien, 2002; Detsky &
Naglie, 1990; Drummond, O'Brien, Stoddart, & Torrance, 1997; Gold, 1996; Manly,
2007; Muennig, 2002, 2008; Pauker & Kassirer, 1978; Porzsolt & Kaplan, 2006;
Thompson & Nixon, 2005; TreeAge Software, 2009; Willan & Briggs, 2006).
Cost. Cost data for this study retrieved from the literature are dated and each
requires an adjustment for inflation (see Drummond et al., 1997; Muennig, 2008; Petitti,
2000 for a discussion of costs and inflation adjustments). It is assumed that the cost in
any given year for any PE laboratory test and/or the cost of any PE imaging test can be
determined and, consequently, adjusted for inflation using information retrieved from the
medical section of the Consumer Price Index (U. S. Department of Labor, 2011). When
calculating adjusted costs in years with the inflation rate remaining constant, the equation
Cn = C0 (l+i) n was appropriate. However, if the rate of inflation fluctuates, the equation
Cn = Cn-i (l+i n ) has been found to be more effective in evaluating adjusted cost, where C
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is the cost and i is the inflation rate for years 1, 2, 3 , . . . and n. Therefore, the adjusted for
inflation costs for years 1, 2, 3 , . . . and n were determined by the following equations:
year l:Ci=C 0 (l+ii)
year2:C 2 = Ci(l+i 2 )
year3:C 3 = C 3 (l+i 3 )

yearn:C n = Cn-i(l+in)
Cost data usually has highly skewed distributions; thus, several techniques are
available for transforming data to produce normality in skewed distributions (see Cohen,
Cohen, West, & Aiken, 2003; Darren, Mallery, & Briggs, 2003; Field, 2003; Keppel &
Wickens, 2004; Leech, Barrett, & Morgan, 2008; Maindonald & Braun, 2007; Maxwell
& Delaney, 2004; Mertler & Vannatta, 2002; Stevens, 2002; Tabachnick & Fidell, 2001;
Willan & Briggs, 2006).
Effectiveness. The effectiveness of a given PE diagnostic strategy is typically
measured by mortality and survival rates (Drummond et al., 1997; Muennig, 2008; Petitti,
2000). Several authors offered comprehensive mathematical presentation of various
methods that have been developed to estimate effectiveness (see Drummond et al., 1997;
Howard, 2009; Muennig, 2008; Petitti, 2000; Willan & Briggs, 2006). Effectiveness in
this study reflected the performance of each PE diagnostic strategy, including failure
rates to detect a PE. Sfrategy failure rates represented 3-month follow-up mortality rates
and 3-month follow-up VTE (i. e. PE or DVT) recurrence rates after implementing a
specific PE diagnostic strategy in patients with suspected PE.
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Incremental cost-effectiveness ratio (ICER). CEA using the decision free model
is a powerful statistical tool that supports complex calculations (see Detsky & Naglie,
1990; Fenwick, 2009a; Jekel et al., 2001; Miller, 2009; Muennig, 2008; Pauker &
Kassirer, 1978; Petitti, 2000; van den Hout, 2009). A PE diagnostic strategy was
considered cost-effective if it meets the general criteria for a cost-effective intervention:
(a) less expensive and at least as effective; (b) more effective and more expensive, with
the additional benefit worth the additional cost; (c) less effective and less expensive, with
the additional benefit of the alternative not worth the additional cost; or (d) cost reduction
with an equal or improved outcome (Petitti, 2000).
When PE diagnostic strategy A is more effective but costs more than alternate
strategy B, the incremental cost-to-incremental effectiveness ratio (ICER) should be
calculated (Detsky & Naglie, 1990; Fenwick, 2009b; Petitti, 2000). The ICER is
computed with the following formula:
LOSt strat:e gy A — LOStstratggy 3

Incremental cost — effectiveness =
Effectivenessstrategy

A

— Effectivenessstrategy

B

PE strategy A is considered the dominant strategy if it is more effective and less
expensive than alternate strategy B (Muennig, 2008; van den Hout, 2009). This
relationship is expressed by the following formulas:
Effectivenessstrategy
LOSt strate gy

A

A

> Effectivenessstrategy

B

< LOSt strate gy B

PE strategy B is considered the dominated strategy if it is less effective and more
expensive than alternate strategy A (Muennig, 2008; van den Hout, 2009). This
relationship is expressed by the following formulas:
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Effectivenessstrategy

B

< Effectivenessstrategy

Loststrategy g > Coststrategy

A

A

Event probabilities. Determining event probabilities was essential in CEA that
incorporates the decision tree model. Probabilities for each possible event and outcome
not retrieved from the literature were calculated. Two statistical concepts were associated
with calculating probabilities. For this research, prior probability of PE was an estimate
of the presence of PE before laboratory or imaging tests were performed. It was derived
from the estimate of the prevalence of PE among patients with suspected PE (Jekel et al.,
2001; Pauker & Kassirer, 1978). Posterior probability of PE was the estimate of the
presence of PE after laboratory or imaging tests were performed or after intervention
(Jekel et al., 2001; Pauker & Kassirer, 1978). Posterior probability estimations for the
first, second, and further tests were calculated based upon Bayes's theorem (see Bayes,
1763; Daniel, 2000; Jekel et al., 2001; Pagano & Gauvreau, 2000). Bayes's theorem is
considered "the foundation for managing and manipulating uncertainty using probability
theory in expert systems" (Bondi, 2007, p. 32).
Within the context of the decision tree model, Bayes's theorem can be used to
answer the following two questions: (a) What is the probability that a patient with a
positive diagnostic test result has a disease? and (b) What is the probability that the
patient with a negative diagnostic test result does not have the disease? These questions
are not answered by either the sensitivity or specificity values of a diagnostic test.
Assuming that PE+ is an event in which a patient has PE and PE- is an event in which a
patient does not have PE, then the posterior probability for a positive PE diagnostic test is
established using the following formula,
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p(PE+/T+) = [p(T+/PE+)p(PE+)]/[p(T+/PE+)p(PE+)+p(T+/PE-)p(PE-)].
The posterior probability for a negative PE diagnostic test is determined using this
formula:
p(PE-/T-) = [p(T-/PE-)p(PE-)]/[p(T-/PE-)p(PE-)+p(T-/PE+)p(PE+)].
The letter p indicates probability, T+ indicates that a specific PE diagnostic test is
positive, T- indicates that the specific PE diagnostic test is negative, and the diagonal line
(/) indicates conditional upon that which follows.
Monte Carlo Simulation Sensitivity Analysis: A Probabilistic Approach
A sensitivity analysis was conducted using a probabilistic approach through a
Monte Carlo simulation (see Bondi, 2007; Manly, 2007; Muennig, 2008; TreeAge
Software, 2009). This method, which was named for the European gambling
establishment, considered probability distributions for each variable in the decision tree
model. A mean and 95% CI for the variable of interest was obtained by sampling each
distribution repeatedly for the overall cost, effectiveness, and incremental costeffectiveness ratio by diagnostic strategy. Available software (TreeAge Software, 2009)
that applies a Monte Carlo simulation offers the option to select the input distribution for
each variable from a large number of distributions. As a result, the simulation provided
the final distribution of each variable as well as the final distribution of incremental costeffectiveness values on a normal distribution, one of the most commonly used
distributions in probability theory and statistics (see Daniel, 2000; Howell, 2002; Kuzma
& Bohnenblust, 2001; Pagano & Gauvreau, 2000; TreeAge Software, 2009).
In the Monte Carlo simulation, the inputs in the decision tree model function as
variables that can indicate a wide range of values, instead of fixed numbers and can allow
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all variable uncertainties to be included in the analysis while reproducing the model
multiple times. The advantages of this simulation included testing all variables
simultaneously, providing the mean and standard deviation, and generating a confidence
interval for the expected outcomes (i.e., cost, effectiveness, and cost-effectiveness ratio).
A Monte Carlo simulation significant at a (alpha) level of .05 required a minimum of
1,000 sets of simulated data, and a simulation significant at a level of .01 required a
minimum of 5,000 sets of simulated data (Manly, 2007). The a level for this research was
set at .05.
The software used in this study (TreeAge Software, 2009) performs CEAs using
the decision free model. It allowed the researcher to conduct Monte Carlo Simulations as
well as one-way, two-way, and three-way sensitivity analyses. It exported to Microsoft
Excel and allowed the production of several charts for the input distributions, the
distribution of outcomes, and the distribution of the incremental outcomes.
One-Way, Two-Way, and Three-Way Sensitivity Analyses: A Deterministic
Approach
In this research, the CEA combined effectiveness data and cost data of PE
diagnostic sfrategies retrieved from studies identified in the literature. Inferential
uncertainty due to possible errors within the data was addressed using a one-way, twoway and three-way sensitivity analysis that assessed the effect of varying model
assumptions on the findings (Muennig, 2008; Petitti, 2000; Willan & Briggs, 2006). The
decision tree CEA model was tested using this sensitivity analysis.
In a one-way, two-way, and three-way sensitivity analysis, a single variable, or a
pair of variables or a group of three variables, respectively, was tested within a range of
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reasonable values while all other variables were held constant. Variables for which there
was uncertainty were tested using a wide range of values from much lower to much
higher than the baseline estimate. Variables for which there was less uncertainty, hence
more confidence, were tested using a narrower range of values. If a PE diagnostic
strategy remained dominant within a range of plausible values for inputs involving
uncertainty, then the model was robust.
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CHAPTER 4
RESULTS
Overview
The purpose of this study was to assess the most cost-effective diagnostic
strategy, among several strategies currently in use for patients with suspected pulmonary
embolism (PE), based upon sfrategy failure rates. This chapter examines the parameter
estimates, the comparisons of decision's alternative, and the sensitivity analysis results.
First, parameter estimates were assessed based upon data retrieved from the literature
with regards to PE diagnostic test direct costs, effectiveness of PE diagnostic strategies as
well as PE diagnostic tests' sensitivity and specificity. Second, alternative decisions
addressing PE diagnostic strategies were evaluated to determine which strategy exerted
influence on the medical decision-making process. Third, Monte Carlo probabilistic
sensitivity analyses and one-way, two-way, and three-way deterministic sensitivity
analyses were conducted to assess the impact of uncertainty on the cost-effectiveness
analysis (CEA) model. Finally, it was determined that Strategy 3, comprising a clinical
decision rule (CDR), a D-dimer test (DD), a compression ulfrasonography (CUS), and a
computed tomography pulmonary angiography (CT), was the most cost effective. This
strategy was compared to alternate strategy 1, comprising a CDR, a DD, and a CT;
alternate strategy 2, comprising a CDR, a DD, a CT, and a CUS; alternate strategy 4,
comprising a CDR, a DD, a VQ lung scan, and a CUS; and alternate strategy 5,
comprising a CDR, a DD, a CT, a CUS, and a PA.

80
Parameter Estimates Results
Pulmonary embolism diagnostic tests and treatment direct costs.
A literature review was conducted to obtain PE diagnostic tests and treatment
direct costs. The predetermined inclusion criteria were met only by five studies
appropriate for inclusion in the analysis. Of them, three are cost-effectiveness analysis
(CEA) studies, one is a management study, and one is an economic review. A list of
studies included in the analysis is presented in Table 9.

Table 9
Studies Included in the Analysis to Obtain PE Diagnostic Tests and Treatment Direct
Costs
Year

Study

Diagnostic Test

First author
DD

CT

CUS

VQ

PA

Tr

X

X

X

X

X

X

Van Erkel

1999

Paterson

2001

X

X

X

X

Doyle

2004

X

X

X

X

Duriseti

2006

X

X

X

X

Stein

2006

X

X

X

X

X
X

Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; Tr = treatment for PE.

Since the annual inflation rates differ, substantially among the years between
1998 and 2010 the direct costs, adjusted for inflation, were determined by the equation
Cn= Cn-i(l+in), where C is the cost and i is the inflation rate for years 1, 2, 3 , . . . , and n.
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Estimations were based upon the studies included in the analysis, while the
Bureau of Labor Statistics within the U.S. Department of Labor provided the Consumer
Price Index for hospital and related services (U. S. Department of Labor, 2011).
Comparisons among the adjusted-for-inflation PE diagnostic testing cost during the
period from 1998 through 2010 are presented in Figures 3 through 8. The frend line
equations and r2 values for the PE diagnostic testing costs adjusted for inflation are
presented in Tables 10 through 15.
D-dimer test (DD) adjusted costs increased linearly during the years 1998-2010
with trend line equation R2 values of more than 98% (see Table 10). The range from the
lowest to the highest DD adjusted cost was $8 (see Figure 3).
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Figure 3. Comparisons of D-dimer test (DD) direct cost for the years 1998-2010 adjusted
for inflation.

Table 10
Trend Line Equations and R Values ofDD Cost Adjustedfor Inflation
Adjusted Cost
D-dimer (DD)

Equation

Study of Unadjusted Cost
R2

First Author

Year

Adjusted Cost 1

YDD1=1.1062x+10.069

RDD,=0.9872

Van Erkel

1999

Adjusted Cost 2

YDD2=1.559x+7.2024

RDD2=0.9994

Duriseti

2006

Adjusted Cost 3

YDD3=1.867x+8.6429

RDD3=0.9994

Stein

2006

Note. Y = adjusted cost; x = time.
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Computed tomography pulmonary angiography (CT) adjusted costs increased
linearly during the years 1998-2010 with trend line equation R2 values of more than 98%
(see Table 11). The lowest-to-highest CT adjusted cost range was $2,112 (see Figure 4).
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Figure 4. Comparisons of computed tomography pulmonary angiography (CT) direct
cost for the years 1998-2010 adjusted for inflation.

Table 11
Trend Line Equations and R Values ofCT Cost Adjustedfor Inflation
Adjusted Cost
CT

Equation

Study of Unadjusted Cost
R^

First Author

Year

Adjusted Cost 1

YCTi=12.445x+l 13.28

RCTI=0.9872

Van Erkel

1999

Adjusted Cost 2

YCT2=32.044x+267.99

RCT2=0.9924

Paterson

2001

Adjusted Cost 3

YCT3=39.993x+239.61

RcT3=0.9946

Doyle

2004

Adjusted Cost 4

YCT4=15.559x+72.024

RcT4=0.9994

Duriseti

2006

Adjusted Cost 5

YCT5=135.29x+626.25

RCT 5 =0.9994

Stein

2006

Note. CT = computed tomography pulmonary angiography; Y = adjusted cost; x = time.
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Compression ultrasonography (CUS) adjusted costs increased linearly during the
years 1998-2010 with trend line equation R2 values of more than 98% (see Table 12). The
range from the lowest-to-highest CUS adjusted cost range was $295 (see Figure 5).
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Figure 5. Comparisons of compression ultrasonography (CUS) direct cost for the years
1998-2010 adjusted for inflation.

Table 12
Trend Line Equations and R Values of CUS Cost Adjustedfor Inflation
Adjusted Cost
CUS

Equation

Study of Unadjusted Cost
Rz

First Author

Year

Adjusted Cost 1

YCUSi=6.3609x+26.095

RcUS1=0.9872

Van Erkel

1999

Adjusted Cost 2

YCus2=17.392x+58.497

Rcus2=0.9924

Paterson

2001

Adjusted Cost 3

YCUs3=15.997x+15.857

Rcus3=0.9946

Doyle

2004

Adjusted Cost 4

YCus4=7.7796x-2.8862

Rcus4=0.9994

Duriseti

2006

Adjusted Cost 5

YCus5=24.506+l 13.44

RcUS5=0.9994

Stein

2006

Note. CUS = compression ultrasonography; Y = adjusted cost; x = time.
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Ventilation-perfusion lung scan (VQ) adjusted costs increased linearly during the
years 1998-2010 with trend line equation R2 values of more than 98% (see Table 13). The
range from the lowest-to-highest VQ adjusted cost range was $824 (see Figure 6).
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Figure 6. Comparisons of ventilation-perfusion lung scan (VQ) direct cost for the years
1998-2010 adjusted for inflation.

Table 13
Trend Line Equations and R Values of VQ Cost Adjustedfor Inflation
Adjusted Cost
VQ

Equation

Study of Unadjusted Cost
Rz

First Author

Year

Adjusted Cost 1

YVQi=62.963x+258.3

RVQi=0.9872

Van Erkel

1999

Adjusted Cost 2

YVQ2=42.536x+143.06

RVQ2=0.9924

Paterson

2001

Adjusted Cost 3

YVQ3=31.994x+31.714

RVQ3=0.9946

Doyle

2004

Adjusted Cost 4

YVQ4=54.458x-20.204

RVQ4=0.9994

Duriseti

2006

Adjusted Cost 5

YVQ5=71.339x-26.467

R V Q 5 =0.9994

Stein

2006

Note. VQ = ventilation-perfusion lung scan; y = adjusted cost; x = time.
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Invasive pulmonary angiography (PA) adjusted costs increased linearly during the
years 1998-2010 with trend line equation R2 values of more than 98% (see Table 14). The
range from the lowest-to-highest PA adjusted cost range was $7,319 (see Figure 7).
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Figure 7. Comparisons of invasive pulmonary angiography (PA) direct cost for the years
1998-2010 adjusted for inflation.

Table 14
Trend Line Equations and R Values of PA Cost Adjustedfor Inflation
Adjusted Cost
PA

Equation

Study of Unadjusted cost
R'

First Author

Year

Adjusted Cost 1

YPAI=47.015x+192.87

RPAI=0.9872

Van Erkel

1999

Adjusted Cost 2

YPA2=74.012x+248.93

RPA2=0.9924

Paterson

2001

Adjusted Cost 3

YPA3=79.985x+79.286

RPA3=0.9946

Doyle

2004

Adjusted Cost 4

YPA4=475.03x-176.23

RPA4=0.9994

Stein

2006

Note. PA = invasive pulmonary angiography test; Y = adjusted cost; x = time.
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PE treatment adjusted costs increased linearly during the years 1998-2010 with
trend line equation R2 values of more than 99% (see Table 15). The range from the
lowest-to-highest treatment adjusted cost range was $191 (see Figure 8).
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Figure 8. Comparisons of PE treatment (Tr) direct cost for the years 1998-2010 adjusted
for inflation.

Table 15
Trend Line Equations and R Values of Treatment Cost Adjustedfor Inflation
Adjusted Cost
Equation

Treatment (Tr)

Study of Unadjusted cost
R^

First Author

Year

Adjusted Cost 1

YTrl =40.755+1096.9

RPAI=0.9976

Van Erkel

1999

Adjusted Cost 2

YTr2 = 0.395+922.76

RpA2=0.9997

Duriseti

2006

Note. Y = adjusted cost; x = time.
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In general, considerable differences among PE diagnostic testing costs were
identified in the literature. Therefore, to resolve the uncertainty surrounding the costs of
these tests, triangular disfributions were applied based upon the adjusted cost estimations
presented. D-dimer test direct costs ranged from $25 to $33 with an expected value of
$28.3 (see Figure 9). The cumulative probability within the first 10th percentile indicated
DD costs at approximately $26.3 or less. At the 50th percentile, the median DD cost was
approximately $28.1, while at or above the 90th percentile DD costs were approximately
$30.8 or greater (see Figure 10).
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Figure 9. D-dimer test (DD) direct cost triangular distribution.
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Figure 10. D-dimer test (DD) direct cost cumulative probability.
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The computed tomography pulmonary angiography (CT) direct costs ranged from
$275 to $2,387, with an expected value of $1,121 (see Figure 11). The cumulative
probability within the 10th percentile revealed that CT direct costs were approximately
$572.5 or less. At the 50th percentile, the median CT cost was about $1,051.6, while at
and above the 90th percentile CT costs were $1,792.2 or greater (see Figure 12).
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Figure 11. Computed tomography pulmonary angiography (CT) direct cost triangular
distribution.
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Figure 12. Computed tomography pulmonary angiography (CT) direct cost cumulative
probability.
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The compression ultrasonography (CUS) direct cost values ranged from $137 to
$432 with an expected value of $292 (see Figure 13). The cumulative probability within
the 10th percentile indicated that CUS direct costs were approximately $207.8 or less. At
the 50th percentile, the median CUS cost was $294.8 while at and above the 90th
percentile the CUS cost values were approximately $371.1 or greater (see Figure 14).
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Figure 13. Compression ultrasonography (CUS) direct cost triangular distribution.
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Figure 14. Compression ulfrasonography (CUS) direct cost cumulative probability.
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The ventilation-perfusion lung scan (VQ) direct costs ranged from $612 to $1,436
with an expected value of $1,003 (see Figure 15). The cumulative probability within the
10* percentile revealed that VQ costs were approximately $782.4 or less. At the 50th
percentile, the median VQ cost was about $994.7, while at or above the 90th percentile
the VQ costs were approximately $1,237.6 or greater (see Figure 16).
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Figure 15. Ventilation-perfusion lung scan (VQ) direct cost triangular distribution.
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Figure 16. Ventilation-perfusion lung scan (VQ) direct cost cumulative probability.
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The invasive pulmonary angiography (PA) direct costs ranged from $1,072 to
$8,381 with an expected value of $3,676 (see Figure 17). The cumulative probability at
the first 10th percentile revealed that the costs were approximately $1,689.02 or less. At
the 50th percentile, the median PA cost was about $3,383.0, while at and above the 90th
percentile the PA cost values were $6,158.3 or greater (see Figure 18).
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Figure 17. Invasive pulmonary angiography (PA) direct cost triangular distribution.
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Figure 18. Invasive pulmonary angiography (PA) direct cost cumulative probability.
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The direct costs of PE treatment ranged from $1,449 to $1,640 with an expected
value of $1,545 (see Figure 19). The cumulative probability at the first 10th percentile
indicated that PE treatment cost was $1,491.8 or less. At the 50th percentile, the median
cost of treatment was $1,544.7, while at or above the 90th percentile treatment cost values
were roughly $1,597.4 or greater (see Figure 20).

Figure 19. PE treatment (Tr) direct cost triangular distribution.
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Figure 20. PE treatment (Tr) direct cost cumulative probability.

in
CN
ID

o
m

94
Table 16 presents a summary of the results of the triangular distribution expected
values and statistics of PE diagnostic testing direct costs adjusted for inflation.

Table 16
Expected Values and Statistics of Triangular Distribution of PE Diagnostic Direct Costs
PE Diagnostic Test

Percentiles

Expected
Value

2.5m

97.5th

DD

28.3

25.6

31.9

CT

1121.3

422.5

2092.0

CUS

291.7

172.5

401.7

VQ

1003.0

698.2

1337.6

PA

3676.3

1376.4

7270.2

Tr

1544.7

1470.6

1639.3

Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; Tr = treatment. Costs are in dollars.

Effectiveness of pulmonary embolism diagnostic strategies.
A literature review of the research regarding the effectiveness of the strategies
employed to diagnose PE was conducted. Of the studies identified, 233 had potential
relevance for strategy 1, 99 had potential relevance for strategy 2, 97 for strategy 3, 47
for sfrategy 4, and 7 articles had potential relevance for sfrategy 5. The predetermined
inclusion criteria were met by six studies addressing strategy 1, two studies discussing
strategy 2, three studies concerning sfrategy 3, four studies examining strategy 4, and two
studies reviewing strategy 5. A summary of the numbers of articles included in the
process to obtain PE diagnostic strategy effectiveness values is presented in Table 17.
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Table 17
Summary of Articles Evaluatedfor Inclusion in the Review ofPE Diagnostic Strategy
Effectiveness
Categories of Evaluation

Strategy 1

Strategy 2

Strategy 3

Strategy 4

Strategy 5

233

99

97

47

7

202

78

74

29

2

31

21

23

18

5

Potentially Relevant Articles
Identified
Articles not Related to PE Test for
PE Diagnosis
Articles Related to PE Test for PE
Diagnosis

In

Ex

In

Ex

In

Ex

In

Ex

In

Ex

6

25

2

19

3

20

4

14

2

3

Note. PE = pulmonary embolism; Strategy 1 = a CDR, a D-dimer test, and a CT; Strategy 2 = a CDR, a Ddimer test, a CT, and a CUS; Strategy 3 = a CDR, a D-dimer test, a CUS, and a CT; Strategy 4 = a CDR, a
D-dimer test, a VQ, and a CUS; Strategy 5 = a CDR, a D-dimer test, a CT, a CUS, and a PA. CDR =
clinical decision rule; CT = computed tomography pulmonary angiography; CUS= compression
ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary angiograph. In =
included articles related to PE test for PE diagnosis that met inclusion criteria; Ex = excluded articles
related to PE test for PE diagnosis that did not meet inclusion criteria.

Studies used in the analysis of PE diagnostic strategy effectiveness, including the
total number of participants as well as effectiveness levels expressed as failure rates, are
presented in Table 18. Differences in the PE diagnostic strategy failure rates were
identified in the literature. To resolve the uncertainty surrounding those failure rates, y
disfributions were applied based upon failure rate estimations (see Table 18). The y
distribution expected values of the strategy failure rates to detect PE demonstrated very
small differences expressed within a .553329 range between a high of 1.099999 and a
low of 0.546667. Specifically, strategy 3 achieved the lowest expected failure rate of
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0.546667. A summary of the y distribution strategy failure rates statistics for the studies
included in this analysis is presented in Table 19.

Table 18
Studies Included in the Analysis to Obtain PE Diagnostic Strategy Failure Rates
Study

Strategy

First Author

Strategy Failure rates (%

Patients
Total n

and Year

Level 1

Level 2

Level 3

Rate < 0.50

0.50 < Rate < 1.00

1.00 <Rat e

Ghanima, 2005

1

432

SFR 2

Hogg, 2006

1

408

SFR 2

van Belle, 2006

1

3306

SFR 2

Nijkeuter, 2007

1

3306

SFR 2

Righini, 2008

1

838

SFR1

Eng, 2009

1

219

SFR1

Anderson, 2005

2&5

858

SFR1

Perrier, 2005

2&5

756

Elias, 2005

3

274

SFR 2

Perrier 2004

3

965

SFR 2

Righini, 2008

3

855

Wells, 2001

4

930

ten Wolde, 2004

4

631

SFR 3

Kearon, 2006

4

1126

SFR 3

Anderson, 2007

4

712

Anderson, 2005

5&2

858

Perrier, 2005

5&2

756

SFR 3

SFR1
SFR 2

SFR 2

SFR1
SFR 2

Note. PE = pulmonary embolism; SFR 1 = strategy failure rate level 1 < 0.50%; SFR 2 = 0.50 % < strategy
failure rate level 2 < 1.00%; SFR 3 = 1.00% < strategy failure rate level 3.
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Table 19
Expected y Distribution Values and Statistics ofPE Diagnostic Strategies Failure Rates
(in Percentage)
Statistic

Strategy 1

Strategy 2

Strategy 3

Strategy 4

Strategy 5

Expected

0.576667

1.099999

0.546667

1.004999

0.725000

Mean

0.576674

1.100821

0.547071

1.005474

0.724849

Standard Deviation

0.142124

0.612938

0.122665

0.152025

0.235165

Median

0.564553

0.989058

0.538462

0.997995

0.699498

Minimum

0.159337

0.020879

0.178322

0.524694

0.062979

Maximum

1.393475

6.052246

1.222180

1.782201

2.113984

2.5th

0.333015

0.247525

0.332183

0.728888

0.338600

10th

0.404102

0.425513

0.396809

0.815425

0.444665

90th

0.765901

1.921855

0.709004

1.204917

1.038356

97.5th

0.887872

2.596096

0.811244

1.324990

1.255302

Percentiles

Note. PE = pulmonary embolism; Strategy 1 = a CDR, a D-dimer test, and a CT; Strategy 2 = a CDR, a Ddimer test, a CT, and a CUS; Strategy 3 = a CDR, a D-dimer test, a CUS, and a CT; Strategy 4 = a CDR, a
D-dimer test, a VQ, and a CUS; Strategy 5 = a CDR, a D-dimer test, a CT, a CUS, and a PA. CDR =
clinical decision rule; CT = computed tomography pulmonary angiography; CUS= compression
ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary angiography.

Sensitivity and specificity of pulmonary embolism diagnostic tests.
A literature review of articles investigating sensitivity and specificity values of
tests to diagnose PE was conducted. Of the 354 articles examining the D-dimer test, 55
addressed sensitivity and specificity values. Of the 517 articles addressing the CT, 28
reviewed sensitivity and specificity. The VQ lung scan diagnostic test was examined in
203 articles: 14 addressed specificity and sensitivity. Six of the 270 CUS studies
addressed sensitivity and specificity, and four of the 119 articles presenting PA as a PE
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diagnostic tool examined these values. A summary of the articles considered for inclusion
in the review process for obtaining sensitivity and specificity values is presented in Table
20. A list of studies analyzed to obtain PE diagnostic test sensitivity and specificity
values is presented in Table 21.

Table 20
Summary of Articles Evaluatedfor Inclusion in the Review ofPE Test Sensitivity and
Specificity
Categories of Evaluation
Potentially Relevant Articles

DD

CT

VQ

CUS

PA

354

517

203

270

119

193

403

133

226

108

161

114

70

44

11

Identified
Articles not Related to PE Test for
PE Diagnosis
Articles Related to PE Test for PE
Diagnosis

In

Ex

In

Ex

In

Ex

In

Ex

In

Ex

55

106

28

86

14

56

6

38

4

7

Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary
angiography; VQ = ventilation-perfusion lung scan; CUS= compression ultrasonography; PA = invasive
pulmonary angiography. In = included articles related to PE test for PE diagnosis that met inclusion
criteria; Ex = excluded articles related to PE test for PE diagnosis that did not meet inclusion criteria.
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Table 21
Studies Included in the Analysis to Obtain PE Diagnostic Test Sensitivity and Specificity
Study First

Year

Type

Study First

Year

Type

Author

Author

Study First

Year

Type

Author

D-dimer Test (DD)
Lucassen

2010

M

Ghanima

2006

M

Chunilal

2002

M

Corwin

2009

R

Grant

2006

R

De Monye

2002

M

Djurabi

2009

R

Kline

2006

M

Dunn

2002

M

Eng

2009

R

Righini

2006

M

Gosselin

2002

M

Gupta

2009

M

Von Lode

2006

R

Reber

2002

M

Kabrhel

2009

M

Bosson

2005

M

Bucek

2001

M

Legnani

2009

M

Di Nisio

2005

M

Castro

2001

R

Than

2009

M

Hogg

2005

R

Kline

2001

M

Toulon

2009

M

Sonne

2005

M

Kovacs

2001

M

De Moerloose

2008

R

Steeghs

2005

M

Reber

2001

M

Ghys

2008

M

Curtin

2004

M

Rodger

2001

R

Gibson

2008

M

Kulstad

2004

R

Gosselin

2000

M

Mitchell

2008

M

Reber

2004

M

Kollef

2000

R

Runyon

2008

M

Righini

2004

M

LaCapra

2000

R

Di Nisio

2007

M

Stein

2004

R

Sijens

2000

M

Froehling

2007

M

Aujesky

2003

M

Ghanima

2007

M

Brotman

2003

R

Parent

2007

M

Brown

2003

M

Aujesky

2006

R

Hainaut

2003

M

Duriseti

2006

M

Brown

2002

M
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Table 21 (continued)
Study First

Year

Type

Author

Study First

Year

Type

Author

Study First

Year

Type

Author

Computed Tomography Pulmonary Angiography (CT)
Gutte

2009

M

Russo

2005

R

Nilsson

2002

M

Reichelt

2009

M

Van Strijen

2005

M

Safriel

2002

Meta

Wang

2009

M

White

2005

M

Adams

2001

M

Brader

2008

M

Eng

2004

M

Coche

2001

M

MacKenzie

2007

M

Reinartz

2004

R

Perrier

2001

M

Stein

2007

R

Righini

2004

M

Velmahos

2001

M

Stein

2007

R

Winer

2004

M

Harvey

2000

R

Heuschmid

2006

M

Coche

2003

M

Rathbum

2000

R

Hayashino

2005

R

Ruiz

2003

M

Katsouda

2005

M

Herold

2002

R

M

Rozycki

2004

M

Theodorou

2003

M

Compression Ultrasonography (CUS)
Shiver

2010

M

Segal

2007

Aywak

2007

M

Elias

2004

Ventilation-Perfusion Lung Scan (VQ)
Gutte

2010

M

Thieme

2008

M

Bajc

2002

M

Gutte

2009

N

Katsouda

2005

M

Cueto

2001

M

Stein

2009

R

Marini

2005

M

Reinartz

2001

M

Sostman

2008

M

Reinartz

2004

M

Blachere

2000

M

Sostman

2008

M

Coche

2003

M

Invasive Pulmonary Angiography (PA)
Perrier

2003

CEA

Van Erkel

1999

E

Larcos

2000

CEA

Stein

1992

M

Note. PE = pulmonary embolism; M = diagnostic management; R = review; Meta = meta-analysis; CEA =
cost-effectiveness analysis; E = economical study.
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The sensitivity and specificity values identified in the literature for the various PE
diagnostic tests reveal significant differences. To resolve the uncertainty surrounding the
values, y disfributions were applied based upon data retrieved from the cited studies. The
y distribution expected values for the PE diagnostic tests illustrated a very high sensitivity
and a very low specificity level for the D-dimer test; a moderate sensitivity and a high
specificity level for the CT, the CUS, and the VQ lung scan; and very high sensitivity and
specificity levels for the PA. The PA demonstrated the highest sensitivity and specificity
values of all the diagnostic tests. Table 22 presents a summary of the results of the y
distribution sensitivity and specificity expected values from the PE diagnostic test studies
included in this analysis.

Table 22
Expected y Distribution Sensitivity and Specificity Values ofPE Diagnostic Tests (in
Percentage)
PE Diagnostic Test

Expected Sensitivity

Expected Specificity

DD

95.17436

47.77547

CT

88.11154

94.56923

CUS

89.95000

94.90000

VQ

82.77500

90.49999

PA

97.24999

97.00000

Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS= compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography. Five sensitivity and specificity levels were established: very low with a value less
than 60%), low with a value between 60 and 19.99%, moderate with a value between 80 and 89.99%), high
with a value between 90 and 95.99%, and very high with a value between 96 and 100%.
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The y distribution mean sensitivity values of the PE diagnostic tests illustrated the
lowest sensitivity level for the VQ lung scan followed by the CT, the CUS, and the DD,
while the PA demonstrated the highest sensitivity level. Table 23 presents a summary of
the results of the sensitivity y distribution statistics for studies included in this analysis.

Table 23
Sensitivity y Distribution Statistics ofPE Diagnostic Tests (in Percentage)
Statistic

DD

CT

CUS

VQ

PA

Mean

95.17372

88.10945

89.95211

82.77985

97.24905

Standard Deviation

0.605346

1.702001

1.082319

3.060102

0.477765

Minimum

92.54764

81.01011

85.37590

71.27853

95.14016

Maximum

98.42711

96.44676

94.46894

97.73141

99.27941

1st

94.76501

86.95498

89.21584

80.69633

96.92572

2nd

95.17191

88.09015

89.95053

82.73046

97.24823

ord

95.58067

89.25084

90.68287

84.82823

97.57306

2.5th

94.00338

84.81504

87.84398

76.89480

96.31592

10th

94.40088

85.93493

88.56492

78.89455

96.63695

90th

95.95058

90.31270

91.34198

86.72416

97.86229

97.5th

96.36435

91.46800

92.07793

88.85643

98.18110

Quartiles

Percentiles

Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography.
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The y distribution mean specificity values of the PE diagnostic tests illustrated the
lowest specificity level for the DD followed by the VQ lung scan, the CT, and the CUS.
The PA test demonsfrated the highest specificity level. Table 24 presents a summary of
the results of the specificity y distribution statistics of the studies included in this
analysis.

Table 24
Specificity y Distribution Statistics ofPE Diagnostic Tests (in Percentage)
Statistic

DD

CT

CUS

VQ

PA

Mean

47.77661

94.56998

94.90292

90.49730

96.99722

1.96198

0.863097

2.497489

2.465599

0.409109

Minimum

40.04181

91.03230

83.93758

79.77953

95.28446

Maximum

55.92826

99.04141

108.8677

100.9065

98.94585

1st

46.43802

93.98669

93.21365

88.82344

96.72200

2nd

47.75553

94.56723

94.88306

90.48401

96.99653

ord

49.08395

95.14589

96.56493

92.1506

97.27361

2.5th

44.00549

92.87477

90.05558

85.71871

96.19148

10th

45.28254

93.46866

91.70814

87.35149

96.47117

90th

50.31514

95.68185

98.13173

93.66573

97.51936

97.5th

51.69914

96.26664

99.8654

95.40051

97.80146

Standard Deviation

Quartiles

Percentiles

Note. PE = pulmonary embolism; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography.
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Evaluation of Alternative Decisions (Da„)
The cost-effectiveness analysis (CEA) revealed that alternative decision 3 (Da3)
was accepted, while all other alternatives were rejected. Alternative decision 3 stated that
at least strategy 3, composed by a CDR, a DD, a CUS, and a CT, would be more costeffective than strategy 1, strategy 2, strategy 4, or sfrategy 5. The results of this
evaluation are summarized in Table 25.

Table 25
Summary of Alternative Decisions Evaluation
Strategies Compared

Type of Analysis

Results

Da,

Strategy 1 vs. all other strategies

CEA

Rejected

Da2

Strategy 2 vs. all other strategies

CEA

Rejected

Da3

Strategy 3 vs. all other strategies

CEA

Accepted

Da4

Strategy 4 vs. all other strategies

CEA

Rejected

Da5

Strategy 5 vs. all other strategies

CEA

Rejected

Alternative
Decision

Note. Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a
CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA =
invasive pulmonary angiography; CEA = cost-effectiveness analysis; Dan = alternative decision.

Detailed evaluation.
The CEA model was applied to a decision tree, and all five strategies were
analyzed (see Figure 21).
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Figure 21. Decision tree CEA model of five PE diagnostic strategies. CEA = costeffectiveness analysis; PE = pulmonary embolism; Strategy 1 = a CDR, a DD, and a CT;
Sfrategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a
CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a
CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed
tomography pulmonary angiography; CUS = compression ulfrasonography; VQ =
ventilation-perfusion lung scan; PA = invasive pulmonary angiography; Tr = treatment;
ng = negative; p = positive; pn = probability; c = cost payoffs; e = effectiveness payoffs.
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Strategy 1, comprising a CDR, a DD, and a CT, appeared in the first arm of the
decision tree. The costs associated with strategy 1 were defined by appropriate triangular
distributions (i.e., cl, c2, and c3). The effectiveness associated with strategy 1 was
defined by appropriate y distributions (i.e., el, e2, and e3). The event probabilities for
strategy 1 were defined by appropriate Bayes's applications (i.e., pi, p2, p3, and p4).
Sfrategy 2, comprising a CDR, a DD, a CT, and a CUS, appeared in the second arm of
the decision tree. The costs associated with strategy 2 were defined by appropriate
triangular distributions (i.e., c4, c5, c6, and c7). The effectiveness associated with
strategy 2 was defined by appropriate y distributions (i.e., e4, e5, e6, and e7). The event
probabilities for strategy 2 were defined by appropriate Bayes's applications (i.e., pi, p2,
p3, p4, p5, and p6). Strategy 3, comprising a CDR, a DD, a CUS, and a CT, appeared in
the third arm of the decision tree. The costs associated with strategy 3 were defined by
appropriate triangular disfributions (i.e., c8, c9, clO, and cl 1). The effectiveness
associated with strategy 3 was defined by appropriate y distributions (i.e., e8, e9, elO, and
ell). The event probabilities for sfrategy 3 were defined by appropriate Bayes's
applications (i.e., pi, p2, p7, p8, p9, and pi0). Strategy 4, comprising a CDR, a DD, a
VQ, and a CUS, appeared in the fourth arm of the decision tree. The costs associated with
strategy 4 were defined by appropriate triangular distributions (i.e., cl2, cl3, cl4, and
cl5). The effectiveness associated with strategy 4 was defined by appropriate y
disfributions (i.e., el2, el3, el4, and el5). The event probabilities for sfrategy 4 were
defined by appropriate Bayes's applications (i.e., pi, p2, pi 1, pl2, pl3, and pl4).
Sfrategy 5, comprising a CDR, a DD, a CT, a CUS, and a PA, appeared in the last arm of
the decision tree. The costs associated with strategy 5 were defined by appropriate
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triangular distributions (i.e., cl6, cl7, cl8, cl9, and c20). The effectiveness associated
with strategy 5 was defined by appropriate y distributions (i.e., el 6, el7, el 8, el9, and
e20). The event probabilities for this strategy were defined by appropriate Bayes's
applications (i.e., pi, p2, p3, p4, p5, p6, pl5, and pl6).
CEA results revealed that strategy 3 was the most cost-effective of the sfrategies.
Strategy 5 was cost-effective; however, strategies 1, 2 and 4 were not cost-effective and
were dominated by strategy 3. The lowest cost was demonstrated by strategy 3, followed
by strategies 1, 4, 2, and 5, respectively. Conversely, the highest effectiveness was
demonstrated by strategy 5, followed by strategies 3, 4, 2, and 1, in that order. The lowest
cost-effectiveness ratio was demonsfrated by strategy 3, followed in order by sfrategies 1,
4, 2, and 5. Table 26 summarizes cost-effectiveness analysis results.

Table 26
Summary of Cost-effectiveness Analysis (CEA) Results
Strategy

Cost

Incremental

Effectiveness

Incremental

C/E

Type of

$

Cost

ALS

Effectiveness

$/ALS

Strategy

Strategy 3

1922.396

99.91767

19.23980

Most C-E

Strategy 1

1952.982

30.5861

99.78456

-0.13310

19.57198

Dominated

Strategy 4

2281.085

358.6892

99.91518

-0.00248

22.83021

Dominated

Strategy 2

2441.230

518.8345

99.91172

-0.00594

24.43387

Dominated

Strategy 5

2483.821

561.4250

99.91999

0.00232

24.85810

C-E

Note. Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a
CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung scan; PA =
invasive pulmonary angiography; C/E = cost-effectiveness ratio; C-E = cost-effective strategy; ALS =
additional lives saved.

The CEA of the five PE diagnostic strategies revealed that strategies 3 and 5
formed a cost-effectiveness frontier. Strategies 1, 2, and 4 were to the left of this frontier
line with higher costs and lower effectiveness levels, indicating domination by strategy 3.
The CEA results are illustrated in Figure 22.

$2,520.0-T

* strategyl
• strategy^

$2,420.0-

A strategy^

o

$2,320.0-

strategy4

$2,220.0-

• strategyS

$2,120.0$2,020.0$1,920.099.780 ALS

99.850 ALS

99.920 ALS

Effectiveness
Figure 22. Cost-effectiveness analysis for five PE diagnostic strategies. Sfrategy 1 = a
CDR, a DD and a CT; Sfrategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR,
a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a
CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test;
CT = computed tomography pulmonary angiography; CUS = compression
ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary
angiography; ALS = additional lives saved.

Individual cost and effectiveness pairs for each recalculation of the model are
presented in the cost-effectiveness scatter plot with a different color representing each
sfrategy (see Figure 23). Strategy 1 cost-effectiveness dots formed an area similar to a
rectangle, indicating a wide range of both costs and effectiveness values. Sfrategy 2 dots
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formed an area similar to a rectangle, indicating a wide range of costs and a narrow range
of effectiveness values. Strategy 3 and 4 dots were concentrated in a small area similar to
a circle, indicating a narrow range of both costs and effectiveness values. Strategy 5 dots
formed an area similar to a rectangle, indicating a wide range of costs and a narrow range
of effectiveness values.
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• sirategy3
$31000o
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i

i
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i

100010ALS

Effectiveness
Figure 23. Cost and effectiveness scatter plot by strategy. 1 = strategy 1; 2 = strategy 2; 3
= sfrategy 3; 4 = strategy 4; 5 = sfrategy 5; Strategy 1 = a CDR, a DD and a CT; Sfrategy
2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a CT;
Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a CUS,
and a PA. CDR= clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS = compression ultrasonography; VQ = ventilationperfusion lung scan; PA = invasive pulmonary angiography; ALS = additional lives
saved.
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Results by alternative decision (Da„).
Dai:

At least sfrategy 1 will be more cost-effective than strategy 2, strategy 3,

strategy 4, or strategy 5.
This alternative decision is rejected. Strategy 1, comprising a CDR, a DD, and a
CT, with a cost of about $1,952.98 and an effectiveness level of 99.78456 was dominated
by strategy 3 (see Table 26). Results for the costs, effectiveness, and cost-effectiveness
ratio of PE diagnostic strategy 1 are presented in Table 27.

Table 27
Statistics ofPE Diagnostic Strategy 1 Cost and Effectiveness
Cost

Effectiveness

C/E

ALS

S/ALS

1952.982

99.78456

19.57198

401.039

0.03935

4.01903

Median

1893.733

99.89000

18.97709

2.5th percentile

1338.345

99.70730

13.41204

97.5th percentile

2800.714

99.86173

28.06723

Statistic
Mean
Standard Deviation

Note. PE = pulmonary embolism; Strategy 1 = a CDR, a DD and a CT. CDR = clinical decision rule; DD =
D-dimer test; CT = computed tomography pulmonary angiography; ALS = additional lives saved.

In strategy 1, the lowest cost was associated with a negative DD not requiring
treatment, while the most expensive cost was associated with the combination of a
positive DD and a positive CT requiring treatment. Specifically, the overall cost of a
negative DD not requiring treatment was $28 (cl). The overall cost of a positive DD
followed by a positive CT requiring treatment was $2,694 (c2). The overall cost of a
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positive DD and a negative CT was $1,150 (c3). The DD and CT branches of sfrategy 1
are presented in Figure 24.
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Figure 24. Decision tree CEA model arm for PE diagnostic strategy 1. CEA = costeffectiveness analysis; PE = pulmonary embolism; Strategy 1 = a CDR, a DD and a CT.
CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary
angiography; Tr = treatment; ng = negative; p = positive; pn = probability; c = cost
payoffs; e = effectiveness payoffs.

The confidence ellipse on the cost-effectiveness plane in Figure 25a illustrates the
region that contains 95% uncertainty surrounding cost and effectiveness comparators of
strategy 1 vs. strategy 3. The dots in the confidence ellipse represent the individual
incremental cost and incremental effectiveness pairs for each recalculation of the model.
The dots in the confidence ellipse in the upper left (north-west) quadrant of the costeffectiveness plane demonstrate that strategy 1 was less effective and more costly than
strategy 3. Thus, strategy 3 dominates strategy 1. The dots of the confidence ellipse in the
lower left (south-west) quadrant of the cost-effectiveness plane indicate that strategy 1
was less effective and less costly than strategy 3. Thus, sfrategy 3 is optimal. The lower
and upper 95% confidence interval limits of the ICER were -5909 and 4015, respectively,
based upon the 2.5th and 97.5th probability distribution percentiles.
The isocontours in Figure 25b illustrate the regions that correspond to 10 regions
of similar frequency of incremental cost and incremental effectiveness of strategy 1 vs.
strategy 3. When the lines are close together, the magnitude of the slope is large,
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indicating steep variation. The willingness-to-pay line intersects the x and y axes at the
origin of the plot, (x, y = 0, 0).
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Figure 25. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs
of sfrategy 1 vs. strategy 3. Strategy 1 = a CDR, a DD and a CT; Sfrategy 3 = a CDR, a
DD, a CUS, and a CT. CDR = clinical decision rule; DD = D-dimer test; CT = computed
tomography pulmonary angiography; CUS = compression ultrasonography; ALS =
additional lives saved.

Da2:

At least strategy 2 will be more cost-effective than strategy 1, strategy 3,

strategy 4, or strategy 5.
This alternative decision is rejected. Strategy 2, comprising a CDR, DD, a CT,
and a CUS, with a cost of $2,441.23 and an effectiveness level of 99.91172 was
dominated by strategy 3 (see Table 26). Results for the costs, effectiveness, and costeffectiveness ratio of PE diagnostic strategy 2 are presented in Table 28.
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Table 28
Statistics ofPE Diagnostic Strategy 2 Cost and Effectiveness
Cost

Effectiveness

C/E

ALS

S/ALS

2441.2300

99.91172

24.43387

402.0882

0.01112

4.02443

Median

2381.8910

99.91174

23.83954

2.5th percentile

1823.9910

99.88986

18.25482

97.5th percentile

3289.8910

99.93346

32.92609

Statistic
Mean
Standard Deviation

Note. PE = pulmonary embolism; Strategy 2 = a CDR, a DD, a CT, and a CUS. CDR = clinical decision
rule; DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = compression
ultrasonography; C/E = cost-effectiveness ratio; ALS = additional lives saved.

In strategy 2, the lowest cost was associated with a negative DD not requiring
treatment. The most expensive cost was associated with the combination of a positive
DD, a negative CT, and a positive CUS requiring treatment. The overall cost of a
negative DD was $28 (c4). The overall cost of a positive DD followed by a positive CT
requiring freatment was $2,694 (c5). The overall cost of a positive DD, a negative CT,
and a positive CUS requiring treatment was $2,986 (c6). The overall cost of a positive
DD, a negative CT, and a negative CUS was $1,441 (c7). The DD, CT, and CUS
branches of strategy 2 are presented in Figure 26.
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Figure 26. Decision tree CEA model arm for PE diagnostic strategy 2. CEA = costeffectiveness analysis; PE = pulmonary embolism; Strategy 2 = a CDR, a DD, a CT, and
a CUS. CDR= clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS= compression ultrasonography; Tr = treatment; ng =
negative; p = positive; pn = probability; c = cost payoffs; e = effectiveness payoffs.

The confidence ellipse on the cost-effectiveness plane in Figure 27a illustrates the
region that contains 95% uncertainty surrounding cost and effectiveness comparators of
strategy 2 vs. strategy 3. The dots in the confidence ellipse are located in the upper left
(north-west) quadrant of the cost-effectiveness plane. This indicates that strategy 2 was
less effective and more costly than strategy 3. Thus, strategy 3 dominates strategy 2. The
lower and upper 95% confidence interval limits of the ICER were -877755 and 716385,
respectively, based upon the 2.5th and 97.5th probability distribution percentiles.
The isocontours in Figure 27b illustrate the regions that correspond to 10 regions
of similar frequency of incremental cost and incremental effectiveness of strategy 2 vs.
strategy 3. When the lines are close together, the magnitude of the slope is large,
indicating steep variation. The willingness-to-pay line intersects the x and y axes at the
origin of the plot, (x, y = 0, 0). (x, y = 0, 0).
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Figure 27. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs
of strategy 2 vs. strategy 3. Strategy 2 = a CDR, a DD, a CT, and a CUS; Sfrategy 3 = a
CDR, a DD, a CUS, and a CT. CDR = clinical decision rule; DD = D-dimer test; CT =
computed tomography pulmonary angiography; CUS = compression ultrasonography;
ALS = additional lives saved.

Da3:

At least strategy 3 will be more cost-effective than strategy 1, strategy 2,

strategy 4, or strategy 5.
This alternative decision is accepted. Strategy 3, comprising a CDR, a DD, a
CUS, and a CT, with a cost of about $1,922,396 and an effectiveness level of 99.91767
was the most cost-effective strategy (see Table 26). Additionally, sfrategy 3 dominates
strategies 1, 2, and 4. Statistical results for the costs, effectiveness, and cost-effectiveness
ratio of PE diagnostic sfrategy 3 are presented in Table 29. The DD, CUS, and CT
branches of strategy 3 are presented in Figure 28.
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Table 29
Statistics of PE Diagnostic Strategy 3 Cost and Effectiveness
Effectiveness

C/E

ALS

$/ALS

1922.396

99.91767

19.23980

132.182

0.00997

1.32290

Median

1911.065

99.91767

19.12639

2.5th percentile

1693.861

99.89809

16.95223

97.5th percentile

2196.657

99.93722

21.98656

Cost
Statistic
Mean
Standard Deviation

Note. PE = pulmonary embolism; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR = clinical decision
rule; DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS = compression
ultrasonography; C/E = cost-effectiveness ratio; ALS = additional lives saved.

In strategy 3, the lowest cost was associated with a negative DD not requiring
treatment, while the most expensive cost was incurred by the combination of a positive
DD, a negative CUS, and a positive CT requiring treatment. The overall cost of a
negative DD was $28 (c8). The overall cost of a positive DD followed by a positive CUS
requiring treatment was $1,865 (c9). The overall cost of a positive DD, a negative CUS,
and a positive CT requiring treatment was $2,986 (elO). The overall cost of a positive
DD, a negative CUS, and a negative CT was $1,441 (cl 1). The DD, CUS, and CT
branches of sfrategy 3 are presented in Figure 28.
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Figure 28. Decision tree CEA model arm for PE diagnostic strategy 3. CEA = costeffectiveness analysis; PE = pulmonary embolism; Strategy 3 = a CDR, a CDR, a DD, a
CUS, and a CT. CDR = clinical decision rule; DD = D-dimer test; CUS= compression
ultrasonography; CT = computed tomography pulmonary angiography; Tr = treatment;
ng = negative; p = positive; pn = probability; c = cost payoffs; e = effectiveness payoffs.

Da4i

At least strategy 4 will be more cost-effective than strategy 1, strategy 2,

strategy 3, or strategy 5.
This alternative decision is rejected. Sfrategy 4, comprising a CDR, a DD, a VQ,
and a CUS, with a cost of $2,281,085 and an effectiveness level of 99.91518 was
dominated by strategy 3 (see Table 26). Results for the costs, effectiveness, and costeffectiveness ratio of PE diagnostic strategy 4 are presented in Table 30.
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Table 30
Statistics ofPE Diagnostic Strategy 4 Cost and Effectiveness
Cost

Effectiveness

C/E

$

ALS

S/ALS

2281.085

99.91518

22.83021

152.315

0.00997

1.52445

Median

2273.688

99.91519

22.75634

2.5th percentile

2003.943

99.89559

20.05730

97.5th percentile

2583.258

99.93480

25.85495

Statistic
Mean
Standard Deviation

Note. PE = pulmonary embolism; Strategy 4 = a CDR, a DD, a VQ, and a CUS. CDR = clinical decision
rule; DD = D-dimer test; VQ = ventilation-perfusion lung scan; CUS = compression ultrasonography; C/E
= cost-effectiveness ratio; ALS = additional lives saved.

In strategy 4, the lowest cost was associated with a negative DD not requiring
treatment, while the most expensive cost was incurred by a positive DD, a negative VQ,
and a positive CUS requiring freatment. The overall cost of a negative DD was $28 (cl2).
The overall cost of a positive DD followed by a positive VQ requiring treatment was
$2,576 (cl3). The overall cost of a positive DD, a negative VQ, and a positive CUS
requiring treatment was $2,868 (cl4). The overall cost of a positive DD, a negative VQ,
and a negative CUS was $1,353 (cl5). The DD, VQ, and CUS branches of sfrategy 4 are
presented in Figure 29.
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Figure 29. Decision free CEA model arm for PE diagnostic sfrategy 4. CEA = costeffectiveness analysis; PE = pulmonary embolism; Strategy 4 = a CDR, a DD, a VQ, and
a CUS. CDR = clinical decision rule; DD = D-dimer test; VQ = ventilation-perfusion
lung scan; CUS= compression ultrasonography; Tr = treatment; ng = negative; p =
positive; pn = probability; c = cost payoffs; e = effectiveness payoffs.

The confidence ellipse on the cost-effectiveness plane in Figure 30a illustrates the
region that contains 95% uncertainty surrounding cost and effectiveness comparators of
strategy 4 vs. sfrategy 3. The dots in the confidence ellipse are located in the upper left
(north-west) quadrant of the cost-effectiveness plane. This demonstrates that strategy 4
was less effective and more costly than strategy 3. Thus, sfrategy 3 dominates strategy
4.The lower and upper 95% confidence interval limits of the ICER were -665274 and
19926, respectively, based upon the 2.5th and 97.5th probability distribution percentiles.
The isocontours in Figure 30b illustrate the regions that correspond to 10 regions
of similar frequency of incremental cost and incremental effectiveness of strategy 4 vs.
strategy 3. When the lines are close together, the magnitude of the slope is large,
indicating steep variation. The willingness-to-pay line intersects the x and y axes at the
origin of the plot, (x, y = 0, 0).
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Figure 30. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs
of sfrategy 4 vs. strategy 3. Sfrategy 3 = a CDR, a DD, a CUS, and a CT; Sfrategy 4 = a
CDR, a DD, a VQ, and a CUS. CDR = clinical decision rule; DD = D-dimer test; CT =
computed tomography pulmonary angiography; CUS = compression ulfrasonography;
VQ = ventilation-perfusion lung scan; ALS = additional lives saved.

Das:

At least strategy 5 will be more cost-effective than strategy 1, strategy 2,

sfrategy 3, or strategy 4.
This alternative decision is rejected. Sfrategy 5, comprising a CDR, a DD, a CT, a
CUS, and a PA, with a cost of approximately $2,483.82 and an effectiveness level of
99.91999 was a cost-effective strategy, while strategy 3 was the most cost-effective
strategy (see Table 26). Results for the costs, effectiveness, and cost-effectiveness ratio of
PE diagnostic strategy 5 are presented in Table 31.
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Table 31
Statistics of PE Diagnostic Strategy 5 Cost and Effectiveness
Effectiveness

C/E

ALS

$/ALS

2483.821

99.91999

24.85810

402.333

0.01000

4.02655

Median

2423.890

99.92000

24.25726

2.5th percentile

1866.426

99.90036

18.67782

97.5th percentile

3332.686

99.93961

33.35305

Cost
Statistic
Mean
Standard Deviation

Note. PE = pulmonary embolism; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical
decision rule; DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS =
compression ultrasonography; PA = invasive pulmonary angiography; C/E = cost-effectiveness ratio; ALS
= additional lives saved.

In strategy 5, the lowest cost was associated with a negative DD not requiring
treatment, while the most expensive cost was associated with a positive DD, a negative
CT, a negative CUS, and a positive PA requiring treatment. The overall cost of a negative
DD was $28 (cl6). The overall cost of a positive DD followed by a positive CT requiring
treatment was $2,694 (cl7). The overall cost of a positive DD, a negative CT, and a
positive CUS requiring treatment was $2,986 (cl8). The overall cost of a positive DD, a
negative CT, a negative CUS, and a positive PA requiring treatment was $6,662 (cl9).
The overall cost of a positive DD, a negative CT, a negative CUS, and a negative PA was
$5,118 (c20). The DD, CT, CUS, and PA branches of sfrategy 5 are presented in Figure
31.
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Figure 31. Decision tree CEA model arm for PE diagnostic strategy 5. CEA = costeffectiveness analysis; PE = pulmonary embolism; Sfrategy 5 = a CDR, a DD, a CT, a
CUS, and a PA. CDR = clinical decision rule; D-dimer test; CT = computed tomography
pulmonary angiography; CUS= compression ultrasonography; PA = invasive pulmonary
angiography; Tr = treatment; ng = negative; p = positive; pn = probability; c = cost
payoffs; e = effectiveness payoffs.

The confidence ellipse on the cost-effectiveness plane in Figure 32a illustrates the
region that contains 95% uncertainty surrounding costs and effectiveness comparators of
strategy 5 vs. strategy 3. The dots in the confidence ellipse are located in the upper right
(north-east) quadrant of the cost-effectiveness plane. This indicates that strategy 5 was
more effective and more costly than strategy 3, but its ICER was greater than the
willingness-to-pay. Thus, sfrategy 3 is optimal. Overall, strategy 5 was a cost-effective
strategy. The lower and upper 95% confidence interval limits of the ICER were 48523
and 681970, respectively, based upon the 2.5th and 97.5th probability distribution
percentiles.
The isocontours in Figure 32b illustrate the regions that correspond to 10 regions
of similar frequency of incremental cost and incremental effectiveness of strategy 5 vs.
strategy 3. When the lines are close together, the magnitude of the slope is large,
indicating steep variation. The willingness-to-pay line intersects the x and y axes at the
origin of the plot, (x, y = 0, 0).
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Figure 32. Incremental cost and effectiveness (ICE) scatter plot and isocontours graphs
of strategy 5 vs. strategy 3. Sfrategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 5 = a
CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test;
CT = computed tomography pulmonary angiography; CUS = compression
ultrasonography; PA = invasive pulmonary angiography; ALS = additional lives saved.

Monte Carlo Simulation CEA Model Sensitivity Analysis Results
Summary of Monte Carlo simulation sensitivity analysis results.
Strategy 3 statistics were used as baseline data with a willingness-to-pay ranging
from $.01 to $3,000 in a Monte Carlo simulation probabilistic sensitivity analysis within
the CEA model. Figure 33 presents the results of this analysis as acceptability curves.
Acceptability curves provide the uncertainty around cost-effectiveness and illustrate the
probability that a sfrategy is cost-effective when compared with alternate strategies. The
acceptability curve representing the optimal sfrategy demonstrates that the costeffectiveness probability of sfrategy 3 increased as the willingness-to-pay increased.
The cost-effectiveness probability ranges determined for each strategy are as
follows: (a) sfrategy 1, 0.0674 to 0.51006; (b) strategy 2, 0 to 0.00023; (c) strategy 3,
0.45675 to 0.90172; (d) sfrategy 4, 0.03062 to 0.03322; and (e) strategy 5, 0 to 0.00003.
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The sum of the cost-effective probabilities at each interval, i.e., the willing-to-pay
amount, for the five PE diagnostic sfrategies is 1.00. The corresponding results at the
willingness-to-pay intervals are presented in Table 32.
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Figure 33. Acceptability curves with a willingness-to-pay from $.01 to $3,000. Strategy 1
= a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Sfrategy 3 = a
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Sfrategy 5 =
a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule; DD = D-dimer test;
CT = computed tomography pulmonary angiography; CUS= compression
ulfrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary
angiography; ALS = additional lives saved.
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Table 32
Acceptability Curves with a Willingness-to-Pay from $.01 to $3,000
Strategy 3

Strategy 4

0

0.45672

0.03322

0

0.46282

0

0.50417

0.03301

0

600

0.41140

0

0.55577

0.03283

0

900

0.35723

0

0.61013

0.03264

0

1200

0.30264

0

0.66498

0.03238

0

1500

0.24932

0

0.71850

0.03218

0

1800

0.19942

0

0.76873

0.03185

0

2100

0.15592

0

0.81256

0.03152

0

2400

0.11961

0

0.84908

0.03131

0

2700

0.09037

0.00007

0.8786

0.03096

0

3000

0.06740

0.00023

0.90172

0.03062

0.00003

W-T-P $

Strategy 1

0.01

0.51006

300

Strategy 2

Strategy 5

Toi al

Notes. Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a
CT, a CUS, and a PA. DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS=
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive pulmonary
angiography.

Monte Carlo simulation of cost by strategy.
Monte Carlo simulation (MCS) revealed sfrategy 1 cost values ranging from
about $1,169.74 to $3,107.04. Within the first 10th percentile, the cost values were
$1,472.47 or less, the median cost value was $1,893.73, and at or above the 90th
percentile, the cost values were $2,538.44 or greater (see Figure 34).
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Figure 34. MCS of cost cumulative probability for strategy 1. Strategy 1 = a CDR, a DD
and a CT; CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography.

MCS revealed strategy 2 cost values ranging from about $1,633.05 to $3,632.07.
Within the first 10th percentile, the cost values was $1,959.52 or less, the median cost
value was $2381.89, and at or above the 90th percentile, the cost values were $3028.56 or
greater (see Figure 35).

Figure 35. MCS of cost cumulative probability for sfrategy 2. Sfrategy 2 = a CDR, a DD,
a CT, and a CUS; CDR = clinical decision rule; DD = D-dimer test; CT = computed
tomography pulmonary angiography; CUS = compression ultrasonography.

MCS revealed strategy 3 cost values ranging from about $1,543.20 to $2,392.84.
Within the first 10th percentile, the cost values was $1,759.13 or less, the median cost
value was $1,911.07, and at or above the 90th percentile, the cost values were $2,106.78
or greater (see Figure 36).
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Figure 36. MCS of cost cumulative probability for strategy 3. Strategy 3 = a CDR, a DD,
a CUS, and a CT; CDR = clinical decision rule; DD = D-dimer test; CUS = compression
ultrasonography; CT = computed tomography pulmonary angiography.

MCS identified strategy 4 cost values ranging from about $1,870.05 to
$2,725.04. Within the first 10th percentile, the cost values was $2,082.96 or less, the
median cost value was $2,273.69, and at or above the 90th percentile, the cost values
were $2,490.71 or greater (see Figure 37).
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Figure 37. MCS of cost cumulative probability for strategy 4. Sfrategy 4 = a CDR, a DD,
a VQ, and a CUS; CDR = clinical decision rule; DD = D-dimer test; CT = computed
tomography pulmonary angiography; VQ = ventilation-perfusion lung scan; CUS =
compression ultrasonography.

MCS identified strategy 5 cost values ranging from about $1,667.69 to $3,671.55.
Within the first 10th percentile, the cost values was $2,001.67 or less, the median cost
value was $2,423.89, and at or above the 90th percentile, the cost values were $3,071.55
or greater (see Figure 38).
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Figure 38. MCS of cost cumulative probability for sfrategy 5. Strategy 5 = a CDR, a DD,
a CT, a CUS, and a PA; CDR = clinical decision rule; DD = D-dimer test; CT =
computed tomography pulmonary angiography; CUS = compression ultrasonography;
PA = invasive pulmonary angiography.

Monte Carlo simulation of incremental cost and effectiveness by strategy.
Incremental cost values were generated from a Monte Carlo simulation (MCS)
independently comparing the sfrategy 3 statistical data set against the data set of each
other sfrategy. The incremental cost values generated when PE strategy 1 was compared
to PE strategy 3, ranged (in dollars) from -614.82 to 919.34. Probability levels increased
as incremental dollar cost increased with the highest attained probability achieved at
.11181 (-$140), after which probability decreased. The probability of attaining
incremental cost values (in dollars) of-614, -300, -220, 100, 260, 340, 420, 580, 740, and
919 was .07082, .10170, .08630, .07047, .06074, .05129, .03165, .01319, and .00005,
respectively (see Figure 39).
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Figure 39. MCS incremental cost probability
of strategy 1 vs. strategy 3. Strategy 1 = a
CDR, a DD and a CT; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR = clinical
decision rule; DD = D-dimer test; CT = computed tomography pulmonary angiography;
CUS = compression ultrasonography.

As Figure 40 indicates, the incremental cost values generated when PE strategy 2
was compared to PE sfrategy 3, ranged (in dollars) from -74.66 to 1,374.52. Probability
levels increased as incremental dollar cost increased with the highest attained probability
achieved at .10002 ($340), after which probability decreased. The probability of attaining
incremental cost values (in dollars) of 74, 130, 270, 410, 550, 690, 900, 1,180 and 1,374
were .00001, .04101, .09414, .09578, .07914, .0682, .04451, .01678, and .00033,
respectively.
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Figure 40. MCS incremental cost probability of sfrategy 2 vs. strategy 3. Strategy 2 = a
CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR =
clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography.

The incremental cost values generated when PE sfrategy 4 was compared to PE
sfrategy 3, ranged (in dollars) from -384.36 to 979.89. Probability levels increased as
incremental costs increased with the highest attained probability achieved at .13889
($380), after which probability decreased. The probability of attaining incremental cost
values (in dollars) of-384, 100, 170, 310, 450, 590, 730, 870, and 979 were .00001,
.04987, .07469, .12732, .13527, .08657, .03631, .00669, and .00017, respectively (see
Figure 41).

133
0.14
0.12
0.1

>•

= 0.08
.a
re

o 0.06
Q.

0.04
0.02
0
o o o o o o o o o o o o o o o o o o o o o
CT><Nimoo*-(«troorv«t<-iooir)fNOiiocoor~^-*-i
m m CM <-i »H •
T-irtrMrorYi^-iriLniDr^oooooio
i

i

i

i

i

,_i

Incremental Cost

Figure 41. MCS incremental cost probability of sfrategy 4 vs. strategy 3. Strategy 3 = a
CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a CUS. CDR =
clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ulfrasonography; VQ = ventilation-perfusion lung
scan.

The incremental cost values generated when PE strategy 5 was compared to PE
strategy 3, ranged (in dollars) from -40.35 to 1,414.90. Probability levels increased as
incremental costs increased with the highest attained probability achieved at. 10020
($370), after which probability decreased. The probability of attaining incremental cost
values (in dollars) of-40, 160, 230, 510, 580, 790, 1,000, 1,280 and 1,414 were .00001,
.03627, .06449, .08767, .07978, .06095, .03997, .01041 and .00068, respectively (see
Figure 42).
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Figure 42. MCS incremental cost probability of strategy 5 vs. strategy 3. Strategy 3 = a
CDR, a DD, a CUS, and a CT; Sfrategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR
= clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography; PA = invasive pulmonary
angiography.

An MCS generated incremental effectiveness values when PE strategy 1 was
compared to PE sfrategy 3. Effectiveness, which is measured as additional lives saved
(ALS), ranged from -.30351 to .02074. Probability increased as incremental effectiveness
increased, with the highest attained probability of .20034 and effectiveness value of-.13,
after which probability decreased. The probabilities of attaining incremental effectiveness
values of-0.31, -0.25, -0.23, -0.15, -0.09, -0.05, -0.01, 0.01, and 0.02 were .00001,
.00099, .00525, .16204, .14292, .03521, .00314, .00072, and .00012, respectively (see
Figure 43).
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Figure 43. MCS incremental effectiveness probability of sfrategy 1 vs. strategy 3.
Strategy 1 = a CDR, a DD and a CT; Strategy 3 = a CDR, a DD, a CUS, and a CT. CDR
= clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography.

An MCS generated incremental effectiveness values when PE strategy 2 and 3
were analyzed. Effectiveness, which is measured as additional lives saved (ALS), ranged
from -0.02783 to 0.016424. Probability increased as effectiveness increased, with the
highest attained probability of .15370 and incremental effectiveness value of-0.006, after
which probability decreased. The probabilities of attaining incremental effectiveness
values of-.028, -.016, -.012, -.01, -.004, .01, .012, .014, and .018 were .00001, .01472,
.06008, .09594, .15366, .00216, .0007, .00014 and .00002, respectively (see Figure 44).
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Figure 44. MCS incremental effectiveness probability of strategy 2 vs. strategy 3.
Strategy 2 = a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a
CT. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS = compression ultrasonography.

An MCS generated incremental effectiveness values when PE sfrategies 4 and 3
were analyzed for effectiveness. Effectiveness, which is measured as additional lives
saved (ALS), ranged from -0.00719 to 0.001929. Probability increased as incremental
effectiveness increased, with the highest attained probability of .19576 and incremental
effectiveness value of .0022, after which probability decreased. The probabilities of
attaining incremental effectiveness values of .00719, -.0052, -.0047, -.0037, -.0012, .0007, .0008, .0018, and .001929 were .00001, .00312, .01098, .0691, .11702, .06513,
.00257, .00009 and .00001, respectively (see Figure 45).
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Figure 45. MCS incremental effectiveness probability of strategy 4 vs. sfrategy 3.
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a
CUS. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS = compression ulfrasonography; VQ = ventilationperfusion lung scan.

An MCS generated incremental effectiveness values when PE strategies 5 and 3
were analyzed for effectiveness. Effectiveness, which is measured as additional lives
saved (ALS), ranged from -0.00031 to 0.005045. Probability increased as incremental
effectiveness increased, with the highest attained probability of 0.18501 and effectiveness
value of 0.0026, after which probability decreased. The probabilities of attaining
incremental effectiveness values of-.00031, .0005, .0014, .0023, .0035, .0041, .0044,
.0047, and .0053 were .00001, .00139, .04456, .1819, .05099, .00717, .00162, .00052,
and .00002, respectively (see Figure 46).

Figure 46. MCS incremental effectiveness probability of strategy 5 vs. strategy 3.
Strategy 3 = a CDR, a DD, a CUS, and a CT; Sfrategy 5 = a CDR, a DD, a CT, a CUS,
and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS = compression ultrasonography; PA = invasive pulmonary
angiography.

Monte Carlo simulation of D-dimer test, computed tomography pulmonary
angiography, compression ultrasonography, ventilation-perfusion lung scan,
invasive pulmonary angiography, and treatment costs.
As graphed in Figure 47, MCS uncovered DD cost values ranging from $25.60 to
$33. Probability increased as DD cost increased, with the highest attained probability of
.417 at a cost of $28, after which probability decreased. Probabilities for the costs (in
dollars) of 26, 30, 32, and 33 were .062, .333, .166, and .021, respectively.
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Figure 47. Probability distribution of D-dimer test (DD) cost.

As graphed in Figure 48, the MCS identified CT cost values ranging from $276 to
$2,374. Probability increased as CT cost increased, with the highest attained probability
of .093 at a cost of $800, after which probability decreased. Probabilities for the costs (in
dollars) of 276, 400, 600, 1,000, 1,400, 1,800, 2,000, 2,200, and 2,374 were .001, .017,
.062, .081, .057, .046, .024, .014 and .002, respectively.
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Figure 48. Probability distribution of computed tomography pulmonary angiography
(CT) cost.
MCS revealed CUS cost values ranging from $137 to $431. Probability increased
as CUS cost increased, with the highest attained probability of. 128 at a cost of $320,
after which probability decreased. Probabilities for the costs (in dollars) of 137, 180, 220,
260, 300, 340, 360, 400 and 431 were .001, .027, .058, .089, .124, .109, .066, .045, and
.004, respectively (see Figure 49).
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Figure 49. Probability distribution of compression ulfrasonography (CUS) cost.

MCS uncovered VQ cost values ranging from $612 to $1,434. Probability
increased as VQ cost increased, with the highest attained probability of .160 at a cost of
$920, after which probability decreased. Probabilities for the costs (in dollars) of 612,
700, 770, 840, 1,050, 1,190, 1,330, 1,400 and 1,434 were .001, .025, .059, .094, .152,
.102, .049, .026, and .003, respectively (see Figure 50).
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Figure 50. Probability distribution of ventilation-perfusion lung scan (VQ) cost.

MCS revealed PA cost values ranging from $1,072 to $8,370. Probability
increased as PA cost increased, with the highest attained probability of .108 at a cost of
$2,000, after which probability decreased. Probabilities for the costs (in dollars) of 1,200,
1,600, 2,400, 3,200, 4,000, 5,200, 6,000, 7,200 and 8,370 were .004, .071, .099, .086,
.072, .055, .041, .023, and .003, respectively (see Figure 51).
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Figure 51. Probability distribution of invasive pulmonary angiography (PA) cost.
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A Monte Carlo simulation unveiled treatment cost (Tr) values ranging from
$1,450 to $1,639. Probability increased as treatment cost increased, with the highest
attained probability of .638 at a cost of $1,600, after which probability decreased.
Probabilities for the treatment costs (in dollars) of 1,520 and 1,639 were .274 and .088,
respectively (see Figure 52).
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Figure 52. Probability distribution of treatment (Tr) cost.

One-Way Sensitivity Analysis
The DD cost in the one-way sensitivity analysis varied from $1 to $101, with all
other factors (parameters) held constant. The analysis revealed that sfrategies 3 and 5
were cost-effective at each amount level (i.e., $1, $31, $71, and $101). Strategy 3 was the
most cost-effective of all strategies and dominated sfrategies 1, 2, and 4 (see Figure 53).
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Figure 53. One-way sensitivity analysis on D-dimer test cost varying from $1 to $101.
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS;
Strategy 3 = a CDR, a DD, a CUS, and a CT; Sfrategy 4 = a CDR, a DD, a VQ, and a
CUS; Sfrategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule;
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS =
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; ALS = additional lives saved.

Figure 54 reveals that the CT cost in the one-way sensitivity analysis varied from
$100 to $3,100, with all other factors held constant. This analysis revealed that strategies
3 and 5 were cost-effective at each amount level (i.e., $100, $700, $1,600, and $3,100).
Strategy 3 was the most cost-effective strategy and dominated strategies 1, 2, and 4.
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Figure 54. One-way sensitivity analysis on CT cost varying from $100 to $3,100.
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS;
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule;
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS =
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; ALS = additional lives saved.

Figure 55 indicates that the CUS cost in a one-way sensitivity analysis varied
from $50 to $1,050, with all other factors held constant. The analysis revealed that
strategies 3 and 5 were cost-effective at each amount level (i.e., $50, $450, $750, and
$1,050). Strategy 3 was the most cost-effective strategy and dominated strategies 1, 2,
and 4.
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Figure 55. One-way sensitivity analysis on CUS cost varying from $50 to $1,050.
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS;
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a
CUS; Sfrategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule;
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS =
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; ALS = additional lives saved.

A one-way sensitivity analysis revealed that the costs of VQ testing varied from
$100 to $2,100 with all other factors held constant. Strategies 3 and 5 were identified as
cost-effective at each amount level (i.e., $100, $700, $1,500, and $2,100). Strategy 3
remained the most cost-effective and dominated strategies 1, 2, and 4 (see Figure 56).
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Figure 56. One-way sensitivity analysis on VQ cost varying from $100 to $2,100.
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS;
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule;
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS =
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; ALS = additional lives saved.

Results from the one-way sensitivity analysis of the cost of PA testing indicated
cost variability from $100 to $9,100, with all other factors held constant. The analysis
revealed that strategies 3 and 5 were cost-effective at each amount level (i.e., $100,

$1,900, $7,300, and $9,100). Strategy 3 was the most cost-effective strategy and
dominated strategies 1, 2, and 4 (see Figure 57).
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Figure 57. One-way sensitivity analysis on PA cost varying from $100 to $9,100.
Strategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS;
Sfrategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule;
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS =
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; ALS = additional lives saved.

The examination of PE freatment costs using a one-way sensitivity analysis
showed that the cost varied from $100 to $4,100, with all other factors held constant. The

analysis revealed that strategies 3 and 5 were cost-effective at each amount level (i.e.,
$100, $1,700, $3,300, and $4,100). Strategy 3 was the most cost-effective strategy and
dominated strategies 1, 2, and 4 (see Figure 58).
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Figure 58. One-way sensitivity analysis on treatment cost varying from $100 to $4,100.
Sfrategy 1 = a CDR, a DD and a CT; Strategy 2 = a CDR, a DD, a CT, and a CUS;
Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy 4 = a CDR, a DD, a VQ, and a
CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA. CDR = clinical decision rule;
DD = D-dimer test; CT = computed tomography pulmonary angiography; CUS =
compression ultrasonography; VQ = ventilation-perfusion lung scan; PA = invasive
pulmonary angiography; ALS = additional lives saved.
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Two-Way Sensitivity Analysis
A two-way sensitivity analysis was employed to examine the impact of CEA
results on simultaneous changes in the costs of two variables. This analysis revealed that
strategy 3 was the dominant sfrategy for any pair of costs, indicating that it was the most
cost-effective strategy. The results were robust for all imaging test changes. Specifically,
the CUS cost varied from $50 to $1,050, the CT cost varied from $100 to $3,100, the VQ
cost varied from $100 to $2,100, the PA cost varied from $100 to $9,100, and the
treatment (Tr) cost varied from $100 to $4,100. The two-way analyses of the CUS and
the CT cost, the CUS and the VQ cost, the CUS and the PA cost, and the CUS and the
treatment cost are presented in Figure 59.
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Figure 59. Two-way sensitivity analysis. Strategy 1 = a CDR, a DD and a CT; Strategy 2
= a CDR, a DD, a CT, and a CUS; Strategy 3 = a CDR, a DD, a CUS, and a CT; Strategy
4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a CUS, and a PA.
CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography pulmonary
angiography; CUS = compression ultrasonography; VQ = ventilation-perfusion lung
scan; PA = invasive pulmonary angiography; Tr = freatment.

Three-Way Sensitivity Analysis
A three-way sensitivity analysis examined the impact of CEA results on
simultaneous changes in the costs of three variables. This analysis revealed that strategy 3
was the dominant strategy for any group of costs, indicating that it was the most costeffective strategy. The results were robust for all imaging test changes. Particularly, the
DD cost varied from $1 to $100, CUS cost varied from $50 to $1,050, the CT cost varied

from $100 to $3,100, the VQ cost varied from $100 to $2,100, the PA cost varied from
$100 to $9,100, and the treatment (Tr) cost varied from $100 to $4,100. The three-way
analyses of the CUS, the CT, and the DD costs are presented in Figure 60.
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Figure 60. Three-way sensitivity analysis. Sfrategy 1 = a CDR, a DD and a CT; Strategy
2 = a CDR, a DD, a CT, and a CUS; Sfrategy 3 = a CDR, a DD, a CUS, and a CT;
Strategy 4 = a CDR, a DD, a VQ, and a CUS; Strategy 5 = a CDR, a DD, a CT, a CUS,
and a PA. CDR = clinical decision rule; DD = D-dimer test; CT = computed tomography
pulmonary angiography; CUS = compression ulfrasonography; VQ = ventilationperfusion lung scan; PA = invasive pulmonary angiography.

CHAPTER 5
SUMMARY
This chapter presents the summary of the findings regarding parameter
estimates, cost-effectiveness analyses, sensitivity analyses, limitations, and implications
for practice and research. Differences between the research findings and those retrieved
from the literature are addressed. Findings from the Monte Carlo simulation (MCS)
probabilistic and one-way, two-way and three-way deterministic sensitivity analyses are
compared.
Discussion
Parameter Estimates.
This research suggests that there is a linear increase in the adjusted-for-inflation
direct costs. This study has demonstrated that frend line equations strongly support a
linear increase in the adjusted-for-inflation direct costs, with high r values indicating that
more than 98% of the variation in the models is explained by these equations (see Tables
10 through 15).
Applying triangular distributions in a CEA to estimate expected direct cost values
of PE diagnostic tests addresses variability in data retrieved from the literature, resolves
uncertainty, and eliminates error in the assigned baseline values. This is a possible
explanation for the differences between the expected cost values applied in the study and
those identified in the literature. Consequently, by applying triangular distributions to
estimate diagnostic test costs, the differences reported in the literature were combined
(see Table 16 and Figures 9 through 20). All test and treatment costs were adjusted based
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upon the estimations: DD ($28); CT ($1,121); CUS ($292); VQ lung scan ($1,003); PA
($3,676); and PE freatment cost for one year ($1,545).
The findings of this dissertation suggest that applying effectiveness based upon
strategy failure rates to detect PE is an accurate way to address effectiveness payoff
values in a CEA model. The use of y distributions in a CEA assists with estimating
expected strategy failure rates of the investigated PE diagnostic tests, addresses
variability in data retrieved from the literature, resolves uncertainty, and eliminates error
in the assigned baseline values. This may explain why the expected strategy failure rates
applied in this study differ from those identified in the literature. Subsequently, by
applying y distributions to estimate PE diagnostic strategy failure rates, the differences
reported in the literature were merged (see Table 19): strategy 1 (.576667); strategy 2
(1.099999); strategy 3 (.546667); strategy 4 (1.004999); and strategy 5 (.72500).
The use of y disfributions facilitates the estimating of sensitivity and specificity
values of PE diagnostic D-dimer and imaging tests data obtained from the literature (see
Tables 22 through 24). The application of y distributions in a CEA to estimate expected
sensitivity and specificity values of the investigated PE diagnostic tests addresses
variability in the data retrieved from the literature, resolves uncertainty, and eliminates
error in the assigned baseline values. It might explain why the expected sensitivity and
specificity values applied in this study differ from those identified in the literature. By
applying y distributions to estimate PE diagnostic test sensitivity, the differences reported
in the literature for sensitivity were combined: DD (95.174%); CT (88.112%); CUS
(89.95%); VQ lung scan (82.775%); and PA (97.25%). Consequently, by applying y
disfributions to estimate PE diagnostic test specificity, the differences reported in the
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literature were combined: DD (47.775%); CT (94.569%); CUS (94.900%); VQ lung scan
(90.5%); PA (97.0%).
The findings of this thesis further suggest that using a series of Bayes's theorem
applications to estimate expected event probability values of the PE diagnostic tests based
upon test sensitivities and specificities, addresses the accuracy of a given test.
Consequently, in strategy 1 the accuracy of the CT is dependent upon the preceding DD
results. In sfrategy 2, the accuracy of the CT is dependent upon the preceding DD results
and the accuracy of the CUS is dependent upon the results of the preceding CT. In
strategy 3, the accuracy of the CUS is dependent upon results from the preceding DD and
the accuracy of the CT is dependent upon the preceding CUS. In strategy 4, the accuracy
of the VQ lung scan is dependent upon the results from the preceding D-dimer test and
the accuracy of the CUS is dependent upon a preceding VQ lung scan. In strategy 5, the
accuracy of the CT is dependent upon the results from the preceding D-dimer test, the
accuracy of the CUS is dependent upon the preceding CT, and the accuracy of the PA is
dependent upon the preceding CUS (see Figure 21).
Cost-Effectiveness Analysis.
The cost-effectiveness analysis results demonstrated that strategy 3, comprising
CDR, a DD, a CUS, and a CT, was the most cost-effective sfrategy and dominated
strategies 1, 2 and 4. Additionally, strategy 5, comprising a CDR, a DD, a CT, a CUS,
and a PA was a cost-effective sfrategy.
There is no assumption in this analysis about the different types of imaging tests.
Imaging tests were clearly used in the model based upon the corresponding cost and
effectiveness values as they were estimated by the statistical methodology of the analysis.
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The use of a CUS after a high clinical probability or a positive D-dimer test is an
appropriate, efficient, and safe approach suggested by several studies (Elias et al., 2005;
Hull et al., 2001; Perrier et al., 2004; Righini et al., 2008; Van Erkel et al., 1999). The use
of a CT after a high clinical probability or a positive D-dimer test and a negative CUS is
considered an appropriate, efficient, and safe approach proposed by several studies (Elias
et al., 2005; Perrier et al., 2004; Righini et al., 2008).
Sensitivity Analysis.
The results of the MCS probabilistic sensitivity analysis were robust for a number
of disfributions regarding PE diagnostic test costs, effectiveness, sensitivities,
specificities, and event probabilities. Consequently, the sensitivity analysis results
demonstrated that with a willingness-to-pay from $.01 to $3,000 strategy 3 demonstrated
the highest probability of being cost-effective in comparison to the other strategies
examined (see Table 32 and Figure 33).
The results of this investigation were robust over an extensive range of one-way,
two-way, and three-way deterministic sensitivity analyses regarding PE diagnostic test
costs (see Figures 53 through 60). The one-way sensitivity analysis revealed that strategy
3 remained the most cost-effective sfrategy in comparison to strategies 1,2,4, and 5
when applying the diagnostic test and treatment costs in various combinations.
Specifically, the variation of D-dimer test costs from $1 to $101 revealed that both
sfrategy 3 and strategy 5 remained cost-effective. The variation of CT costs from $100 to
$3,100 revealed that both strategy 3 and strategy 5 remained cost-effective. The variation
of CUS costs from $50 to $1,050 revealed that both strategy 3 and sfrategy 5 remained
cost-effective. The variation of VQ lung scan costs from $100 to $2,100 revealed that

157
both strategy 3 and strategy 5 remained cost-effective. The variation of PA costs from
$100 to $9,100 revealed that both strategy 3 and sfrategy 5 remained cost-effective. The
variation of PE treatment cost from $100 to $4,100 revealed that both strategy 3 and
strategy 5 remained cost-effective. In all cases for each variation, strategy 3 dominated
strategies 1, 2, and 4.
Implications for Practice and Research
This research contributed to theory, methodology, and medical decision-making
by exploring the boundaries of a complex medical diagnostic system, addressing
uncertainty, and decision theory; providing a method specifically designed to assist
medical decision-making under uncertainty; and assessing PE cost-effective strategies.
The ability to determine the cost-effectiveness of diagnostic sfrategies may prove to be a
valuable health policy planning tool at the national, state, or local level as well as for
providers of health insurance programs. It also may prove vital for saving resources
within a limited health budget, especially for countries facing deficit problems and/or a
financial crisis such as Greece and Portugal (see IMF, 2011; OECD, 2010), or for smaller
countries experiencing problems related to their occupation by foreign troops; for
example, Cyprus (see Eleftheriou, 2009; IMF, 2011).
This thesis advocates for a clinical decision rule and a D-dimer test as a component of
any PE diagnostic strategy. Therefore, an extensive use of D-dimer testing is
recommended by this analysis. The increase in D-dimer test frequency will result in a
substantial cost reduction of the overall PE diagnostic testing cost due to the decreased
use of imaging tests. This shift in imaging test usage is valuable to low and intermediate
clinical decision rule categories. The findings of this research also suggest that applying

triangular and y distributions in a CEA facilitates the assessment of parameter estimates,
addresses variability in data retrieved from the literature, resolves uncertainty, and
eliminates error in the assigned baseline values. Further research is required to confirm
these findings in a prospective study that establishes assumptions about the types of Ddimer and imaging tests performed. Finally, further research should be conducted to
evaluate whether the methods implemented in this study are applicable for other diseases,
such as for lung and cardiovascular diseases.
Conclusion
In conclusion, this CEA research suggests that, among the five PE diagnostic
strategies investigated, the most cost-effective strategy appears to be strategy 3,
comprising a CDR, a DD, a CUS, and a CT. An initial diagnosis should begin with a
CDR and a DD since a negative DD rules out clinically suspected PE. If a positive DD is
determined, then the diagnosis of PE should be investigated by performing a CUS. In
patients with a positive CUS, a treatment should be applied; patients with a negative or
nondiagnostic CUS require further investigation employing a CT. Alternatives to this
approach such as strategy 5, which is composed of a CDR, a DD, a CT, a CUS, and a PA,
appears to be a cost-effective, but it is a more expensive sfrategy than strategy 3. This
strategy includes PA, which is an invasive test. Strategy 1, which consists of a CDR, a
DD, and a CT, is a highly effective non-invasive technique but appears to be more
expensive than strategy 3. Future work is needed to validate these findings in a
prospective clinical trial before the delivery of a clinical recommendation.
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